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Preface 
This sub-study forms part of a larger study, the Bellville South Africa Study, in which risk factors 
for type 2 diabetes mellitus and cardiovascular disease were investigated in the mixed-ancestry 
population of Bellville South, South Africa. 
 
A. Title of the larger study (The Bellville South Africa Study): 
This is an epidemiological study that aims to elucidate obesity, diabetes, hypertension and the 
metabolic syndrome in adults from urban communities of the Bellville South, Western Cape, South 
Africa. 
  
A.1 Ethics reference: Cape Peninsula University of Technology Health and Wellness Sciences 
Research Ethics Committee: CPUT/HWS-REC 2008/002 and CPUT/HWS-REC 2010 
 
A.2 Background: 
Recent data have shown that the prevalence of type 2 diabetes mellitus in the mixed-ancestry 
(coloured) population (26,3%) has more than doubled within the last decade. Moreover, about 
18,1% of people with the disease are not aware of their condition and are therefore not receiving 
interventions with proven benefits for the adverse health consequences of diabetes. The increasing 
diabetes figures around the world are largely attributed to environmental changes that promote the 
adoption of unhealthy behaviour, resulting in the development of obesity. This in turn, is 
implicated in insulin resistance and inflammation and the subsequent progression to diabetes and 
cardiovascular disease. 
 
A.3 Selected published articles from The Bellville South Africa Study: 
Erasmus, R.T., Soita, D.J., Hassan, M.S., Blanco Blanco, E., Vergotine, Z., Kengne, A.P., Matsha, 
T.E. 2012. High prevalence of diabetes mellitus and metabolic syndrome in a South African mixed 
ancestry population: The Bellville-South Africa study - baseline data. S. Afr. Med. J., 102:841-844. 
 
Matsha, T.E., Hassan, M.S., Kidd, M., Erasmus, R.T. 2012. The 30-year cardiovascular risk profile 
of South Africans with diagnosed diabetes, undiagnosed diabetes, pre-diabetes or normoglycaemia: 
the Bellville, South Africa pilot study. Cardiovasc. J. Afr., 23:5-11. 
 
Matsha, T.E., Soita, D.J., Hassan, M.S., Hon, G.M., Yako, Y.Y., Kengne, A.P., Erasmus, R.T. 2013. 
Three-year's changes in glucose tolerance status in the Bellville South cohort: rates and phenotypes 
associated with progression. Diabetes Res. Clin. Pract., 99:223-230. 
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Matsha, T.E., Hassan, M.S., Hon, G.M., Soita, D.J., Kengne, A.P., Erasmus, R.T. 2013. Derivation 
and validation of a waist circumference optimal cutoff for diagnosing metabolic syndrome in a 
South African mixed ancestry population. Int. J. Cardiol., 168:2954-2955. 
 
B. The sub-study investigated in this thesis: 
Molecular investigation of genetic factors associated with insulin resistance and obesity in a South 
African population 
 
B.1 Ethics reference number: Research Ethics Committee of Stellenbosch University: HREC 
Ref. No: N09/05/146 
 
B.2 Background to the sub-study: 
The aetiology of insulin resistance is complex and influenced by both environmental and genetic 
factors. In the present study, the focus is on the genetic factors that may predispose individuals to 
insulin resistance, subsequent type 2 diabetes mellitus and cardiovascular disease. The independent 
and joint effects of specific variants in genes associated with insulin resistance and diabetes were 
investigated, in order to enable a better understanding of the molecular and pathophysiological 
basis that may contribute to insulin resistance within the mixed-ancestry study population. 
Furthermore, insulin resistance is associated with both type 2 diabetes mellitus and cardiovascular 
disease, in which hyperinsulinaemia leads to insulin resistance. In addition, hyperinsulinaemia 
worsens the state of subclinical cardiovascular disease/atherosclerosis in type 2 diabetes mellitus, 
the major cause of mortality in diabetes subjects. Based on this evidence, the focus of the present 
study was to investigate whether indices of insulin resistance aid in the stratification of subclinical 
cardiovascular disease/atherosclerosis risk in mixed-ancestry South Africans. 
 
B.3 Dissertation presentation: 
This dissertation was written according to the prescribed guidelines of the Stellenbosch University. 
The dissertation is presented as an ‘article format thesis’. The norm is that at least three journal 
articles, with the candidate as the major contributor, must be included. At least two of these articles 
must be already published. Technical presentation of the thesis must follow the guidelines as 
stipulated, that is: the ‘article format thesis’ requires that the text of the articles must be retyped for 
inclusion in the dissertation according to standard guidelines. It is not acceptable to insert copies or 
off-prints of published articles directly into the dissertation. 
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Vergotine, Z., Kengne, A.P., Pillay, T.S., Erasmus, R.T., Matsha, T.E. Indices of insulin resistance 
and markers of sub-clinical cardiovascular disease in mixed-ancestry South Africans. In the 
International Federation of Clinical Chemistry and Laboratory Medicine, WorldLab Congress, 
2014 June 22-26, Istanbul: Turkey. 
 
Vergotine, Z., Yako, Y.Y., Hon, G.M., Erasmus, R.T., Kengne, A.P., Matsha, T.E. Gly972Arg 
variant of the insulin receptor substrate-1 gene is not associated with type 2 diabetes, HOMA-IR 
and obesity in the mixed ancestry population of South Africa. Proceedings of the 13th Asia-Pacific 
Federation for Clinical Biochemistry and Laboratory Medicine Congress, 2013 October 27-30, 
Bali.
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Abstract 
Background: The aetiopathogenesis of type 2 diabetes and the associated insulin resistance have 
been shown to have a strong genetic basis. Several genetic variants of the peroxisome proliferator-
activated receptor gamma (PPARG) and the insulin receptor substrate (IRS) 1 genes have been 
associated with the metabolic states of obesity, insulin resistance and type 2 diabetes in Caucasian 
populations. Furthermore, insulin resistance is strongly associated with diabetes and subsequent 
cardiovascular disease. These are increasingly common in low- to middle -income countries, 
including South Africa. Limited information is currently available regarding genetic associations 
with insulin resistance in African populations. 
Objectives: (1) To identify subjects with insulin resistance and determine the frequencies of the 
single nucleotide polymorphisms in the PPARG and IRS1 genes and examine the associated risk of 
insulin resistance and type 2 diabetes mellitus in a mixed-ancestry South African population. (2) To 
investigate the relationship between indices of insulin resistance and carotid intima media 
thickness, a marker of subclinical cardiovascular disease/atherosclerosis. 
Methods: A total of 856 (235 males) mixed-ancestry adults drawn from an urban community of 
Bellville South, Cape Town were genotyped for PPARG Pro12Ala (rs1801282, G>C), Pro115Gln 
(rs1800571, G>T), Val290Met (rs72551362, G>A), Pheu388Leu (rs72551363, T>A), Arg397Cys 
(rs72551364, C>T), His449His (rs3856806, C>T) and IRS1 Gly972Arg (rs 1801278, G>A). The 
oral glucose tolerance test was performed and cardiometabolic risk factors measured. Insulin 
resistance was estimated by the homeostasis model assessment of insulin resistance, the 
homeostasis model assessment of functional beta-cells, the quantitative insulin-sensitivity check 
index, the fasting insulin resistance index and the glucose/insulin ratio. Carotid intima media 
thickness was measured in longitudinal section at the far wall of the distal common carotid arteries, 
2 cm from the bifurcation, at three consecutive end-points, 5-10 mm apart. 
Results: The genotype frequencies of PPARG Pro12Ala, IRS1 Gly972Arg and PPARG His449His 
were 10,4%, 7,7% and 23,8% respectively. No mutations were found for PPARG Pro115Gln, 
Val290Met, Pheu388Leu and Arg379Cys. In a model containing both PPARG Pro12Ala and  
IRS1 Gly972Arg alleles and their interaction term, the presence of the PPARG Pro12 resulted in a 
64% risk of prevalent type 2 diabetes mellitus and was associated with higher 2 hour post-OGTT 
insulin levels in subjects with normoglycaemia. The PPARG Pro12 was associated with insulin 
resistance and interacted with IRS1 Gly972Arg, increasing the risk of type 2 diabetes mellitus. The 
PPARG His449His allele T frequency was about 14% and in an additive genetic model significantly 
reduced the risk of diabetes by 44%. After adjustment for age, gender, body mass index and 
diabetes status, the fasting plasma glucose (β=0,087;p=0,042) and glucose/insulin ratio  
(β=0,026; p=0,026) were associated with carotid intima media thickness. However, the effect on 
the overall model performance was marginal, R
2
<29,7%. 
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Conclusion: The PPARG Pro12 was associated with insulin resistance and showed a gene-gene 
interaction with the unfavorable polymorphism IRS1 Gly972Arg, leading to an increased risk of 
type 2 diabetes mellitus. In contrast, the PPARG His449His T allele showed a protective effect 
against the risk of developing diabetes. Furthermore, indices of insulin resistance such as 
homeostatis model assessment of insulin resistance, quantitative insulin-sensitivity check index, 
fasting insulin resistance index and the glucose/insulin ratio were weakly associated with carotid 
intima media thickness in the risk stratification of cardiovascular disease in this population. 
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Opsomming 
Agtergrond: Die sterk genetiese grondslag van die etiopatogenese van tipe 2 diabetes en verwante 
insulienweerstand is reeds bevestig. Verskeie genetiese variante van die peroksisoomprolifereerder 
geaktiveerde reseptor gamma (PPARG) en die insulienreseptor substraat (IRS)1 gene hou verband 
met die metabolise sindroom van vetsug, insulienweerstand en tipe 2 diabetes in Kaukasiese 
bevolkings. Verder word insulienweerstand sterk verbind met gevolglike kardiovaskulêre siekte in 
diabetes mellitus. Laasgenoemde toestande neem toe in lae- en middelinkomste lande, Suid Afrika 
ingesluit. Beperkte inligting is tans beskikbaar aangaande die genetiese verwantskappe van 
insulienweerstand in Afrika bevolkings. 
Doel: (1) Om proefpersone met insulienweerstand te identifiseer, die voorkoms van 
enkelnukleotiedpolimorfismes in PPARG en IRS1 gene te bepaal en die verwante risiko vir 
insulienweerstand en tipe 2 diabetes in ‘n Suid-Afrikaanse bevolking van gemengde herkoms te 
ondersoek. (2) Om die verwantskappe tussen insulienweerstandsindekse en karotis intima media 
dikte as ‘n merker van subkliniese kardiovaskulêre siekte/aterosklerose te bepaal. 
Metode: ‘n Steekproef van 856 (235 mans) volwassenes van gemengde herkoms uit ‘n stedelike 
gemeenskap in Bellville Suid, Kaapstad, is gegenotipeer vir PPARG Pro12A1a (rs1801282, G>C), 
Pro115Gln (rs1800571, G>T), Val290Met (rs72551362, G>A), Pheu388Leu (rs72551363, T>A), 
Arg397Cys (rs72551364, C>T), His449His (rs3856806, C>T) en IRS1 Gly972Arg (rs 1801278, 
G>A). Orale glukosetoleransie toetse is uitgevoer en kardiometaboliese risikofaktore is gemeet. 
Insulienweerstand is geraam deur die homeostasemodel assessering vir insulienweerstand, die 
homeostasemodel assessering van funksionale betaselle, die kwantitatiewe insuliensensitiwiteit 
kontroleerindeks, die vastende insulienweerstandsindeks en glukose/insulien verhouding. Carotids 
intima media dikte is gemeet in longitudinale snit teen die verre wand van die distale gemene 
karotis arteries, 2 cm vanaf die bifurkasie, by drie opeenvolgende eindpunte,  
5-10 mm uit mekaar. 
Resultate: Die voorkoms van PPARG Pro12Ala, IRS1 Gly972Arg and PPARG His449His 
genotipes was onderskeidelik 10,4%, 7,7% en 23,8%. Geen mutasies van PPARG Pro115Gln, 
Val290Met, Pheu388Leu of Arg379Cys is gevind nie. In ‘n model wat beide die PPARG Pro12Ala 
en IRS1 Gly972Arg allele en hul interaksieterm bevat het, het die teenwoordigheid van  
PPARG Pro12 gelei tot 64% risiko vir tipe 2 diabetes en verband gehou met verhoogde 2-uur  
post-OGTT insulienvlakke in studiepersone met normoglisemie. ‘n Verband is aangedui tussen 
PPARG Pro12 en insulienweerstand en daar was interaksie met IRS1 Gly972Arg wat die risiko vir 
tipe 2 diabetes verhoog. Die PPARG His449His T-allel se voorkoms was ongeveer 14% en het die 
diabetesrisiko met 44% verlaag in ‘n saamgestelde genetiese model.Na aanpassings vir ouderdom, 
geslag, liggaamsmassa indeks en diabetes status, is ‘n verband getoon tussen beide vastende 
plasmaglukose (β=0,087; p=0,042) en glukose/insulienverhouding (β=0,026; p=0,026), en karotis 
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intima media dikte. Die uitwerking op die gehele model was egter gering, R
2
<29,7%. 
Gevolgtrekking: ‘n Verwantskap is getoon tussen PPARG Pro12 en insulienweerstand en ‘n  
geen-geen interaksie het voorgekom met die ongunstige IRS1 Gly972Arg polimorfisme wat lei tot 
verhoogde risiko vir tipe 2 diabetes. Die PPARG His449His T-allel het in teenstelling ‘n 
beskermende uitwerking getoon teen die risiko vir diabetes. Verder was daar ‘n swak verband 
tussen indekse van insulienweerstand soos homeostasemodel assessering, die kwantitatiewe 
insuliensensitiwiteit kontroleerindeks, die vastende insulienweerstandsindeks en glukose/insulien 
verhouding, en karotis intima media dikte vir risikogroepering vir kardiovaskulêre siekte in hierdie 
bevolking. 
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Outline of the dissertation 
 
This dissertation is a compilation of four studies regarding genetic factors associated with insulin 
resistance (IR) and type 2 diabetes mellitus (T2DM), with focus on the peroxisome proliferator-
activated receptor gamma (PPARG) and insulin receptor substrate (IRS)1 genes, as well as the use 
of IR indices in cardiovascular disease (CVD) risk stratification. The dissertation is arranged in a 
series of six chapters as follows: 
 
Chapter 1: Provides an overview of the literature related to the condition defined as IR based on 
the molecular pathway, pathogenesis, aetiology, associated disease conditions with IR and CVD, 
various assessment methods of insulin resistance/sensitivity (IR/S) and subclinical atherosclerosis, 
epidemiology and the genes associated with IR. 
 
Chapter 2: Presents a detailed research methodology. 
 
Chapter 3: Examines the independent and joint effects of PPARG Pro12Ala and IRS1 Gly972Arg 
variants on markers of IR and T2DM. The findings of this chapter combine two papers that were 
published in the South African Medical Journal and BioMedical Central Genetics Journal in 2014. 
 
Chapter 4: Examines the association between cardiometabolic traits, PPARG His449His and other 
low frequency PPARG polymorphisms. This paper was accepted for publication in the 
International Journal of Endocrinology in 2014. 
 
Chapter 5: Examines the relationship between indices of IR and carotid intima media thickness 
(CIMT), a marker of subclinical CVD. The manuscript draft prepared. 
 
Chapter 6: Provides a summary of the findings, an integrated discussion and conclusion as well as 
the limitations of the study with recommendations. 
 
References: A reference list is included for all the chapters at the end of the dissertation. 
 
Appendices: Listed at the end of the dissertation. 
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CHAPTER 1 
 
LITERATURE REVIEW 
 
1.1 INTRODUCTION 
Insulin resistance (IR) is a pathophysiological condition wherein normal insulin levels fail to 
maintain normal glucose homeostasis. Since the discovery of insulin in 1922 (Banting et al., 1922) 
this anabolic hormone was shown to play a critical role in the maintenance of glucose homeostasis 
through the effects of insulin secretion and action to promote glucose transport into muscle and 
adipose tissue and to inhibit glucose output by the liver. Resistance to these metabolic actions of 
insulin is typically defined as IR due to the reduced sensitivity to insulin (Reviewed by Wilcox, 
2005; Reaven, 2005; Ye, 2007). 
 
In normal glucose homeostasis the pancreas beta cells secrete the glucagon and insulin hormones 
that by synergistic actions blood glucose levels are regulated. Glucagon is secreted in response to 
low blood glucose levels and stimulates the liver to breakdown glycogen to release glucose and to 
convert non-carbohydrate macronutrients into glucose. Insulin is secreted in response to high blood 
glucose levels and has an opposing effect to glucagon by suppression of hepatic glycogenolysis, 
stimulation of hepatic glucose uptake for glycogenesis and facilitation of glucose uptake in the 
insulin-responsive muscle and adipose tissue. In response to reduced blood glucose levels secretion 
of insulin is decreased to facilitate hepatic glycogenolysis and lipolysis in the adipose tissue. In 
abnormal glucose homeostasis multiple disturbances may occur namely, hyperglycaemia, impaired 
insulin secretion, IR, compensatory hyperinsulineamia with progression to impaired glucose 
tolerance (IGT) and consequent type 2 diabetes mellitus (T2DM) (Reviewed by DeFronzo, 2004; 
Szablewski, 2011). 
 
In the development of IGT from normal there is a marked increase in the glucose-stimulated blood 
insulin levels known as compensatory hyperinsulineamia. The latter condition results from the 
inadequate effect of insulin to regulate the blood glucose levels even with normal insulin levels. An 
inability to maintain an adequate compensatory insulin response results in the progression to IGT 
which is further associated with severe insulin resistance. Although insulin secretion is increased, 
beta cell sensitivity to glucose is reduced and tissue sensitivity to insulin is diminished which in 
concert contributes to the development of type 2 diabetes mellitus (Cefalu, 2001; Bliss, 1993; 
Himsworth, 1936; DeFronzo, 2004; DeFronzo, 2009; Reaven, 1975). 
 
Himsworth (1936) was the first to recognise diabetes mellitus on the basis of hyperglycaemia 
occurring both in the presence (insulin resistance) and absence (insulin deficiency) of insulin. As 
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such IR is a key pathogenic feature of T2DM where both normal and elevated insulin levels 
produce a diminished biological response commonly referred to as impaired sensitivity to insulin-
mediated glucose disposal (DeFronzo, 2009; Cefalu, 2001; Bliss, 1993). Later studies confirmed 
the role of IR in the pathogenesis of T2DM and showed association with obesity, metabolic 
syndrome (MetS) and cardiovascular diseases (CVD) (Reviewed by Reaven, 1988; DeFronzo, 
1992; Rao, 2001; Reaven, 2005; Ye, 2007).  
 
1.2 INSULIN SIGNALLING PATHWAY (NORMAL) 
The signalling mechanism involved in various biological responses to insulin action is initiated by 
binding of the hormone to the cell membrane and activation of insulin receptor tyrosine kinase. 
This results in the stimulation of intracellular signalling cascades (White & Kahn, 1994). An 
overview of the insulin signalling pathway via the insulin receptor substrate 
(IRS)1/phosphatidylinositol 3-kinase (PI 3-kinase) / protein kinase B (Akt) pathway and the  
Ras / mitogen-activated protein (MAP) kinase pathways are briefly discussed below in Figure 1.1: 
p 3 (Reviewed by Hooper, 2011). 
 
Under normal physiological conditions, insulin mediates its actions through binding to the insulin 
receptor (INSR) ß subunits, which when phosphorylated activate the tyrosine kinase activity of the 
insulin responsive substrate (IRS) proteins. The tyrosine phosphorylation reactions activate insulin / 
insulin growth factor (IGF) receptors, which in turn, activate the phosphatidylinositol 3-kinase (PI 
3-kinase) and extracellular signal-regulated kinase (ERK) cascades, after which the insulin 
signalling pathways diverge. Phosphorylated IRS proteins bind specific src-homology-2 domain 
proteins (SH2) that proceed with the IRS1 / PI 3-kinase / Akt pathway, resulting in 
autophosphorylation of the INSR and activation that phosphorylates several adaptor/scaffold 
molecules, including Shc, APS, CAP, c-Cbl and the IRS proteins. Tyrosyl phosphorylation of these 
proteins within specific motifs serves to recruit downstream effectors. Phosphorylation of the 
insulin receptor substrate (IRS)1 or the insulin receptor substrate (IRS)2 leads to recruitment of 
effectors such as the protein phosphatase SHP2, the adaptor protein Nck and the lipid kinase,  
PI 3-kinase. The IRS1 and IRS2 binds to SH2 domains in the 55- or 85-kDa regulatory subunits of 
PI 3-kinase, an important enzyme that promotes: translocation of glucose transporter proteins, 
glycogen and lipids; protein synthesis; anti-lipolysis and; the control of hepatic gluconeogenesis 
(Reviewed by Shepherd et al., 1996; White & Kahn, 1994; White, 1998). 
 
The metabolic actions via PI 3-kinases act on serine and threonine kinases such as Akt / protein 
kinase B/ PKB (Wang et al., 1999), protein kinase C (PKC) (Kotani et al., 1998) and 
phosphatidylinositol (PI) dependent protein kinases 1 and 2 (PIPD 1&2). The catalytic subunit of 
PI 3-kinase, p110 phosphorylate PI biphosphate leading to the formation of PtdIns (3, 4, 5)P3 that is 
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the downstream effector of Akt/protein kinase B (PKB). Activated Akt enters cytoplasm it leads to 
phosphorylation and inactivation of glycogen synthase kinase (GSK) 3. Phosphorylation of 
glycogen synthase by GSK3 inhibits glycogen synthesis thus the inactivation of GSK3 by Akt 
promote glucose storage as glycogen (Reviewed by Hooper, 2011). Activated Akt / protein kinase 
B also phosphorylates its 160-kDa substrate (AS160), which stimulates the translocation of insulin-
mediated glucose transporter (GLUT) 4 from intracellular vesicles to the plasma membrane (Sano 
et al., 2003). In addition, PI 3-kinase independent pathway provides a second signal to recruit 
GLUT4 to the plasma membrane through activation of the Cbl-CAP complex. Cbl interacts with 
the adaptor protein Crk that in turn activates members of the GTP-binding proteins, TC10 that 
promote GLUT4 translocation (Saltiel & Khan, 2001). 
 
 
 
Figure 1.1 An overview of the insulin signalling pathway (Reviewed by Hooper, 2011) 
 
Abbreviaitons: AKT, protein kinase B; C3G, Rho-family guanine nucleotide exchange factor associated with Cbl-CAP 
complex; Cbl, Crk, CAP, complex of adaptor proteins; elF2B, binding protein dephosphorylate to promote protein 
synthesis; GLUT, glucose transporter; GRB2, growth factor receptor-bound protein 2 an adaptor protein that activate 
the MAPK cascade, GSK, glycogen synthase kinase; IRS, insulin receptor substrate family; mTOR, mammalian target of 
rapamycin; MAPK pathway, mitogen-activated protein kinase mitogenic responses independently of IRS; PDK, protein 
kinase 3-phoshoinositide-dependent protein kinase required for AKT activation; PI 3-K, phosphatidylinositol 3-kinase; 
p110 and p85, catalytic subunits of PI 3-kinase; PtdIns(3,4,5)P3, phosphorylate phosphatidylinositol biphosphate; SHC, 
substrate for the insulin receptor; SREBP, steroid regulatory element-binding protein involved in protein synthesis; TC10, 
GTP-binding protein family which promote GLUT4 translocation. 
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The Akt also activates mammalian target of rapamycin (mTOR) an atypical serine/threonine 
protein kinase that belongs to the PI 3-kinase related kinase family that interacts with several 
proteins to form mTORC1 and mTORC2. The mTORC1 is activated by nutrients, growth factors 
and cellular energy status. The substrates of mTORC1 are p70 ribosomal S6 kinase (S6K) and elF-
4E-binding protein (4E-BP1) through which mTOR1 controls protein synthesis. The mTORC2 is 
activated by association with ribosome in response to growth factors in growing cells. mTORC2 
regulates the actin cytoskeleton, cell survival through phosphorylation of Akt and protein kinase C 
(Dazert & Hall, 2011; Zinzalla et al., 2011). 
 
In the second pathway, the Ras / MAP kinase pathway, Ras proceeds through an adaptor protein 
that links IRS1 to the Ras/MAP kinase pathway. Growth factor receptor-bound protein 2 (GRB2), 
an adaptor protein involved in signal transduction/cell communication, recruits the SOS complex to 
tyrosyl phosphorylated transforming protein 1 (SHC), which mediates p21ras. This activates the 
Ras / Raf / MAP kinase (MAPK) / MEK kinase cascade by binding to isoforms ERK1 and ERK2. 
The Ras pathway activates transcription factors and stimulates growth by promoting the actions of 
insulin's mitogenic effects (Shulman, 1999; Cusi et al., 2000; Schmitz-Peiffer & Whitehead, 2003). 
 
1.3 PATHOPHYSIOLOGY OF INSULIN RESISTANCE 
Insulin resistance is a condition in which cells fail to respond adequately to circulating insulin 
resulting in high blood glucose levels referred to as impaired insulin-induced glucose uptake. This 
condition is caused by defects in the insulin signalling pathway, which in turn, increases the 
secretion of insulin (hyperinsulinaemia) as a compensatory mechanism to maintain normal blood 
glucose levels associated with type 2 diabetes mellitus (Boden, 2005; Moller & Kaufman, 2005; 
reviewed by Ye, 2013). In addition, a cluster of cardiovascular disorders that are independent risk 
factors for CVD have been shown to be strongly associated with insulin resistance. These disorders 
include dyslipidaemia, obesity, hypertension, glucose intolerance and endothelial dysfunction (ED) 
and seem to interact to promote the development of diabetes and CVD/atherosclerosis (DeFronzo, 
2010; Ikmal et al., 2013). Of these, obesity has been shown to be the most prominent risk factor for 
the development of IR, where the dysfunction in adipose tissue to insulin action leads to an 
increase in lipolysis (hyperlipidaemia), resulting in elevated free fatty acids (Wajchenberg, 2000; 
DeFronzo, 2004; Garg, 2004). Overstimulation of insulin by elevated plasma FFA levels in obese 
individuals contribute to the increase in plasma insulin levels as a compensatory action and account 
for up to 50% of IR in obese patients with type 2 diabetes mellitus (Boden, 2001; Mc Garry, 2001; 
Boden & Shulman, 2002; Ye, 2007; He et al., 2011). 
 
Alternate mechanisms are proposed to be involved in the multistep process of insulin resistance. 
These include mitochondrial dysfunction (Ozcan et al., 2009; Szendroedi et al., 2012), endoplasmic 
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reticulum stress (Szendroedi et al., 2012), hypoxia (Hosogai et al., 2007; Ye, 2007; Wood et al., 
2009; Prieto et al., 2014) and oxidative stress (Evans et al., 2003; Furukawa et al., 2004; Graham & 
Adler, 2014). Furthermore, IR is associated with a wide spectrum of metabolic disorders and has 
been shown to play a crucial role in the pathogenesis of PCOS (Diamanti-Kandarakis & Dunaif, 
2012), non-alcoholic fatty liver (Masuoka & Chalasani, 2013) and lipodystrophy (Semple et al., 
2011).  
 
1.4  MOLECULAR MECHANISM OF INSULIN RESISTANCE 
Several defects in the insulin signalling pathway have been identified, mostly at post-translational 
level with impaired phosphorylation of the insulin receptors in response to insulin that resulted in 
insulin resistance. The basis of IR, determined by the insulin signalling cascades, is classified into 
three categories where the primary effect is either at the pre-receptor level or at the post-receptor 
level. 
 
1.4.1 The pre-receptor level 
The pre-receptor causes of IR involve the production of abnormal insulin and anti-insulin 
antibodies to the insulin receptors (INSR). Genetic mutations result in the formation of defective 
insulin, that is: proinsulin is not converted to insulin and thereby affects the binding of insulin to 
the insulin receptors (Tager et al., 1979; Chan et al., 1987; Steiner et al., 1990). 
 
1.4.2 The post-receptor level 
At the post-receptor level, the transmembrane receptor on the cell surface INSR, the defective 
signal transduction in the IRS1 / PI 3-kinase / Akt pathway, mutations in the IRS proteins, rare 
mutations in GLUT4 and various serine kinases lead to insulin resistance (Taylor et al., 1990; Ye, 
2007; He et al., 2011). 
 
The INSR is activated by insulin, IGF-I, IGF-II and belongs to the large class of tyrosine kinase 
receptors (Ward & Lawrence, 2009). The INSR is involved in the post-receptor signalling pathway 
with a key role in the regulation of glucose homeostasis, which if disrupted, can result in various 
metabolic states including diabetes (Belfiore et al., 2009). A number of causes related to the 
development of IR have been identified at the INSR level. A decrease in the number of receptors 
can lead to failure of tyrosine kinase activity, thereby reducing the binding of insulin. It is 
suggested that diabetes may be due to a slightly decreased affinity of the receptor for insulin or 
decreased kinase activity, possibly driven by environmental factors such as obesity (Taira et al., 
1989). Relatively rare mutations of the INSR gene have been reported to induce IR and 
lipodystrophy, among other metabolic disorders (Reviewed by Pankov, 2013). In lipodystrophy, 
the primary adipose tissue defects induce IR at the post-receptor level by impairing the ability of 
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insulin to suppress hepatic gluconeogenesis, leading to hyperglycaemia and hyperinsulinaemia 
(Semple et al., 2011). The excess energy is stored as lipids in ectopic sites, which lead to severe 
metabolic dysregulation resulting in IR, dyslipidaemia, reproductive and liver complications and 
other chronic complications related to diabetes and cardiovascular diseases (Vatier et al., 2013). 
 
Studies regarding IR in animal and human models have consistently shown a reduced strength in 
the insulin signalling via IRS1 / PI 3-kinase / Akt pathway, resulting in decreased glucose uptake 
and utilisation in insulin target tissues (Kahn & Flier, 2000; Pessin & Saltiel, 2000). A number of 
serine kinases have been identified that phosphorylate serine residues of IRS1 and weaken the 
insulin signal transduction. This reduces the ability of the IRS protein to attract PI 3-kinase and 
thereby minimises its activation (Birnbaum, 2001; Aguirre et al., 2002; White, 2003), which can 
lead to degradation of the IRS1 protein (Shah et al., 2004). In contrast, excessive serine 
phosphorylation of IRS proteins can be detrimental for normal metabolic insulin signalling 
downstream and can result in insulin resistance. 
 
Several defects in the insulin signalling pathways in the skeletal muscle of T2DM subjects have 
been identified, mostly at the level of post-translational regulation of key enzyme activity 
(Ducluzeau et al., 2001), including impaired phosphorylation of insulin receptors and IRS1 in 
response to insulin (Arner et al., 1987; Björnholm et al., 1997; Cusi et al., 2000). The induction of 
PI 3-kinase, PKC and Akt kinase activity was also reduced (Krook et al., 1998; Cusi et al., 2000; 
Krook et al., 2000). This induction appears to be critical in the mechanism of insulin action on 
GLUT4 translocation and glucose transport (Bandyopadhyay et al., 1997; Drazin, 2006). In another 
study, skeletal muscle of diabetic subjects showed impaired insulin activation of the IRS1 / PI 3-
kinase / Akt signalling pathway, which is a critical step in the regulation of glucose transport in 
response to insulin (Le Marchand-Brustel et al., 1995; Choi & Kim, 2010). However, the 
expression of the GLUT4 gene was normal in the muscle of diabetic subjects (Garvey et al., 1988), 
with the impaired glucose uptake probably due to altered trafficking or the impaired function of 
glucose transporter 4. The resistance to insulin stimulation was related to impaired insulin signal 
transduction (Pedersen et al., 1990; Dohm et al., 1991; Kim et al., 1999). 
 
Various other serine kinases are reported to promote serine phosphorylation of IRS1, such as  
c-JUN N-terminal kinases (JNKs), stress-activated protein kinases, PKC and tumour necrosis factor 
alpha (TNFα). Activation of JNKs by free fatty acids (FFAs), stress and inflammation increase 
serine phosphorylation of IRS1, thereby reducing insulin signalling (Hirosumi et al., 2002). 
However, when JNKs activation is blocked, the defects induced by FFAs are prevented (Gao et al., 
2004). Pro-inflammatory PKC has also been found to cause serine phosphorylation of IRS1, with 
increased PKC and activity of JNKs in the skeletal muscle of obese and T2DM subjects, 
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demonstrating a potential role in the pathogenesis of insulin resistance (Itani et al., 2001; 
Bandyopadhyay et al., 2005). The TNFα was shown to be increased in the adipose tissue of obese 
and IR subjects (Hotamisligil & Spiegelman, 1994; Qi & Pekala, 2000). The TNFα was also found 
to block insulin signalling by promoting serine phosphorylation of IRS1, resulting in a decline in 
IRS1 associated PI 3-kinase activity (Hotamisligil et al., 1996; Drazin, 2006). 
 
The mTOR pathway was also found to cause IR as mTOR blocks insulin signalling when 
stimulated by nutrients and insulin. IR occurs when high mTOR/S6K activity follows over-
activation by nutrients, cytokines, insulin and other hormones degrading the IRS proteins 
(Reviewed by Blagosklonny, 2012; Tremblay et al., 2005). The mTOR/S6K kinase signalling 
pathway was also found to modify insulin-stimulated glucose transport in skeletal muscle cells. 
Inhibition of insulin-mediated PI 3-kinase activity leads to increased serine/threonine 
phosphorylation of IRS1 and decreases binding of the p85 subunit of PI 3-kinase to IRS1 thereby 
decreasing cellular glucose uptake (Tremblay et al., 2005, Tremblay et al., 2001). Over-stimulation 
of beta cells leads to increased insulin secretion, which eventually fails and results in type 2 
diabetes mellitus (Blagosklonny, 2012). 
 
Another molecular mechanism that can lead to IR is a disruption in the balance of the number of  
PI 3-kinase regulatory subunits (Ueki et al., 2002). A balance exists between the regulatory 
subunits p85α and p85-p110 heterodimer, with the latter responsible for the PI 3-kinase activity 
(Shepherd et al., 1998). An imbalance between the subunits could increase or decrease PI 3-kinase 
activity because both p85α and p85-p100 compete for the same binding site on the tyrosine-
phosphorylated IRS proteins. This was evident in studies in which IR states were induced by human 
placental hormone (Barbour et al., 2004), obesity and diabetes (Bandyopadhyay et al., 2005). 
 
Furthermore, defects at the post-receptor level in the insulin signalling pathway have been linked to 
a large number of disease associated conditions related to the development of insulin resistance. 
For example, polycystic ovarian syndrome (PCOS), a metabolic and a reproductive disorder, has 
been reported to confer a significant increased risk for T2DM associated with IR, independent of 
obesity (Diamanti-Kandarakis & Dunaif, 2012). The major defect in the insulin action reported was 
possibly caused by serine phosphorylation of the INSR and IRS1, an early stage of insulin 
transduction present in both adipocytes and skeletal muscle (Dunaif et al., 2001; Ciaraldi et al., 
1992; Diamanti-Kandarakis & Dunaif, 2012). Apart from the defects in the insulin signalling 
pathway, mitochondrial dysfunction was also suggested as a possible contributor to IR in PCOS 
skeletal muscle (Diamanti-Kandarakis & Dunaif, 2012). 
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1.5 LIFESTYLE RISK FACTORS 
The modifiable lifestyle factors that affect IR include physical activity and diet. Studies show 
physical activity may reduce body weight, increase FFA oxidation in skeletal muscle and may 
thereby contribute to a lower risk of IR associated with obesity (Balkau et al., 2008; Malin & 
Kirwan, 2012; Hellgren et al., 2014). The influence of dietary fat composition on the development 
of IR in humans show that high-fat diets can lead to changes in adiposity, insulin sensitivity (IS) 
and mitochondrial dysfunction (Coelho et al., 2011). An excess of calories leads to 
hyperinsulinaemia, which increases the expression of the SREBP-1c in the beta cells, resulting in 
lipogenesis and obesity (Unger & Scherer, 2010; Coelho et al., 2011). 
 
The non-modifiable factors identified that affect IR are ethnicity, gender and age. Population 
studies have shown non-Caucasians are more IR than Caucasians (Svec et al., 1992; Harris, 1990; 
Haffner et al., 1997; Chandalia et al., 1999; Kasim-Karakas, 2000; Wild et al., 2004). The highest 
rates of T2DM are found among Native Americans, with a high incidence of IR in the Pima Indians 
from Arizona in the United States and in natives of the South Pacific islands, such as the Nauru 
(Knowler et al., 1978; Wild et al., 2004). A high prevalence of T2DM is also seen to be more 
predominant in Hispanic and African-American populations than in Caucasians and reported to be 
associated with a higher incidence of insulin resistance (Svec et al., 1992; Kasim-Karakas, 2000; 
Stefan et al., 2004). 
 
Gender differences in body composition show that men have higher visceral adiposity associated 
with IR risk factors, such as elevated FFA levels and insulin secretion (Couillard et al., 1999), 
whilst women have peripheral fat distribution associated with improved IS, compared with central 
adiposity (Snijder et al., 2003). Oestrogen has a favourable effect on insulin and glucose 
homeostasis (Louet et al., 2004), adipose tissue distribution and pro-inflammatory markers (Dantas 
& Sandberg, 2005). However, lack of oestrogen synthesis in men is associated with insulin 
resistance (Smith et al., 1995). A high prevalence of IR in ageing people and was found to 
contribute to increased risk of diabetes, mainly due to increased visceral adiposity, imbalance of 
sex hormones and lack of physical activity (Gabriely et al., 2002; Sakurai et al., 2010). 
 
1.6 ESTIMATION OF INSULIN RESISTANCE/SENSITIVITY 
The gold standard for the estimation of IR is the hyperinsulinaemic euglycaemic clamp (HEC) 
technique, a reference method for the direct quantification of insulin sensitivity. The alternative 
method is the minimal model analysis of frequently sampled intravenous glucose tolerance 
(DeFronzo et al., 1979; Bergman et al., 1979; Muniyappa et al., 2008). In the HEC technique, 
insulin is infused to achieve steady-state conditions for plasma insulin, blood glucose and the 
glucose infusion rate (DeFronzo et al., 1979). The several rates of insulin infusion allow the 
Stellenbosch University  https://scholar.sun.ac.za
 9 
 
establishment of a relationship between the whole body glucose disposal and plasma insulin levels. 
This enables the discrimination between the states of decreased IR and/or the altered maximal 
capacity to dispose of glucose (Robert, 1995). The glucose measurements taken under clamp 
conditions are used to assess whether hepatic glucose is suppressed, thus enabling the 
differentiation between hepatic and peripheral insulin resistance. However, this technique has been 
found to be cumbersome and only applicable to a small number of subjects within research centres, 
which limits its usefulness in large epidemiology studies (Muniyappa et al., 2008). 
 
There are several non-invasive alternatives to the HEC technique, among which the oral glucose 
tolerance test (OGTT) has been used to diagnose glucose tolerance and type 2 diabetes mellitus. 
The OGTT reflects the efficiency of the body to dispose of glucose after an oral glucose load or 
meal, with multiple measures of glucose and insulin being obtained at different intervals. Several 
surrogate markers are derived from this indirect quantification method for insulin sensitivity 
(Muniyappa et al., 2008; Borai et al., 2011). These surrogate markers are based on dynamic tests, 
taking into account both the fasting steady-state conditions and the postload glucose and insulin 
levels. The estimation of IS with OGTT correlates well with the clamp technique (Matsuda & 
DeFronzo, 1999; Hanley et al., 2003). 
 
Currently, simpler indices such as the homeostasis model assessment insulin resistance (HOMA-
IR), homeostasis model assessment of functional beta-cells (HOMA-β%) (Matthews et al., 1985) 
and the quantitative insulin sensitivity check index (QUICKI) (Katz et al., 2000) are used in most 
studies for IR assessment (Borai et al., 2009; Antuna-Puente et al., 2011). These OGTT-derived 
indices mimic the physiological response of the postload glucose-insulin interaction and are 
estimated from a fasting blood sample that is taken following an oral glucose load (Borai et al., 
2011). The HOMA-IR index is regarded as a simple, inexpensive and reliable surrogate measure of 
IR that has been validated against the HEC technique and found to reflect more hepatic than 
peripheral IR, whereas the HOMA-β% is a much less robust estimate of beta cell function (Wallace 
et al., 2004; Boyko & Jensen, 2007; McAuley et al., 2007; Buchanan et al., 2010). The QUICKI 
index is very similar to HOMA-IR but is based on the logarithms and reciprocal of the fasting 
glucose-insulin product. Results of this index showed greater accuracy than HOMA-IR over a 
broad range of IS, and it was found to have a stronger correlation with the HEC technique (Katz et 
al., 2000; Yokoyama et al., 2004). These indices have since been upgraded and modified by 
including additional parameters into the formulae. For example, the substitution of the fasting  
C-peptide for insulin in the HOMA-IR formula can be used for subjects with diabetes that are 
insulin treated (Li et al., 2004). The addition of a fasting non-esterified fatty acid concentration into 
the QUICKI formula has been reported to improve the assessment of IR through better correlation 
with the clamp-based index of insulin sensitivity (Ijzerman et al., 2009). 
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Several population studies have since validated these simple, inexpensive surrogate markers and 
highlighted important limitations that should be taken into account when they are used in large 
epidemiologic studies (Borai et al., 2007; Borai et al., 2011). Furthermore, studies in biochemical 
markers with insulin regulated proteins found them to be more reliable markers of IR than fasting 
insulin levels (Birkeland et al., 1993; Maddux et al., 2006; Borai et al., 2011). For example, the 
ratios of biochemical markers such as leptin/adiponectin and triglycerides (TG) / high density 
lipoprotein cholesterol (HDL-c) are shown to be useful markers of insulin resistance (Oda et al., 
2008; Roa et al., 2009; Finucane et al., 2009). To ensure reliability, it is suggested that a 
combination of biomarkers and other parameters, such as the anthropometric measurements of age, 
gender and ethnicity, be used to estimate insulin resistance (Borai et al., 2011). 
 
1.7 DISEASE CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE AND 
CARDIOVASCULAR DISEASE 
Over the years, several studies have identified obesity as a major risk factor for the development of 
IR, T2DM, MetS and CVD, thereby providing evidence that these conditions may all be 
interwoven. 
 
1.7.1 Obesity induced insulin resistance 
Obesity-associated risk factors that may induce IR include the following: (1) hyperinsulinaemia 
and FFAs; (2) inflammation; and (3) fat distribution. 
 
1.7.1.1 Hyperinsulinaemia and free fatty acids 
Defects in the insulin signalling pathway cause IR, which in turn, increases secretion of insulin 
(hyperinsulinaemia) (Boden, 2005; Moller & Kaufman, 2005; Reviewed by Ye, 2013). The 
dysfunction in adipose tissue of insulin action leads to an increase in lipolysis (hyperlipidaemia), 
resulting in elevated free fatty acids (Wajchenberg, 2000; Garg, 2004; DeFronzo, 2004). Higher 
lipolysis activity in visceral adiposity seems to be primarily responsible for the excessive IR-related 
FFA flux to the liver and skeletal muscle (DeFronzo, 2004; Kovacs & Stumvoll, 2005). In the 
muscle, increased FFAs are found to promote fatty acid oxidation, leading to accumulated glucose-
6-phosphate and intramyocellular triglyceride storage, with a decrease in glucose uptake (Randle et 
al., 1963). 
 
Further studies concerning the mechanism by which increased FFAs induce IR in muscle showed 
that this inhibition of glucose transport activity seems to be linked to the decreased IRS1 associated 
with PI 3-kinase activity (Cline et al., 1999; Dresner et al., 1999; Shulman, 1999). The PI 3-kinase 
is an important enzyme involved in the translocation of glucose transporter proteins, glycogen, 
lipid and protein synthesis, as well as anti-lipolysis and control of hepatic gluconeogenesis (Wilden 
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et al., 1992; Shepherd et al., 1996; White, 1998; Rhodes & White, 2002). Furthermore, FFAs are 
involved with hepatic autoregulation in the liver, in which FFAs stimulate gluconeogenesis but not 
hepatic glucose production. However, defects in hepatic autoregulation due to increased FFA flux 
leads to increased hepatic glucose production, which results in the decrease of glycogen storage in 
the liver (Boden, 2001; Lam et al., 2003). In addition, insulin secretion is altered in response to the 
increased FFAs, and this obstructs insulin suppression of glycogenolysis, thereby interfering with 
the glucose-stimulated insulin secretion (Boden, 2001; Lam et al., 2003; Delarue & Magnan, 2007). 
 
Free fatty acids are also known to cause defects in insulin signalling through interference via 
protein kinase C-induced serine phosphorylation of IRS1 (Yu et al., 2002). This causes significant 
functional alterations that could have adverse effects on glucose transport (Pessin & Saltiel, 2000; 
Chavez et al., 2003; Bhattacharya et al., 2007). Evidence indicates that FFAs may be involved in 
diabetes and obesity by mediating insulin resistance (Randle et al., 1963; Boden, 1997; Shulman, 
1999; Boden & Shulman, 2002; Kovacs & Stumvoll, 2005; Delarue & Magnan, 2007). 
 
1.7.1.2 Inflammation  
During the inflammatory response in adipose tissue, adipocytes increase the secretion of  
pro-inflammatory cytokines, causing systemic inflammation (Reviewed by Coppack, 2001; Ye, 
2013). Adiponectin, TNFα and leptin have been associated with obesity and insulin resistance. It is 
suggested that of these, adiponectin is a stronger marker for both IR and the risk of T2DM by 
contributing to both IS and glucose homeostasis (Lawlor et al., 2005). Significantly higher 
adiponectin levels were observed in females, possibly due to the inhibitory effect of androgens on 
adiponectin (Nishizawa et al., 2002), higher visceral adiposity in females (Couillard et al., 1999) or 
lower IS found in males (Geer & Shen, 2009). These differences may contribute to a more insulin-
sensitive environment in females than in males (Geer & Shen, 2009). Furthermore, genetically 
determined levels of adiponectin were also found to influence IS in the development of IR and 
diabetes, independent of adiposity (Gao et al., 2013). 
 
TNFα was the first cytokine associated with the pathogenesis of obesity and insulin resistance. The 
increased expression of TNFα was positively correlated with adiposity and insulin resistance 
(Hotamisligil et al., 1993; Hotamisligil & Spiegelman, 1994; Ryden et al., 2002; Ruan & Londish, 
2003). The TNFα produced by the macrophages that infiltrate adipose tissue is highlighted as a 
major link between inflammation and insulin resistance (Sanshiro et al., 2013). This cytokine 
activates pro-inflammatory signal cascades that inhibit the INSR signalling through serine 
phosphorylation of IRS1, thereby reducing the GLUT4 gene expression (Weisberg et al., 2003).  
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Other cytokines associated with obesity-induced IR and inflammation include interleukin-6 (IL-6) 
(Kim et al., 2009), plasminogen activator inhibitor-1 (PAI-1) (Alessi et al., 2007), retinol-binding 
protein 4 (RBP4) (Yang et al., 2005) and resistin (Bajaj et al., 2004). 
 
Leptin was found to be significantly higher in obese women and strongly correlated with IR, 
despite adjusting for body mass index (BMI) and gender (Silha et al., 2003). Higher leptin 
concentraion was also reported in females compared with males, associated with larger adipocytes 
and with subcutaneous fat (Garaulet et al., 2000). Gender differences in the concentration of leptin 
may be due to oestrogen (Garaulet et al., 2000). An increase in body fat mass has also been linked 
to leptin and IR (Cnop et al., 2002), but others reported an independent relationship with body fat 
mass (Appleton et al., 2002; Fischer et al., 2002). 
 
Inflammation was also found to inhibit insulin signalling activity in adipocytes and hepatocytes, 
while the insulin action in muscle was unaffected (White, 2002; Ye, 2011). Several mechanisms 
involving two pathways were proposed to explain this interference in insulin signalling, where 
signalling molecules in the inflammatory pathways such as IkB∞ kinase β (IKKβ) and JNK 1 were 
found to be activated in adipose tissue and the liver. The serine kinase isoform IKKβ was found to 
inhibit insulin signalling by phosphorylation of IRS1 at multiple serine residues in adipocytes (Gao 
et al., 2002), and the activity of JNK involved in the pathogenesis of IR by phosphorylation of IRS1 
in humans inhibited the signalling pathway in response to tumour necrosis factor alpha (Aguirre et 
al., 2000). 
 
1.7.1.3 The role of fat distribution 
Over the last 25 years, a large number of studies investigated the association of body fat 
distribution and metabolism in obesity with IR and diabetes (Tchernof & Després, 2013). Adiposity 
measurements are usually defined in terms of BMI, waist circumference (WC) and the region of fat 
distribution in terms of visceral adiposity (VAT) or central / intra-abdominal and subcutaneous 
adiposity (SAT) (Kahn & Flier, 2000). Both VAT and SAT release elevated FFAs into the 
circulation with adverse effects, which include the inhibition of insulin-stimulated glucose uptake, 
glycogen synthesis and glucose oxidation (Boden, 2001). The VAT is metabolically more active 
than SAT with regard to the increased FFA flux. The increased FFAs promote IR at a cellular level 
by an increased production of hepatic very low-density lipoprotein (Giorgino et al., 2005).  
 
Furthermore, VAT is linked with ED and the production of significantly higher levels of 
proinflammatory cytokines compared with subcutaneous adiposity. These pro-inflammatory 
cytokines include C-reactive protein (CRP), IL-6 and PAI-1, which could possibly explain the 
stronger association of VAT with insulin resistance (Hashimoto et al., 1998; Lemieux et al., 2001; 
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Kershaw & Flier, 2004; Preis et al., 2010). Differences in the cytokine secretion profiles were also 
reported between the SAT and visceral adiposity. The SAT was found to release increased leptin 
levels, whereas VAT mainly releases TNFα, which in turn influenced the secretion of adiponectin 
(Ouchi et al., 2003; Reviewed by Fain, 2010). The inverse association between VAT and 
adiponectin levels was reported to be of higher significance than the association between SAT and 
adiponectin (Kershaw & Flier, 2004; Kwon et al., 2005; Lawlor et al., 2005). Low levels of 
adiponectin, higher leptin levels and low-grade inflammation generally observed in obesity have 
been associated with IR and metabolic syndrome (Matsuzawa et al., 2004). 
 
1.7.2 Insulin resistance, type 2 diabetes mellitus, metabolic syndrome and cardiovascular 
disease 
 
1.7.2.1 Type 2 diabetes mellitus 
An abundance of pathways leads to IR, in which the combination of IR and hyperinsulinaemia 
provoke multiple associated diseases. Among these, the progression of T2DM, MetS and CVD 
have shown significant adverse health effects. The association of obesity and T2DM has been well 
studied, with obesity being the major promoter of insulin resistance (Kahn & Flier, 2000). The 
association between obesity and IR is a key feature of most individuals with T2DM, which results 
in the reduced response of the insulin-sensitive tissue to insulin; thereby contributing to the lower 
IS (Hossain et al., 2007). Thus, the obesity-induced IR fuels the development of T2DM, in which 
beta cell dysfunction and inadequate insulin secretion cause elevated fasting blood glucose levels 
(hyperglycaemia), possibly resulting in glucotoxity (Garvey et al., 1985; Kahn et al., 2006). Insulin 
resistance is established as a strong link between T2DM and CVD. Insulin resistance accompanied 
with ED in T2DM patients, worsens the state of subclinical CVD/atherosclerosis, which is a major 
cause of mortality in diabetic individuals (Ikmal et al., 2013). Furthermore, with the increased 
obesity and MetS prevalence rates, CVD mortality and morbidity are expected to increase further, 
posing a greater burden on public health care systems (Go As et al., 2013). 
 
1.7.2.2 Metabolic syndrome  
Metabolic syndrome comprises a cluster of risk factors of metabolic origin, including: 
hyperglycaemia, obesity, dyslipidaemia and hypertension. Insulin resistance has been identified as 
a key factor in the development of the obesity, dyslipidaemia and hypertension associated with 
metabolic syndrome (Reaven, 1995, Reaven, 2012, Metabolic Syndrome Clinical Key, 2013). The 
atherogenic lipoprotein profile of IR/hyperinsulineamia includes the presence of smaller, denser 
very low density lipoproteins that initiate lipoprotein changes resulting in increased levels of 
remnant particles, small low density lipoproteins and low HDL-c, all defined as risk factors for 
cardiovascular  diseases (Reaven, 2005, Reaven 2012). Although not all cases of IR develop 
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T2DM, most share some of the cluster of characteristics of MetS and this increases their risk of 
cardiovascular diseases (Reaven, 2012). Obesity, especially central adiposity, promotes IR that 
mediates all the metabolic disturbances associated with MetS and insulin resistance.  
Cardiovascular disease morbidity in the obese and overweight T2DM subjects has often been 
ascribed to metabolic syndrome (Reaven, 2005; Després et al., 2008; Metabolic Syndrome Clinical 
Key, 2013). This is supported by evidence that showed MetS to confer a 5-fold increased risk of 
T2DM and a 2-fold increased risk of CVD over a five to ten year period (Alberti et al., 2009). 
 
1.7.2.3 Cardiovascular disease  
Insulin resistance and CVD share many characteristics, including dyslipidaemia, hypertension and 
hyperglycaemia. Insulin resistance promotes the development of a highly atherogenic lipid profile 
with high TG and low HDL-c and is associated with both diabetes mellitus and cardiovascular 
diseases (Pansuria et al., 2012). The changing lipid profile associated with IR, referred to as 
dyslipidaemia, is initiated by increased FFAs due to the defective uptake by adipocytes and leads to 
increased hydrolysis of tryglycerides (Ginsberg, 2000; Boden & Shulman, 2002). Furthermore, IR 
facilitates the development of hypertension via increased reabsorption of sodium and water by 
kidney tubule cells, resulting in volume-retention with increased sympathetic stimulation and renin-
angiotensin activity (Berne et al., 1992; Galletti et al., 1997; Furuhashi et al., 2004; Lamounier-
Zepter et al., 2006). Hypertension is strongly associated with two major risk factors for CVD, 
namely arterial stiffness and left ventricular dysfunction referred to as vascular ED, and may lead 
to atherogenesis (Vlachopoulos & O'Rourke, 2000; Hsueh & Quiñones, 2003; Crichton et al., 
2014).  
 
Lastly, IR leads to hyperglycaemia in which changes in the glycaemic status can alter lipoprotein 
and lipid flux that in can in turn modulate IS and glucose disposal. Hyperglycaemia may also 
directly affect inflammation, IS, altered carbohydrates and lipid metabolism in the liver, which may 
add to vessel injury (Mazzone et al., 2008). Multiple risk factors that contribute to the development 
of IR, e.g. dyslipidaemia and hyperglycaemia, have also been found to contribute to endothelial 
dysfunction. The progression of IR to T2DM is similar to the progression of ED to atherosclerosis 
(Reviewed by Pansuria et al., 2012; Ikmal et al., 2013). 
 
Over the years it has become clear that IR and ED play a central role in the pathogenesis of 
atherosclerosis. Atherosclerosis is a disease of arterial lipid deposition characterised by a defined 
series of changes in the vessel wall during atherogenesis referred to as endothelial dysfunction 
(Radar & Daugherty, 2008). During early onset of the atherogenic process changes in the 
endothelial cell phenotype impairs the release of nitric oxide (NO), which has multiple vascular 
protective actions (Hsueh et al., 2003). This occurs through reduced biosynthesis of NO and 
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increased degradation of oxidative stress. In addition, insulin has also been shown to be involved in 
vascular actions through stimulation of the production of NO by the endothelium, leading to 
vasodilation for increased blood flow and glucose disposal in skeletal muscle (Baron & Clark, 
1997; Vincent et al., 2004). 
 
During the early stages of atherosclerosis impaired insulin signalling also occurs within various 
pathways in the macrophages and endothelial and vascular smooth cells (Bornfeldt & Tabas, 2011). 
Altered insulin signalling in endothelial cells results in the development of ED, which has been 
highlighted as an important mechanism contributing to progressive atherosclerosis, along with the 
pro-inflammatory state induced by IR (Aziz & Wheatcroft, 2011). Furthermore, in IR the alteration 
in insulin signalling PI 3-kinase pathways result in imbalances between NO production and 
secretion of vasoconstrictor endothelin-1 (ET-1), both of which contribute to a pro-atherogenic 
effect (Muniyappa, 2013, Ikmal et al., 2013). The inhibition of the anti-atherogenic PI 3-kinase 
mediated insulin receptor-signalling pathway and over activity of the pro-atherogenic MAP kinase 
pathway in IR states lead to accelerated atherosclerosis (Bansilal et al., 2007). Insulin resistance is 
also characterised by hyperinsulineamia; increased FFA, TG and LDL and decreased HDL-c levels; 
NO deficiency; and release of various pro-inflammatory cytokines leading to inflammation. All of 
the latter further worsen ED and contribute to atherosclerosis (Crosio & DeFronzo, 2006; Ikmal et 
al., 2013; Muniyappa, 2013). 
 
1.8 ASSESSMENT OF SUBCLINICAL ATHEROSCLEROSIS 
Nitric oxide deficiency result in ED which is one of the early events in atherogenesis referred to as 
subclinical atherosclerosis and precedes the development of plaques resulting in the stiffening, 
hardening and eventual occlusion of the arteries (Celermajer et al., 1992; Balasubramanian et al., 
2012; Ikmal et al., 2013; Muniyappa, 2013). The different stages of atherosclerosis have been 
assessed using several non-invasive methods. The most common of these is B-mode ultrasound 
used to assess brachial artery flow-mediated dilation (FMD), carotid intima media thickness 
(CIMT) and carotid plaques. 
 
The FMD measurement evaluates the function of the endothelium in the brachial artery. The 
endothelium controls vascular function and structure by the production and release of nitric oxide. 
This technique measures the ability of the arteries to respond with endothelial NO release during 
reactive hyperaemia (flow-mediated) after a 5-minute occlusion of the brachial artery with a blood 
pressure cuff. Abnormal values represent ED (Celermajer et al., 1992; Patti et al., 2005). Impaired 
FMD is predisposing to atherosclerosis and CVD and is a significant predictor of target organ 
damage after adjustment for several known risk factors (Patti et al., 2005; Yang et al., 2014). 
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The CIMT refers to the structural anatomical thickness of the arterial wall and is a valuable marker 
in screening for subclinical atherosclerosis (Pignoli et al., 1986). This method provides a graded 
measure of vascular damage obtained by measurements of the common carotid arteries with a  
B-mode image composed of two parallel echogenic lines separated by a hypoechoic space. The 
distance between the two lines, i.e. the B-mode image of the intimal and medial thicknesses, are 
measured and then correlated with the thickness of different combinations of tunicae evaluated by 
gross and microscopic examination (Pignoli et al., 1986; Bertoni et al., 2007). Increased CIMT is 
associated with CVD and is an independent predictor of future clinical events such as myocardial 
infarction and stroke (Cobble & Bale, 2010). Large clinical studies have also shown that CIMT 
predicts CVD risk which includes the Kuoppio Ischaemic Heart Disease Study (Salonen & 
Salonen, 1991), the Cardiovascular Health Study (O’Leary et al., 1992), the Rotterdam Study (Bots 
et al., 1997), the Atherosclerosis Risk in Communities Study (Chambless et al., 1997), the Malmo 
Diet and Cancer Study (Rosvall et al., 2005) and the Carotid Atherosclerosis Progression Study 
(Lorenz et al., 2010). 
 
In the advanced stages of atherosclerosis appearance of carotid plaques and progression to 
calcification leads to atrial wall injury. The carotid plaques are focal lesions containing lipids and 
fibrous tissue in the arterial wall that either partially or completely obstructs the lumen, particularly 
in areas with a severely thickened arterial wall. The presence of calcium in the vessel wall is 
measured by the coronary artery calcification (CAC) score that is determined by electron beam or 
multi-slice computed tomography (Agatston et al., 1990; Frink et al., 1970). In a systematic review 
by Peters et al. (2012) it was concluded that CAC scoring improved stratification of CVD risk 
categories when added to traditional risk factors (Peters et al., 2012). 
 
In addition to these techniques two newer tests have been developed namely, echo particle image 
velocimetry (EPIV) and magnetic resonance imaging (MRI) velocimetry. The EPIV technique is 
used in measurements of shear wall stress through vector analysis of the blood velocities on the 
wall at the carotid bifurcation. Change in the shear wall stress is considered a causative factor in 
atherosclerosis and possible rupture of focal lesions (Taxon, 1995; Shaaban & Duerinckx, 2000). 
EPIV analysis a range of parameters namely: vascular speed profile, velocity vector, speeds maps 
and haemodynamic blood flow to the wall shear stress (DeMarchi & White, 2012; Castellon & 
Bogdanova, 2013). Magnetic resonance imaging velocimetry on the other hand assesses changes in 
the carotid wall thickness by parameters of the velocity profile, shear rate and the general flow 
stress of the wall. The MRI velocimetry technique is more sensitive and reliable than echo particle 
image velocimetry (Castellon & Bogdanova, 2013). 
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1.9 EPIDEMIOLOGY OF INSULIN RESISTANCE AND TYPE 2 DIABETES MELLITUS 
Insulin resistance is a common pathophysiological trait that covers a broad clinical spectrum, in 
which the decreased ability of insulin to perform its biological functions represent the primary 
physiological defect underlying a constellation of traits, commonly referred to as IR Syndrome 
(IRS)/Syndrome X /MetS. These traits include IR/hyperinsulinaemia, glucose intolerance, visceral 
obesity, dyslipidaemia, hypertension and increased prothrombic and anti-fibrinolytic states 
(National Cholesterol Education Program, 2002). There is no known global prevalence rate for 
insulin resistance. 
 
However, an overview of the worldwide and South African prevalence rates of obesity and T2DM 
are briefly discussed because of the pivotal role IR plays in the development of these metabolic 
states. The IR status in humans is associated with the global increase in obesity, which is driven by 
environmental changes in diet and physical activity, including a substantial genetic influence 
leading to the development of common metabolic disorders such as T2DM and cardiovascular 
diseases (World Health Organization (WHO), 2004). 
 
1.9.1 Global prevalence of obesity and type 2 diabetes mellitus 
Obesity is currently emerging as a global epidemic, affecting more than 200 million men and 
almost 300 million women worldwide, accounting for 10% of the adult population (WHO, 2013). 
In developing countries, the epidemic of obesity over the last few decades has been the driving 
force leading to an increased prevalence of IR, MetS and T2DM that is predicted to increase the 
risk of developing atherosclerosis. In 2010, it was estimated that worldwide, 285 million (6,4%) 
individuals between the ages of 20 to79 years had been diagnosed with T2DM, with an expected 
rise to 552 million (9,9%) diabetics by 2030  (Shaw et al., 2010; Whiting et al., 2011). According 
to the International Diabetes Federation (IDF), estimates for 2013 showed a substantial increase 
from their 2010 predictions, with 382 million adults (8,3%) reportedly diagnosed with diabetes. 
The majority of these individuals were aged between 40 and 59 years, and 80% of them lived in 
low- and middle-income countries. However, the burden of disease is not only measured by the 
number of people with diabetes but is also based on the increasing number of deaths caused by the 
disease. In 2013, about half the deaths in adults were related to diabetes, with most under the age of 
60 years, whilst in developing countries such as Sub-Saharan Africa, the proportion was reported to 
be as high as 75% (IDF, 2013). 
 
In the African region, it is estimated that 19,8 million people have diabetes, of which at least 64% 
are undiagnosed cases. Diabetes-related deaths for 2013 have been reported to be as high as 522 
600 (IDF, 2013). This rapid increase in diabetes is linked to an increase in lifestyle-related, non-
communicable diseases, especially the rising obesity prevalence in urbanised African populations 
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(IDF, 2013). Important changes in lifestyle as a result of the rapid urbanisation of African 
populations include smoking, drinking, urban poverty and dietary changes, in which the traditional 
high-carbohydrate / low-fat diet has been replaced by a high-fat / high-carbohydrate Western diet 
(MacIntyre et al., 2002). In Sub-Saharan African populations, obesity has also been identified as a 
major risk factor that predisposes to diabetes (Wilkinson et al., 2005). The increase in the 
prevalence of T2DM is closely linked to the rise in obesity, with about 90% of diabetes cases being 
attributed to excess weight (Bos & Agyemang, 2013; MacIntyre et al., 2002; Voster, 2002). Insulin 
resistance-associated diseases are increasing worldwide, with developing countries in Africa 
following a similar trend but with variations reported between ethnic populations, mainly due to 
genetic and environmental differences (Reimann et al., 2007). 
 
1.9.2 South African prevalence of obesity and type 2 diabetes mellitus 
The highest rate of obesity among adults in Sub-Saharan Africa is found in South Africa. Reports 
for 1998 showed the overall prevalence of overweight and obesity to be 29% in males and 56% in 
females (Goedecke et al., 1998), while current reports show a substantial increase in obesity, with 
rates of 39% reported in males and 69,3% in females (Ng et al., 2014). Overall prevalence rates of 
overweight and obesity according to ethnicity are available from an earlier study (Puoane et al., 
2002), while more recent data for ethnic groups are available for obesity only. Puoane et al. (2002) 
demonstrated the highest prevalence of overweight and obesity in black females (58,5%), followed 
by females of mixed-ancestry (52%), white females (49,2%) and Indian females (48,9%). 
According to a recent survey by the South African Medical Research Council, 33% of black 
females and 25% of coloured, white and Indian females over the age of 35 years were reported to 
be obese (overweight not included) In contrast, the survey reported the highest prevalence of 
obesity (overweight not included) in white males (18%), followed by Indian males (9%), coloured 
males (8%) and black males (6%) (Self-Medication Association of South Africa (SMASA), 2013). 
 
Global estimates of the incidence of diabetes are based on risk factors, in which obesity in 
particular is identified as a major risk factor (Barnes, 2011). In South Africa, rapid changes in the 
structure of diet, physical activities and obesity patterns in urban areas have had a great impact on 
the prevalence of disease risk related to obesity and diabetes (Reviewed by Vorster et al., 2002). In 
2000, diabetes was ranked among the top ten leading causes of death in South Africa, with a 
prevalence rate of 5,5% for individuals over 30 years old, accounting for 4,3% of deaths and a total 
of 258 000 disability-adjusted life years (DALY). One DALY represents the loss of the equivalent 
of one year of full health (Bradshaw et al., 2007). Recent reports from the IDF Diabetes Atlas 
(2013) showed an increase in prevalence to 8,3% (Guariguata et al., 2014). 
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The prevalence of T2DM in the South African mixed-ancestry (coloured) population has increased 
from 10,8% in 1999 (Levitt et al., 1999) to 26,3% in 2012 (Erasmus et al., 2012). Early 
epidemiological studies investigating diabetes in black South Africans reported lower prevalence 
rates for this group than for the mixed-ancestry population, with rates varying between 0,02% to 
1,3% (Seftel & Abrahams, 1960; Jackson, 1972). However, later studies using the WHO 1985 
criteria showed an increased prevalence rate for black South Africans ranging from 4% to 8% 
(Levitt et al., 1993; Omar et al., 1993; Mollentze et al., 1995). More recent studies reported 
prevalence rates according to urban and rural areas. In a study by Erasmus et al. (2001) the 
prevalence of diabetes was 4,5 % with the highest incidence of diabetes observed in the age group 
from 40-59 years in peri-urban Xhosa speaking factory workers from Transkei, South Africa. 
Motala et al. (2008) reported 3,9% overall prevalence of diabetes in rural black Africans, 3,5% in 
males and 3,9% in females, with a marked increase (8,8%, not age adjusted) in the age group 55 to 
65 years (Motala et al., 2008). Peer et al. (2012) reported an increased prevalence (13,1%) and also 
a higher peak age (65 to 74 years) in black Africans in an urban setting. The high rate of diabetes 
was attributed to the raised adiposity that was present in ≥ 50% of the total study sample and in 
over 80% of the participants with diabetes (Peer et al., 2012). Following the trend of Sub-Saharan 
African countries, the burden of diabetes is expected to increase even further due to the high rates 
of IGT and the extremely high rates of obesity observed in the black and mixed-ancestry 
populations in South Africa. 
 
Evidence from earlier population based epidemiological studies reported a relatively high 
occurrence of IR and T2DM in black South African women (Levitt et al., 1993; Van der Merwe et 
al., 2000). Van der Merwe et al. (2000) demonstrated a higher degree of IR in black, obese females 
than in white, obese females, even though black females had less VAT. Similar SAT levels were 
found in both groups (sample size N = 20). However, the centralisation of fat still conferred risk 
(Jennings et al., 2009). Jennings et al. (2009) demonstrated that VAT, as measured by WC, was a 
better predictor of HOMA-IR than the IDF or ATP III metabolic syndrome criteria. 
 
1.10 GENETICS OF INSULIN RESISTANCE 
Insulin resistance and pancreatic beta cell dysfunction are the two major diabetes-related 
phenotypes influenced by genetic and environmental factors. However, most of the T2DM 
susceptibility loci are linked to insulin secretion rather than IR (Imamura & Maeda, 2011). The 
GWAS carried out primarily in individuals of European descent have been identified about 40 
susceptibility loci for T2DM by 2010 (Dupuis et al., 2010; Voight et al., 2010; Brunetti et al., 
2014). The numbers of new loci being discovered are continuously increasing with genetic studies 
currently identifying more than 65 genetic variants that increase the risk of T2DM by 10 - 30% 
(Ayub et al., 2014; Morris et al., 2012). Of these the majority are directly linked to pancreatic beta 
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cell dysfunction, with only a few directly mapped to insulin resistance (Scott et al., 2007; Zeggini 
& McCarthy, 2007; Sladek et al., 2007; Zeggini et al., 2008; Imamura & Maeda, 2011). The 
paucity of IR genes found through GWAS could possibly be explained by several reasons. The 
lower heritability of IR traits that indicates a stronger influence of environmental covariates, 
ascertainment criteria may impose constrains around the IR measurues that result variance, the 
measures of IS in large epidiomology studies may be poorly correlated with IR at tissue or 
molecular level, variants that affect IR may be less frequent and have more modest effect sizes 
(Florez et al., 2008). 
 
In addition, T2DM risk alleles at three loci, namely peroxisome proliferator-activated receptor 
(PPARG), fat mass and obesity-associated (FTO) and Krüppel-like factor 14 (KLF14) genes have 
also been associated with higher fasting insulin and reduced IS (Voight et al., 2010). There also 
appears to be an overlap with the obesity, IR and T2DM loci. For example, the FTO gene (Scuteri 
et al., 2007) was first identified as a T2DM susceptibility locus (Scott et al., 2007; Zeggini & 
McCarthy, 2007), with other studies that showed a strong association between the FTO variants 
and T2DM, mostly mediated by an increase in body weight with varying degrees of association 
with insulin resistance (Frayling et al., 2007; Omori et al., 2008). 
 
Recently the importance of T2DM loci, well known in other populations, has been investigated in 
Africans. Of these loci the role of candidate genes transcription factor 7-like 2 (TCF7L2), PPARG, 
potassium inwardly-rectifying channel J11 (KCNJ11), CAPN10 and several other GWA genes 
namely, potassium voltage-gated channel (KCNQ1), MLXIPL, SLC308, ENNP1 and IGF2BP2 
associations with T2DM and phenotypic traits were examined (Danquah et al., 2013; Turki et al., 
2012; Turki et al., 2013; Mtiraoui et al., 2012). The TCF7L2 gene is involved in insulin secretion 
and the most strongly associated with T2DM in Caucasians (Dupius et al., 2010) as well as in 
African Americans (Saxena et al., 2012), which was also confirmed in Ghanaians (Danquah et al., 
2013), Nigerians (Helgason et al., 2007) and Tunisians (Turki et al., 2013; Mtiraoui et al., 2012). 
However, the protective allele against T2DM of the PPARG gene (Sanexa et al., 2012) was rare in 
Ghanaians but absent in black South Africans from Zulu descent (Danquah et al., 2013; Pirie et al., 
2010). Similarly the risk-conferring alleles of KCNJ11 and CAPN10, which are both related to 
insulin secretion, were not significantly associated with T2DM in Ghanaians or black South 
Africans (Danquah et al., 2013; Pirie et al., 2010). Furthermore, in Tunisians no association with 
T2DM was found with KCNQ1, ENNP1, MLXIPL, IGF2BP2 and PPARG but KCNJ11 and 
SLC308 were associated with type 2 diabetes mellitus (Turki et al., 2012; Mtiraoui et al., 2012). 
 
The interest in this study is the IR loci of which the PPARG, IRS1, glucokinase (GCK), 
glucokinase (hexokinase 4) regulator (GCKR) and insulin-like growth factor 1 (IGF1) have already 
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been identified (Watanabe, 2010; Povel et al., 2012). In addition, a few other genes were also found 
to be associated with both T2DM and IR, namely the INSR, growth factor receptor-bound 14 
(GRB14), transcription elongation regulator 1-like (TCERG1L) and sterol regulatory element-
binding transcription factor 1 (SC4MOL) (Brunetti et al., 2014). These IR loci are briefly 
summarised below in Table 1.1: p 21. 
 
1.10.1 Common variants in the PPARG gene associated with insulin resistance 
The PPARG gene is a member of the super family of nuclear receptors involved in adipocyte 
differentiation (Evans et al., 2004). The PPARG form heterodimers with retinoid X receptors 
(RXRs) that bind to a complex of oligonucleotides containing peroxisome proliferator response 
elements and together with functional co-activators lead to an increase in the transcription of target 
genes (Mukherjee et al., 1987). Genetic studies have consistently demonstrated that common 
PPARG gene variants show profound phenotypic effects such as changes in the 
lipid profile in adipose tissue and insulin action, leading to human metabolic disease states, obesity, 
IR, T2DM and cardiovascular diseases (Gurnell, 2003; Heikkinen et al., 2007; Costa et al., 2009). 
 
Table 1.1 Genetic loci associated with insulin resistance 
 
Loci Disease(s)/Trait(s) Reference(s) 
PPARG 
 
Association with IS, IR and diabetes Altshuler et al., 2000 
Buzetti et al., 2004 
Lohmueller et al., 2003 
Ludovico et al., 2007 
Sanexa et al., 2012 
IRS1 Reduced IS 
Loss of IRS1 function  
Reduced HOMA-IR, high fasting insulin, reduced 
expression of IRS1 protein  
Decreased IS and increased insulin  
Adverse metabolic profile 
Marini et al., 2003 
Almind et al., 1996 
Marchetti et al., 2002 
Dupuis et al., 2010 
Rung et al., 2009 
Kilpelainen et al., 2013 
GCK Increased fasting and postprandial blood glucose  
Increased HOMA-IR  
Metabolic syndrome traits 
Rose et al, 2005 
Sparso et al., 2008 
GCKR Decreased fasting insulin, HOMA-IR and T2DM 
risk, higher TG and lower glucose levels  
Lower IS and increased C–peptide levels 
Decreased glucose levels, increased IS, reduced 
T2DM risk  
Impaired fasting reduced HOMA-IR, dyslipidaemia 
and modest reduced T2DM risk 
Orho-Melander et al., 2008 
Beer et al., 2009 
Ingelsson et al., 2010 
Orho-Melander et al., 2008 
Sparso et al., 2008 
IGF1 Associated with fasting insulin and HOM-IR, lower 
IS and T2DM 
 
Dupuis et al., 2010 
Ingelsson et al., 2010 
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INSR Reduced expression of both INSR protein and INSR 
mRNA levels 
Severe insulin resistance 
Type A syndrome of extreme insulin resistance 
Voight et al., 2010 
Raffan et al., 2011 
Alzahrani et al., 2012 
Moller et al., 1994 
Domínguez-García et al., 2014 
FTO Associated with obesity, T2DM, increase in body 
weight and higher fasting insulin  
Frayling et al., 2007 
Omori et al., 2008 
Voight et al., 2010 
KLF14 Primary effect on insulin action, associated with 
increased diabetes risk  
Voight et al., 2010 
Wang et al., 2014 
GRB14 Attenuate insulin action by inhibiting catalytic 
activity of INSR 
Béréziat et al., 2002 
TCERG1L Associated with increased risk of T2DM Positively 
associated with both fasting insulin and IR 
Chen et al., 2012 
SC4MOL Associated with fasting insulin and IR Chen et al., 2012 
 
 
1.10.1.1 PPARG domains 
There are three splice variants of the PPARG (also referred to as PPAR y) gene namely, PPAR y1, 
y2 and y3, which differ at their 5-prime ends and are each under the control of their own promoter. 
The splice variants, PPAR y1 and PPAR y2 are highly expressed in adipose tissue (Lohman et al., 
1998). The PPARG protein consists of several functional domains that are used to demonstrate how 
the different genetic variations impair PPAR y function (Chandra et al., 2008). The various single 
amino acid mutations (Table 1.2: p 23) are scattered in the following functional domains of the 
PPARG nuclear receptor: the ligand independent transcriptional activation function domain 1 
(AF1); the DNA binding domain (DBD); and a powerful ligand-binding domain (LBD) (Chandra 
et al., 2008). The DBD facilitates interaction with specific binding sites for peroxisome proliferator 
response elements (PPREs) in the target gene promoters, while the LBD mediates the 
heterodimerisation with RXR, which contains the ligand-dependent activation function domain 2 
(Chandra et al., 2008). 
 
1.10.1.2 PPARG gene: common variants 
The Pro12Ala variant occurs in the AF1 domain and can result in reduced transactivation ability 
and decreased binding affinity of PPARG y2 to PPRE on deoxyribonucleotides (DNA) (Deeb et al., 
1998; Masugi et al., 2000). Pro115Gln and the rare frame shift mutations, A553ΔAAAiT and 
C1984ΔAG are also in the same AF1 domain. The Pro115Gln variant affects the PPARG 
phosphorylation and activates PPARG (Ristow et al., 1998), whilst the frame shift mutations result 
in truncated proteins in the DNA binding domain. This further affects heterodimer formation and 
PPARG interaction with the target gene promoters (Savage et al., 2003; Knouff & Auwerx, 2004). 
Cys114Arg, Cys131Tyr and Cys162Trp are variants in the DBD of PPARG that encode proteins 
that are unable to bind to DNA and lack transactivation ability (Agostini et al., 2006). 
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Table 1.2 PPARG common variants associated with insulin resistance and diabetes 
Variant(s) Disease (s)/Trait(s) Reference(s) 
Pro12Ala Conflicting results of associations with 
IS, IR and T2DM 
Meta-analysis associated Pro12Ala 
variant as risk factor for T2DM 
Linkage disequilibrium with C1431T  
No protection from T2DM development 
Associated with lower insulin levels, 
lower BMI, higher IS and higher HDL-c 
levels 
Reduced weight gain and improved IS 
Increased BMI, especially in obese 
subjects 
Reduced lipolipase activity, leptin, 
adiponectin and resistin levels 
Increased leptin 
Decreased incidence of CVD 
Deeb et al., 1998 
 
Altshuler et al., 2000 
 
Willer et al., 2007  
Sladek et al., 2007  
Tonjes et al., 2006 
Zeggini & McCarthy, 2007 
Simón et al., 2002 
Schneider et al., 2002  
Radha et al., 2007 
Bidzińska-Speichert et al., 2005 
Doney et al., 2004 
Pro115Gln Severe IR in obese individuals Ristow et al. 1998 
Pro495Leu, 
Val290Met or V318M 
Partial lipodystrophy, dyslipidaemia, 
severe IR, T2DM, fatty liver and 
hypertension 
Barrosso et al., 1999 
Savage et al., 2003 
Pheu388Leu Partial lipodystrophy and dyslipidaemia Hegele et al., 2002 
His447His (silent) or 
C 1431T or C161T 
Increased BMI and fat mass 
Increased leptin and resistin levels 
Reduced risk of T2DM  
Costa et al., 2009 
Meirhaeghe et al., 1998 
Valve et al., 1999  
Haseeb et al., 2009  
Tai et al., 2004 
Morris et al., 2012 
Arg425Cys, Arg397Cys Partial lipodystrophy, T2DM Agarwal & Garg, 2002 
A-14G 
C-681G 
C689T 
Partial familial lipodystrophy, IR and 
MetS 
Increased low density lipoprotein (LDL) 
Increased BMI 
Al-Shali et al., 2004 
Meirhaeghe et al., 2003 
Meirhaeghe et al., 2005 
A553ΔAAAiT 
C1984ΔAG 
Hyperinsulinaemia, hypertension, 
T2DM, MetS, dyslipidaemia and 
hyperlipidaemia  
Knouff & Auwerx, 2004  
Savage et al., 2003 
A-2819G T2DM and diabetic retinopathy Costa et al., 2009 
Ser289Cys Colorectal cancer, hypertension, 
dyslipidaemia and overweight but not 
T2DM 
Capaccio, et al. 2010 
Cys114Arg,Cys131Tyr 
Cys162Trp, Arg357X 
Partial lipodystrophy, IR, severe 
dyslipidaemia low HDL, increased 
triglycerides 
Agostini et al., 2006 
 
The balance of the rare loss-of-function mutations Pro495Leu, Val318Met, Pheu388Leu, Arg357X, 
Arg425Cys and Ser289Cys occur in the LBD of PPARG. In the presence of a synthetic ligand, 
these mutations result in a reduction of PPARG transactivation, thereby affecting its ability to 
recruit cofactors, ligands and RXR alpha (Barroso et al., 1999; Agarwal & Garg, 2002; Hegele et 
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al., 2002; Savage et al., 2003; Capaccio et al., 2010). In addition, four variants in the PPARG 
putative promoter have also been identified: C-681G, C689T, A2819G and A-14G. Evidence 
shows associations of these variants with increased low density lipoprotein (LDL) levels and 
diabetes. A-14G results in decreased activity of the PPARG 4 promoter that could affect the 
expression of some PPARG molecular targets (Meirhaeghe et al., 2003; Al-Shali et al., 2004; 
Meirhaeghe et al., 2005; Costa et al., 2009). 
 
1.10.2 Variants in the IRS1 gene associated with insulin resistance 
 
1.10.2.1 IRS1 gene: common variants 
Similar to PPARG, the IRS1 gene has various mutations with varying levels of association with 
obesity, IR and type 2 diabetes mellitus. These have been identified in population studies, as well 
as in animal models (Sesti et al., 2001; Mercado et al., 2002). The IRS1 was the first substrate of 
the insulin receptor substrate (IRS) proteins to be identified and localised to human chromosome 
2q36-37 (White, 1997). The IRS1 gene encodes a protein that is phosphorylated by the insulin 
receptor tyrosine kinase where mutations in this gene are associated with T2DM and susceptibility 
to insulin resistance (Jellema et al., 2003; Sesti et al., 2001; Sun et al., 1991; Rung et al., 2009). 
 
The most studied mutation in IRS1 is a relatively infrequent glycine to arginine substitution at 
position 972 (Gly972Arg variant), which was found to impair insulin signalling in muscle, fat and 
pancreatic beta cells (Almind et al., 1996; Sesti et al., 2001; Marchetti et al., 2002). The functional 
role of the IRS1, Gly972Arg variant was highlighted when associations with both IR and reduced 
insulin action were found (Claussen et al., 1995; Sesti et al., 2001; Stumvoll et al., 2001). Carriers 
of the Arg972 variant showed significantly reduced IS with high values for serum TG, total/HDL-c 
ratios, FFA levels, systolic blood pressure, microalbuminuria and intima-media thickness. This 
suggests that the IRS1 Gly972Arg variant could contribute to the risk for the atherosclerosis/CVD 
association with diabetes, due to the development of IR-related metabolic abnormalities (Marini et 
al., 2003). The association of the Gly972Arg variant of IRS1 with diabetes and its related traits has 
been investigated in different ethnic groups with conflicting results. In a meta-analysis study 
conducted by Jellema et al. (2003), the authors reported the Gly972Arg variant to be associated 
with an increased risk for type 2 diabetes mellitus. However, this association was not found in other 
large case-control studies (van Dam et al., 2004; Florez et al., 2004; Bezzerra et al., 2004; Zeggini 
et al., 2004; Morini et al., 2009). 
 
In addition, three variations near the IRS1 locus have been identified showing evidence of 
associations with obesity, IR and type 2 diabetes mellitus. In a study by Rung et al. (2009), the SNP 
rs2943641, located about 547 kb upstream of the IRS1 gene, was associated with T2DM, IR and 
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hyperinsulinaemia in a population of French and Danish subjects. The rs2943641 risk allele C 
showed a reduced HOMA-IR with higher fasting insulin and a lower insulin area under the curve 
from the oral glucose tolerance test. This allele was also associated with reduced expression of the 
IRS1 protein and reduced insulin-induced phosphatidylinositol 3-OH kinase activity in human 
skeletal muscle (Rung et al., 2009). Similarly, evidence of an association between the SNP 
rs4675095 in IRS1 and HOMA-IR was also reported. Although this SNP had too small an effect to 
pass standard GWAS significance thresholds or in LD with rs2943641, it could possibly be an 
independent factor associated with the IRS1 gene (Dupuis et al., 2010). The SNP rs2943650 is 
located 500 kb upstream of the IRS1 gene and is an important mediator of insulin and IGF1 
signalling. The major allele of rs2943650 was associated with an adverse metabolic profile, and 
results showed a decrease in body fat percentage, associated with higher TG and lower HDL-c 
levels. Furthermore, the increased ratio of insulin/glucose area under the curve and the decreased IS 
were strongly associated with insulin resistance (Kilpeläinen et al., 2013). 
 
1.10.2.2 IRS domains 
Studies have shown that two regions of the IRS1 domains are important for interaction with the 
INSR, namely a pleckstrin homology (PH) domain, located at the NH2-terminal end of IRS1 and a 
phosphotyrosine binding (PTB) domain that is located near the PH domain (Myers et al., 1995; 
Eck et al., 1996). The IRS1 PTB domain consists of a compact seven-stranded 3-sheet structure and 
is capped by a long a-helix at the top end and by a short a-helix at the bottom end. One helical turn 
that connects with β4 and β5 strands, forms the binding site for the NPXY motif of the insulin 
receptor/s (Eck et al., 1996). The phosphorylation of the NPXY motif of the juxtamembrane 
domain of the INSR is important because it leads to a recruitment of IRS1 (Eck et al., 1996; White, 
1997). The PH and PTB domains at the N-terminus appear to connect IRS1 to the activated INSR, 
with the C-terminal region containing a number of tyrosine phosphorylation motifs that are 
phosphorylated directly by the insulin receptor/s (Yenush et al., 1996). 
 
1.10.2.3 IRS1 gene: rare variants 
Extensive studies regarding several rare amino acid substitutions of the IRS1 gene identified the 
following: Ser892Gly, Ala512Pro, Ala94Thr, Met613Val, Ser1043Tyr, Cys1095Tyr, Ser809Pheu, 
Pro170Arg, Met209Thr, Gly819Arg, Arg1221Cys and the novel T608R (See Table 1.3: p 26). 
 
The functional impact of the Ser892Gly variant in vitro has been studied. This variant is located 
directly upstream to the SH2 binding site of the GRB-2, which links IRS1 to the mitogenic 
Ras/MAP kinase pathway (Laakso et al., 1994; Sesti et al., 2001). Overall, a frequency of 0,017% 
for the Ser892Gly variant was found in diabetic subjects, with similar results also reported in the 
Finnish, Turks and Mexican American populations. In the Turkish population it was reported that 
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both the variants Ala512Pro in non-diabetic subjects and Ser892Gly, in diabetic subjects. However, 
no association with any of these rare variants was found (Funda et al., 2005). 
 
Table 1.3 IRS1 genes: rare variants associated with human metabolic disease 
Variant(s) Effect on the insulin signalling 
pathway/disease/trait 
Reference(s) 
Gly819Arg 
Arg1221Cys 
Involved in the binding of the SHP-2 protein but with no 
effect on the expression or function of IRS1 gene 
 
Imai et al., 1997 
Met613Val 
Ser1043Tyr 
Cys1095Tyr 
 
No significant associations found with T2DM, BMI, 
glucose and insulin levels in various populations studied 
Sánchez-Corona et al., 2004 
Funda et al., 2005 
Ser892Gly 
Ala94Thr 
Ala512Pro 
 
Located directly upstream to the SH2 binding site of the 
GRB-2 that links IRS1 to the mitogenic RAS/MAP kinase 
pathway 
Decreased BMI 
No associations found with glucose, insulin or BMI for 
any of these variants 
 
Laakso et al., 1994 
Funda et al, 2005 
Sánchez-Corona et al., 2004 
T608R May contribute to IR by impairing the metabolic signalling 
through PI3-kinase-dependent pathways 
 
Esposito et al., 2003 
 
 
 
 
Ser809Pheu 
Pro170Arg 
Met209Thr 
Only found in T2DM individuals 
Diminishes the binding of IRS1 to the insulin receptor due 
to structural changes in the PTB domain of the IRS1 
protein 
Decreased MAP kinase and PI 3-kinase activities  
 
Ura et al., 1996 
Eck et al., 1996  
 
The Ala512Pro variant was also found in Danish and French Caucasians but was absent or rare in 
Finnish, Japanese and South Indian populations (Almind et al., 1993). In Mexican Americans, a 
modest relationship between the Ala94Thr variant and a decreased BMI, (30,4 kg/m2 versus 24,0 
kg/m2; p=0,035), was reported (Sánchez-Corona et al., 2004). In Iberian Caucasians, the Ala94Thr 
and Ser892Arg variants were not detected, but Ala512Pro variant was found in 1/60 non-diabetic 
subjects (Celi et al., 2000). The mutations Met613Val, Ser1043Tyr and Cys1095Tyr are rare in 
Mexican Americans (Sanchez-Corona et al., 2004) and absent in the Turkish population (Funda et 
al., 2005). There were no significant associations reported with any of these variants for diabetes, 
BMI, glucose and insulin levels. Among Pima Indians, none of these missense mutations were 
found in either the diabetes or non-diabetes subjects (Celi et al., 1995). 
 
In Japanese T2DM subjects, three additional polymorphisms have been described, namely the 
Pro170Arg, Met209Thr and Ser809Phe (Ura et al., 1996). The two amino acid substitutions, 
Pro170Arg (P107R) and Met209Thr (M209T), are located in the PTB domain of IRS1 and appear 
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to diminish the binding of IRS1 to the INSR due to structural changes in the PTB domain of the 
IRS1 protein (Eck et al., 1996). The 32D IR cells expressing P170R and M209T showed a 
reduction in MAP kinase activity due to the decreased binding of IRS1 to the INSR, together with 
decreased phosphorylation (Yoshimura et al., 1997). The binding of IRS1 to the INSR is important 
for the phosphorylation of IRS1 (Eck et al., 1996; Yonezawa et al., 1992). Therefore, the reduced 
phosphorylation of P170R and M209T could be due to the reduced binding to the INSR. In turn, 
the reduced phosphorylation of IRS1 could lead to reduced binding sites for SH2 proteins, such as 
GRB2, SHP-2 and PI 3-kinase, resulting in decreased MAP kinase and PI 3-kinase activities. 
Although the functional significance of the Ser809Phe IRS1 variant was not studied in vitro it was 
only found in T2DM subjects (Ura et al., 1996). Whilst in a study with mice, diabetic carriers of 
Pheu809 showed higher HbA1c, fasting glucose and postprandial glucose levels than non-diabetic 
subjects (Withers et al., 1998). 
 
1.10.3 Glucokinase and glucokinase (hexokinase 4) regulator variants associated with insulin 
resistance 
The common GCKR, P446L variant SNP rs1260326 has been associated with an inverse 
relationship between glucose and triacylglycerol levels (Orho-Melander et al., 2008). The glucose-
lowering leucine allele was also associated with decreased fasting insulin, HOMA-IR, reduction of 
T2DM risk (Dupuis et al., 2010) and increased triacylglycerol and TC levels (Teslovich et al., 
2010). A study of the functional characteristics of the P446L GCKR variant in humans showed the 
GCKR regulation of GCK was significantly reduced over different concentrations of fructose-6-
phosphate (F6P), leading to increased GCK activity that resulted in an increased glycolytic flux and 
glucose uptake in the liver (Beer et al., 2009). The increased glycolysis could possibly raise the 
levels of other liver metabolites, and this could explain why variation in GCKR is associated with 
higher TG and lower glucose levels in humans (Beer et al., 2009). 
 
The SNP rs780094 in GCKR, which is associated with glycaemic traits in the GWAS genetic loci 
of T2DM, showed a strong association with the minor A allele and hypertriacylglycerolaemia 
(Diabetes Genetics, 2007; Scott et al., 2007). The minor A allele of rs780094 was also associated 
with impaired fasting, insulin release, reduced HOMA-IR, dyslipidaemia and a modest decreased 
risk of type 2 diabetes mellitus (Sparso et al., 2008). This fasting blood glucose-raising allele of 
GCKR rs780094 was also associated with lower IS and an increased C-peptide level (Ingelsson et 
al., 2010). The T allele showed a modest association with decreased plasma glucose levels and 
increased IS that improved IR and reduced the risk of type 2 diabetes mellitus (Scott et al., 2007; 
Orho-Melander et al., 2008). The index SNP, rs780094, is in strong LD with the missense variant 
P446L, where the fasting glucose-raising allele inhibits GCK activity in the presence of F6P (Beer 
et al., 2009), thus leading to increased hepatic glucose production. In another variation in the 
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pancreatic beta cell promoter of GCK, SNP rs1799884 allelle A was signiﬁcantly associated with 
increased fasting and post-OGTT levels of circulating glucose, increased HOMA-IR and MetS 
traits (Rose et al., 2005). Furthermore, results in an additive model reported a significant increase 
in the fasting serum insulin levels by the G alleles for both the GCK SNP rs1799884 and GCKR 
SNP rs780094, which could contribute to the difference in metabolic traits observed (Sparso et al., 
2008). 
 
1.10.4 IGF1: common variant associated with insulin resistance 
The SNP rs35767, 1.2 kb upstream of IGF1 is one of only two loci found to be a genome-wide 
significant locus similar to the GCKR SNP rs1260326. The G allele of IGF1, SNP rs35767, was 
also associated with fasting insulin, HOMA-IR and type 2 diabetes mellitus (Dupuis et al., 2010; 
Imamura & Maeda, 2011). In humans with IR and diabetes, IGF1 SNP rs35767 was also shown to 
increase IS and lowers the blood glucose (Moses et al., 1996; Clemmons et al., 2005). In another 
study by Ingelsson et al. (2010), the fasting insulin-raising allele of the IGF1 SNP rs35767 was 
associated with lower IS using various indices for the assessment of insulin resistance. 
Furthermore, mutations in IGF1 resulted in a deficiency of IGF1 levels, a condition characterised 
by reduced growth rate with normal growth hormone levels. Administration of recombinant DNA 
derived IGF1 has shown to restore normal growth, with improvement in both glycaemic control 
and insulin sensitivity (Vaessen et al., 2001; Rietveld et al., 2004; Iñiguez et al., 2006). The IGF1 
SNP rs35767 is possibly another IR locus. This is based on the associations reported with IS, 
fasting insulin, glycaemic traits and HOMA-IR (Watanabe, 2010; Imamura & Maeda, 2011). 
 
1.11 JUSTIFICATION FOR THE STUDY 
The investigations in this dissertation are based on the findings of the larger study that reported a 
prevalence of diabetes in more than 25% of the mixed-ancestry population of Bellville South, 
South Africa, with nearly half of the subjects not being aware of their diabetic status (Erasmus et 
al., 2012). These increasing diabetic figures are not limited to the mixed-ancestry population but 
are also observed in the black African population, which had previously been thought to be at low 
risk for cardiometabolic disease traits. For example, since the last study in the 1990s by Levitt et al. 
(1993) in black South Africans, a marked increase in the prevalence rate of diabetes from 8% to 
13,1% was observed (Peer et al., 2012). The increasing diabetes figures around the world are 
largely attributed to the environmental changes that promote the adoption of unhealthy behaviours 
and the development of obesity, which in turn are implicated in IR and inflammation and 
subsequent progression to T2DM and cardiovascular diseases. 
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The aetio-pathogenesis of T2DM and associated IR is shown to have a strong genetic basis 
(Brunetti et al., 2014; Povel et al., 2012; Watanabe, 2010). However, in South Africa and Africa in 
general, genetic abnormalities that can fully account for the increase in obesity and diabetes have 
not been identified. Therefore, in this study, two key genes that were shown to be associated with 
diabetes in Caucasians were selected for investigation namely PPARG and IRS1. 
 
The PPARG and IRS1 loci were identified as candidate genes for IR, as associations between gene 
variants and impaired IS have been observed which increase the risk of developing type 2 diabetes 
mellitus. The PPARG gene is involved in the regulation of adipocyte gene expression and glucose 
metabolism, while the IRS1Gly972Arg variant alters insulin action. The specific hypothesis behind 
the proposed investigation is that specific identified sequence variants in the PPARG and/or IRS1 
genes, independently or together with obesity, can contribute to the development of IR in a South 
African mixed-ancestry population with a high incidence of T2DM and CVD risk. 
 
1.12 OBJECTIVES 
The specific objectives for the study were as follows: 
 
 the assessment of  IR in participants using various surrogate markers of IR e.g. HOMA-IR, 
fasting insulin resistance index (FIRI), HOMA-β%, glucose and insulin ratio and QUICKI; 
 
 to determine the allele and genotype frequency of the identified sequence variants of 
PPARG and IRS1 genes; 
 
 to explore the role of specific sequence variants of PPARG and IRS1 genes and their 
potential associations with either independent or joint effects that may influence IR and 
may have phenotypic influences on more than one IR Syndrome trait; and 
 
 to investigate IR indices as a clinical tool for improved risk prediction of subclinical 
CVD/atherosclerosis. 
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CHAPTER 2 
 
RESEARCH METHODOLOGY 
 
2.1 ETHICS 
The sub-study was approved by the Research Ethics Committee of Stellenbosch University 
(Reference Number: HREC N09/05/146) (Ethics certificate: Appendix A) and the Bellville South 
Africa Study by the Cape Peninsula University of Technology (CPUT), Health and Wellness 
Sciences Research Ethics Committee (Reference Numbers: CPUT/HWS-REC 2008/002 and 
CPUT/HWS-REC 2010). All participants signed consent forms after all the procedures were fully 
explained to them in the language of their choice. These included consent for their blood samples to 
be stored and used in future studies, including genetic analysis (Consent form: Appendix B), of 
which the current study formed a part. Each participant was assigned a unique code that was used 
for confidentiality purposes, and all data collection documents (Questionnaire: Appendix C) and 
biological specimen containers reflected this code. Electronic data were password protected, and all 
documentation was securely locked in fireproof cabinets. The study was conducted according to the 
Code of Ethics of the World Medical Association (Declaration of Helsinki). 
 
2.2 STUDY SETTING AND POPULATION 
 
2.2.1 The Bellville South Africa Study 
The Bellville South Africa Study setting, survey design and procedures are described in detail in 
previous research (Erasmus et al., 2012; Matsha et al., 2013; Zemlin et al., 2011). Briefly, eligible 
participants were invited to take part in a community-based survey from January 2008 to March 
2009 (Cohort 1) and January 2011 to November 2011 (Cohort 2). The sub-study is an extension of 
the Bellville South Africa Study conducted in Bellville South between 2008 and 2011. Bellville 
South, a suburb of Cape Town, in South Africa, is a traditionally mixed-ancestry township formed 
in the late 1950s. According to the 2011 population census, the population of Bellville South was 
29 301 with an average household size of 4,84 individuals during the time of the recruitment of 
participants. Most of the residents in this community have lived there for over five years and in 
many cases, their entire lives. The socio-economic condition of the people is average, with 37% of 
households having a monthly income of R3 200 or less. The target population for the Bellville 
South Africa Study included subjects that were 16 years or older, resulting in a total of 16 168 
individuals, of which 14 352 were of mixed-ancestry origin. Of these, 1256 individuals were 
randomly selected for participation in the Bellville South Africa Study. 
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2.2.2 The sub-study 
The population for the sub-study was selected from the database used in the Bellville South Africa 
Study and included a total number of 946 participants, comprising of 642 random participants 
between the ages 35-65 years and 304 voluntary participants, age range 16-95 years, of which 90 
were excluded due to missing data, which resulted in 856 participants (235 males and 621 females) 
consenting to genetic studies. Of the 856 participants, study 1 and 2 combined (Chapter 3) n = 787, 
study 3 (Chapter 4) n = 820 and study 4 (Chapter 5) n = 515 participants were included in analysis 
(Figure 2.1: p 32). The diabetes status of the study population was based on a history of doctor-
diagnosis, a fasting plasma glucose ≥7,0 Mmol/L and/or a 2-hour post-oral glucose tolerance test 
with plasma glucose ≥11,1 Mmol/L. This study was conducted at the Department of Biomedical 
Sciences, CPUT and the Division of Chemical Pathology, Tygerberg Hospital at Stellenbosch 
University, South Africa. 
 
2.2.2.1 Selection criteria for the study population 
Inclusion criteria 
 South African citizens of mixed-ancestry origin  
 age group 16 to 95 years 
 participants who consented to genetic analysis 
  
Exclusion criteria 
 acute illness 
 other race than mixed ancestry particpants 
 participants that did not consent to genetic analysis  
 participants with incomplete information on the database 
 pregnant females 
 
2.3 DATA COLLECTION AND MANAGEMENT 
Data was captured on an Excel spreadsheet, and the statistical package, R (version 3.0.0 {2013-04-
03}, the R Foundation for Statistical Computing, Vienna, Austria) was used. See Section 2.7 for the 
statistical analysis used in this study. 
 
2.3.1 Questionnaire 
To obtain the medical information and samples of the participants, a detailed protocol describing 
the data collection procedures (questionnaires and physical examinations) was developed. The team 
members consisting of professional nurses and field workers were trained, and a pilot study in a 
neighbouring community with similar demographics was performed to validate the questionnaire  
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INCLUSION CRITERIA:  
Mixed ancestry South Africans; Age group > 16 years; 
Participants who consented to genetic analysis 
 
 
 
 
  
 
Figure 2.1 Flow-diagram of the population for the sub-study selected from the Bellville South 
Africa Study database. 
Abbreviations: Carotid Intima Media Thickness (CIMT), Insulin Receptor Substrate (IRS) 1, Peroxisome proliferator-
activated receptor gamma (PPARG), Insulin Resistance (IR) 
 
Study 4 
IR indices and CIMT 
N=13 excluded missing 
information on database  
N= 515 participants 
 
 
Study 3 
Rare PPARG variants 
N= 121 excluded missing data 
on genetic variable 
N= 820 participants 
 
Study 1 & 2 
PPARG and IRS1 genes 
N=154 excluded missing data on 
genetic variables 
N= 787 participants 
 
                   
COHORT 1:  2008/2009  
(Baseline study) 
N=956 
COHORT 2:  2011 
(Follow-up study): 2008/2009; N=210 
New participants; N=318 
 
N= 946 participants (Cohorts: 2008/2009 & 2011) 
 
EXCLUSION CRITERIA:  
Acute illness; other races than mixed ancestry; participants 
that did not consent to genetic analysis; incomplete 
information on database; pregnant females 
NOTE: participants from 2011 were only used if DNA was 
insufficient / unavailable in 2008/2009 
N= 90 participants excluded on basis of exclusion criteria 
 
N=856 participants (235 males and 621 females) 
Participants who consented to genetic analysis 
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and synergise the workflow. A supervisor was allocated to each team to monitor the performance of 
the personnel and calibrate equipment according to a standard protocol. In addition, weekly 
meetings were held to assess progress, solve problems and re-train the research team (if necessary). 
A questionnaire, designed to retrospectively obtain information on lifestyle factors, such as 
smoking and alcohol consumption, physical activity, diet, family history of CVD and T2DM and 
demographics, was administered by trained personnel (Questionnaire: Appendix C). The 
questionnaire was adapted from several existing standards and recognised sources (Bradshaw et al., 
1995; Ewing, 1984) and was pre-tested in a neighbouring community with similar demographics. 
Information regarding medication taken by participants was obtained through clinic cards and 
records that participants brought to the study site. The more detailed the information retrieved, the 
more accurate and complete the database, allowing for more association tests during the statistical 
analysis. 
 
2.3.2 Anthropometric and metabolic parameters 
Professional nurses and field workers trained in the use of prescribed standardised techniques 
conducted anthropometric measurements and biochemical analyses. These standardised techniques 
and associated data-collection methods were piloted and used in a research project aimed at 
investigating the prevalence of obesity, diabetes, metabolic syndrome and cardiovascular risk 
among adults in the Bellville South, Western Cape Province. In the pilot study, a careful selection 
of instruments with adequate detection limits and sensitivity was carried out to enhance the 
accuracy and validity of results. Statistical measures in the form of repeated measures were used to 
ensure inter- and intra-validity. Measurements and analyses were performed, as detailed in the 
sections below. The principles and performance characteristics of assays used in this dissertation 
are summarised in Appendix D. 
 
2.3.2.1 Anthropometric measurements 
Weight measurements were obtained using a digital bathroom electronic scale (Fuzhou Sunny 
Electronic Co., Ltd., China). All heavy clothing and shoes were removed. The scale was calibrated 
and standardised using a weight of known mass. The subjectd were asked to stand in the middle of 
the scale platform after the scale had been zeroed. It was ensured that the subjects’ weight was 
evenly distributed with the arms hanging relaxed along their sides. Readings were taken to the 
nearest 0,1 kg. Height was measured using a stadiometer (Anand Medical Exports, India).The 
subject was asked to stand on a flat surface that was at a 90° angle to the vertical lever/board of the 
stadiometer. The scapula and the buttocks were in contact with the wall/ board, with the buttocks 
and the heels in the same vertical line. The subject was then asked to take a deep breath while 
maintaining a fully upright position. The required accuracy was 0,1 cm (Lohman, Roche, Martorell, 
1988). The BMI was calculated for each subject as: weight (kg) ÷ [height (m)]
2
. 
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The waist measurement was taken with the subject in an erect position, abdomen relaxed, arms at 
the sides and feet together. This measurement was performed facing the subject in a horizontal 
plane, with a non-elastic tape measure placed at the level of the natural waist. The natural waist is 
defined as the narrowest part of the torso as seen from the anterior view. In obese subjects, it may 
be difficult to see the waist narrowing and therefore, the smallest circumference measured in the 
area between the ribs and the iliac crest was taken. The measurement was taken three times at the 
end of a normal expiration and the average recorded. The required accuracy was 0,1 cm. The hip 
circumference was measured as the maximal circumference over the buttocks, using a non-elastic 
tape. The field worker had to squat beside the subject so that the maximum extension of the 
buttock in the horizontal plane at this level could be taken without compressing the skin. The 
measurement was taken three times, and the average of the measurements recorded. The required 
accuracy was 0,1 cm. The waist-to-hip ratio was calculated as the average of the waist 
circumference divided by the average of the hip circumference. This was recorded to four decimal 
places. 
 
2.3.2.2 Blood pressure 
Blood pressure measurements were carried out according to the World Health Organization (WHO) 
guidelines (Chalmers et al., 1999). Measurements were performed using a semi-automatic digital 
blood pressure monitor (Rossmax PA, USA) on the right arm, with the participant in a sitting and 
relaxed position, and not having ingested coffee or smoked for 30 minutes before the measurement. 
The cuff was placed at a point midway between the olecranon and acromion to ensure an accurate 
measurement. After a ten-minute rest period, three readings were taken at five-minute intervals, 
and the lowest of the three readings was taken as the blood pressure. 
 
2.3.2.3 Biochemical analysis 
Fasting blood samples were used for all the biochemical measurements. Prior to screening, the 
fasting state was determined in an interview on the morning of the examination. Participants with 
no history of doctor-diagnosed diabetes mellitus underwent a 75 g OGTT, as recommended by 
WHO (Alberti & Zimmet, 1998). Plasma glucose was measured by an enzymatic hexokinase 
method, glycated haemoglobin (HbA1c) by a turbidimetric inhibition immunoassay, and the 
creatinine measurement was obtained by using the standardised creatinine assay (Cobas 6000, 
Roche Diagnostics, Germany). Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-
c), triglycerides (TG) and γ-glutamyltransferase (GGT) were estimated by enzymatic colourimetric 
methods (Cobas 6000, Roche Diagnostics). The glomerular filtration rate (GFR) was estimated by 
the 4-variable Modification of Diet in Renal Disease (MDRD) equation (Levey et al., 1999; Levey 
et al., 2006) applicable to standardised serum creatinine values. Low-density lipoprotein 
cholesterol (LDL-c) was calculated using Friedewald’s formula (Friedewald et al., 1972.). Insulin 
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was determined by a micro-particle enzyme immunoassay (Axsym, Abbot). C-reactive protein was 
measured by a high-sensitivity CRP assay, based on the highly sensitive Near Infrared Particle 
Immunoassay rate methodology (Immage Immunochemistry System; Beckman Coulter), with a 
lower limit of detection of 0,2 mg/L. 
 
2.4 ASSESSMENTS OF INSULIN RESISTANCE/SENSITIVITY 
The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated according to 
the formula: HOMA-IR= [fasting insulin concentration (mIU⁄ L) x fasting plasma glucose (mM)]/ 
22,5; while homeostasis model assessment of functional beta-cells (HOMA-β%) were estimated 
using the formula: 20 × fasting insulin (mIU/L)/fasting glucose (mM) − 3.5. The fasting insulin 
resistance index (FIRI) was calculated with the formula: [fasting insulin (mIU/L) × fasting glucose 
(mM)]/25 and the quantitative insulin sensitivity check index (QUICKI) as: 1/ [log (fasting insulin 
(mIU/L) × log (fasting glucose (mM)]. 
 
2.5 CAROTID INTIMA MEDIA THICKNESS 
 
2.5.1 Carotid artery ultrasound protocol 
Two qualified sonographers measured carotid intima media thickness (CIMT) in longitudinal 
section at the far wall of the distal common carotid arteries, 2 cm from the bifurcation, at three 
consecutive end-points, 5 mm to 10 mm apart. Carotid intima media thickness was reported in 
millimetres and used as a measure of subclinical CVD/atherosclerosis. The ultrasound examination 
was performed according to the ‘As Low As Reasonably Achievable’ (ALARA) principle to avoid 
biological effects that may be associated with ultrasound. The exposure output of the machine was 
kept to a low value with the thermal index <1, which still resulted in an accurate diagnosis 
(Kremkau, 2006). The mean of six readings (three from each side) was calculated for each 
participant using a portable B-mode and spectral Doppler ultrasound scanner equipped with 
cardiovascular imaging software. The GE LOGIQ e® (General Electric Healthcare, Germany) 
high-performance multipurpose colour compact ultrasound system included new imaging 
CrossXBeam technologies, with multi-frequency virtual apex on the phased array cardiac 
transducer (3S-RS wide band phased probe 1.7-4.0 MHz) for echocardiography, and a linear wide-
band vascular transducer (8L-RS 4.0-12 MHz linear probe) to improve diagnostic confidence and 
imaging clarity for the carotids. 
 
2.6 GENETIC ANALYSES 
Samples were genetically analysed, initially with the extraction of DNA from whole blood, 
followed by genotyping and subsequently, automated sequencing. 
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2.6.1. DNA extraction 
Venous blood samples were collected from consenting adults by professional medical nurses in 
specimen tubes containing ethylenediaminetetraacetic acid (EDTA). The samples were transported 
to the laboratory at room temperature and stored at -20°C if immediate extraction was not possible. 
Genomic DNA was extracted from the venous blood samples using a modified salting out 
procedure (Miller et al., 1988). A volume ranging from 5-10 mL of whole blood was transferred 
from an EDTA tube into a 50 mL Falcon tube. Cold lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 
0,1 mM EDTA, pH 7,4) was added, according to the volume of blood used (30 mL of cold lysis 
buffer for every 10 mL of blood), to produce a final volume of 40 mL. All reagents used in the 
subsequent steps were adjusted accordingly. The mixture was then placed on ice for 15 minutes 
and inverted every five minutes. This mixture was centrifuged at 1500 rpm (400 x g) for 10 
minutes at 4°C (J-6M/E centrifuge, Beckman, United Kingdom). The supernatant was carefully 
discarded and the pellet (white blood cells) resuspended in 0,9% phosphate buffered saline (PBS) 
(2,68 mM KCl, 136,89 mM NaCl, 6,46 mM Na2HPO4.2H2O, 1,47 mM KH2PO4, pH 7,4). This was 
followed by centrifugation at 1500 rpm for 10 minutes, after which the supernatant was discarded 
and the pellet resuspended in nuclear lysis buffer (10 mM Tris, 400 mM NaCl, 2 mM EDTA, 
pH 8,2), 0,3 mg/mL Proteinase K and 1% (w/v) sodium dodecyl sulphate (SDS). The contents were 
mixed well and incubated at 55°C overnight. Thereafter, 6 M NaCl was added to the solution, and 
the tubes were shaken vigorously for one minute. The mixture was centrifuged at 2500 rpm (1500 
x g) for 30 minutes. The supernatant containing the DNA was transferred to a clean Falcon tube 
and the pellet discarded. The supernatant was vortexed for 15 seconds, followed by centrifugation 
at 2500 rpm (1500 x g) for 15 minutes. This supernatant was transferred to a clean Falcon tube 
without the foam or the pellet. Two volumes of cold 99,9% (v/v) ethanol (C2H60) was added to 
each tube and agitated to precipitate the DNA. The DNA was removed using a sterile pipette tip, 
placed in a clean 1,5 mL Eppendorf tube and washed with cold 70% (v/v) ethanol. The tube was 
centrifuged using a benchtop microcentrifuge (Microcentrifuge® Lite, Beckman Coulter™) at 
8000 rpm (6000 x g) for two minutes. The ‘washing step’ was repeated until the pellet was clear. 
The ethanol was discarded and the tube left at room temperature to dry. Depending on the size of 
the pellet, 200-800 μL of Tris-EDTA (TE) buffer (10 mM Tris, 1 mM EDTA) was added to 
dissolve the DNA. To ensure a homogenous solution the DNA was dissolved by shaking the tubes 
using a rotator at room temperature. 
 
2.6.1.1 Purity of DNA 
The isolated DNA was quantified in terms of the DNA concentration and purity by using the 
Nanodrop® ND-100 Spectrophotometer v3.0.1 (NanoDrop Technologies Inc, DE 19810 USA). 
The NanoDrop® UV/VIS spectrophotometer was employed to determine accurately the nucleic 
acid concentration in a sample, which was recorded in nanograms per microlitre (ng/μL). Where 
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possible, the DNA samples were diluted to obtain a final concentration of 200 ng/μL. The quality 
and purity of the DNA were determined by measuring the ratio of absorbance at 260 nm and 
280 nm, whereby a ratio of approximately 1,8 to 2,0 was considered to be of good quality. 
 
2.6.2 Molecular analysis of the Single Nucleotide Polymorphisms 
The SNPs were genotyped using the real-time polymerase chain reaction (RT-PCR). The 
conventional polymerase chain reaction (PCR) was used to validate genotypes that could not be 
determined by RT-PCR, by the sequencing of the amplified PCR products. Positive controls 
(samples with known genotypes) were identified for both methods. 
2.6.2.1 Real-time polymerase chain reaction 
Real-time polymerase chain reaction assays were used for SNP genotyping according to the 
manufacturer’s instructions (TaqMan genotyping assay; Applied Biosystems, South Africa). The 
assays were carried out using the BioRad MiniOpticon Real time PCR system (BioRad) and 
corresponding software (CFX Manager).TaqMan genotyping combines hybridisation and 
5´nuclease activity of polymerase coupled with fluorescence detection. This method utilises four 
oligonucleotides: two allele-specific probes and a pair of PCR primers flanking the region 
containing the polymorphism of interest. A reaction mix was produced to contain 5 µL TaqMan 
Universal PCR Master Mix, 0,25 µL Assay Mix, 1-3 ng DNA template and distilled water to a final 
volume of 10 μL. For each run, a positive control (any of the samples with a known genotype 
according to the sequencing results) was included, as well as a minimum of three non-template 
controls. 
 
The allele-specific probes carry a fluorescent reporter dye at one end and a non-fluorescent 
quencher at the other end. The probes contained different fluorescent reporter dyes, including VIC 
and FAM to differentiate between the amplification of each of the alleles. VIC has an emission 
maximum of 554 nm, thus emitting a green-yellow colour and in this study, was used to measure 
the minor allele presence or absence. FAM, 6-carboxyfluorescein, is the most commonly used 
fluorescent dye and fluoresces blue in colour at 517 nm. During the extension stage of PCR, the 
polymerase enzyme only cleaves on the hybridised probe that is perfectly matched, thus freeing the 
reporter dye from the quencher. This generates the florescence signal in the absence of the 
quencher. On the other hand, the mismatched probe remains intact and shows no florescence. This 
allows detection of both alleles during the reaction based on the hybridisation of the respective 
probes. The signal of the dye is dependent on the amount bound to the double-stranded DNA, thus 
increasing proportionally with the generated quantity of amplicons, with a linear increase until a 
plateau is reached. An amplification plot was used to display the fluorescence over the cycles. 
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For allelic discrimination, the fluorescence results were viewed once the cycles were completed, 
hence, endpoint quantitative-PCR. 
 
2.6.2.2 Polymerase chain reaction 
The success of PCR assays are dependent on the quality of the primer sets. Standard guidelines 
were followed for designing primers, with special attention to appropriate melting temperatures, 
primer lengths, GC content, hairpin loops and the complementarity of the primers. The primers 
were designed from the reference nucleotide sequence flanking the polymorphisms of interest 
(Primers designed : Appendix E).Free available primer design programmes such as Primer3plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/) and Integrated DNA 
Technologies (http://eu.idtnda.com) were used for designing the primer sets. The primers were 
synthesised by Integrated DNA Technologies and supplied by White Head Scientific (Cape Town, 
South Africa). The primers were rehydrated according to the manufacturer’s instructions: a stock 
solution of 100 µM was prepared in nuclease-free water, allowed to stand at room temperature for 
four hours to dissolve, after which it was further diluted to a 20 µM working solution. A master 
mix was made up to contain 5-10 µg DNA template, 0,24 µM of both forward and reverse primers, 
1 x buffer, 1,0 mM magnesium chloride (MgCl2), 0,3 µM dNTP, 1,25 µL DNA polymerase, and 
distilled water was added to yield a final volume of 50 μL reaction mixture. Both the peroxisome 
proliferator-activated receptor gamma (PPARG) and insulin receptor substrate (IRS)1 gene variants 
were amplified in a Perkin Elmer 2720 thermal cycler (Applied Biosystems, USA). This included 
initial denaturation at 95°C for three minutes, 35 cycles of denaturation at 95°C for 30 seconds, 
annealing at 54°C–55°C for 45 seconds depending on the primer set used (detailed in Appendix 
E.), extension at 72°C for 45 seconds and final extension at 72°C for five minutes. 
 
Amplicons, which ranged from 200 to 380 base pairs, were electrophoresed on 2% agarose gel and 
visualised in a GelDoc system (BioRad, GmbH, South Africa).The gel was prepared by weighing 2 
g of agarose powder (White Head Scientific, South Africa) and dissolving it in 100 mL of 5 mM 
di-sodium boratedecahydrate buffer, pH adjusted to 8,5. The low conductivity of di-sodium 
boratedecahydrate buffer allows gels to be run at a high voltage and speed, thereby separating the 
DNA fragments faster. The solution was heated in a microwave oven until the powder was 
completely dissolved. The solution was allowed to cool without solidifying before adding 0,1% 
ethidium bromide. This was poured into a casting tray (7 x 15 cm) with combs inserted to create 
wells and allowed to set at room temperature before loading the samples. Amplicons (8 µL each) 
were mixed with 5 µL of 6 x loading buffer (Fermentas, Cape Town, South Africa) and loaded onto 
the gel. A 100-base pair DNA molecular marker was run simultaneously as a marker. The gels were 
run at 140 volts for 30 minutes and viewed under the GelDoc XR System (Bio-Rad Laboratories, 
Cape Town, South Africa). 
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2.6.2.3 Sequencing 
For sequencing, the PCR product was purified using Exonuclease I and Shrimp Alkaline 
Phosphatase (Inqaba Biotechnologies, South Africa) according to the manufacturer’s instructions. 
This was performed by adding 5U of Shrimp Alkaline Phosphatase and 5U of Exonuclease I to 5 
µL of the PCR product. The mixture was incubated at 37ºC for 15 minutes, followed by heating at 
80ºC for 15 minutes to deactivate the enzymes. The concentration and purity of the PCR product 
was checked using the Nanodrop® according to the manufacturer’s specifications. Where 
necessary, samples were diluted to the desired concentration using nuclease-free water. Purified 
amplicons were sequenced using a BigDye terminator version 3.1 cycle sequencing kit (Applied 
Biosystems) according to the manufacturer’s instructions and resolved on an ABI 3130X ® 
Genetic Analyzer (Applied Biosystems, USA) at the Central Analytical Facility, Stellenbosch 
University. The sequencing data were further analysed using the Geospiza’s FinchTV version 1.4 
software programmes. 
 
2.7 STATISTICAL ANALYSIS 
Data are presented as mean (standard deviation, SD) or median (25th-75th percentiles) for 
continuous variables and as count and percentage for categorical variables. For group (sex, 
diabetes status) comparisons, the chi square test and student t-test were used. Where necessary, 
traits were log-transformed to approximate normality prior to analysis. The SNPs were tested for 
departure from the Hardy-Weinberg Equilibrium (HWE) expectation via a chi square goodness of 
fit test. All analyses used the statistical package R (version 3.0.0 {2013-04-03}, the R Foundation 
for Statistical Computing, Vienna, Austria). The R package genetics was used for genetic frequency 
distributions, allelic association, HWE and linkage dysequilibrium (LD) testing. The HWE 
describes the equilibrium at a single locus in a randomly mating population (Gillespie, 2004). 
HWE frequencies detail unchanged genotype proportions in a large population from generation to 
generation, providing there are no evolutionary forces such as mutation, migration and selection 
(Reviewed by Lewis & Knight, 2012). It allows for the prediction of genotype frequencies from 
the knowledge of gene frequencies. LD measures the correlation between SNP alleles at sites in the 
same region of the genome. Many different statistical measures to quantify LD between two SNPs 
have been proposed, with D´ and r2 being the most widely used (Devlin & Risch, 1995). Linear 
regression models were used for the analysis of quantitative traits and logistic regression models 
for dichotomous traits, always assuming additive models for the SNPs. Using linear and logistic 
models enabled the adjustment of all analyses for the known confounders, as specified in the 
results. 
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The additive allelic association of each SNP with each trait, overall and according to the T2DM 
status, was investigated and tested for heterogeneity by adding the interaction term of T2DM and 
each SNP to a model that contained the main effects of T2DM and the relevant SNP. The 
interaction term is defined as the interdependence of effects at two loci. If the disease risk caused 
by the presence of risk alleles at two loci can be inferred from the marginal effects of the presence 
of each risk allele individually, then no interaction is present. When the joint effects of risk alleles 
at both loci are much larger (or smaller) than implied by the marker-specific effects, then 
interaction exists (Reviewed by Lewis & Knight, 2012). The continuous associations between 
CIMT and the indices were assessed graphically with the use of a correlation matrix before and 
after applying the Box-Cox power (Box & Cox, 1964) transformations to improve the shape of the 
associations. The ‘Covariance Estimation for Multivariate t Distribution’ method was then used to 
derive the correlation coefficients, while minimising the potential effects of outliers (Kent et al., 
1994). The Steiger t-test was used to compare correlation coefficients among indices. Regression 
coefficients used to indicate the size of the association of each of the indices with CIMT was 
derived from robust multiple linear regression models that included each of the four variables of 
interest: age, sex, BMI and diabetes status. The significance level was set at 0,05. 
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CHAPTER 3 
 
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA 
Pro12Ala INTERACTS WITH THE INSULIN RECEPTOR 
SUBSTRATE 1 Gly972Arg AND INCREASES THE RISK OF INSULIN 
RESISTANCE AND DIABETES IN A MIXED-ANCESTRY 
POPULATION FROM SOUTH AFRICA 
 
3.1 BACKGROUND 
Insulin resistance is a fundamental aetiopathogenic factor for T2DM and is also linked to a wide 
array of other pathophysiological derangements including hypertension, hyperlipidaemia, 
atherosclerosis and polycystic ovarian disease (Reaven, 1997). The gold standard method for 
assessing IR/S is the euglycemic hyperinsulinemic clamp (Polonsky et al., 1988; DeFronzo et al., 
1979). However, this technique is cumbersome, particularly for large-scale epidemiological 
studies. Thus, relatively simple, non-invasive alternative techniques validated against the 
euglycemic clamp have been proposed. The homeostasis model assessment of insulin resistance 
(HOMA-IR) (Matthews et al., 1985) and quantitative insulin sensitivity check index (QUICKI) 
(Katz et al., 2000) methods are commonly used for IR and IS respectively. It is well recognised 
that the development of IR and T2DM is, in part, modulated by the gene-gene interaction 
processes. 
 
The peroxisome proliferator-activated receptor gamma (PPARG) and the insulin receptor substrate 
(IRS)1 genes have been shown to be associated with both IR and type 2 diaebtes mellitus (Buzetti 
et al., 2004; Ludovico et al., 2007; Gouda et al., 2010; Trombetta et al., 2013; Jellema et al., 2003; 
Sesti et al., 2001 ). The PPARG is a member of the super family of nuclear receptors reported to be 
involved in the regulation of adipocyte differentiation (Evans et al., 2004), lipid metabolism and 
insulin sensitivity (Buzetti et al., 2004). Several variants in the PPARG gene have been identified, 
with the most prevalent variant being the Pro12Ala polymorphism, resulting from the CCA-to-
GCA missense mutation in codon 12 of exon B that encodes the NH2 terminal residue (Auwerx, 
1999; Vigouroux et al., 1998; Stumvoll & Haring, 2002). This polymorphism has been shown to 
produce a protective effect against IR and type 2 diaebtes mellitus (Trombetta et al., 2013; 
Stumvoll & Haring, 2002; Mori et al., 2001). On the other hand, the most common polymorphism 
in the IRS1 gene is the Gly972Arg variant located near the src homology 2 (SH2) protein binding 
sites between the two consensus motifs Y939MKM and Y987MTM. These potentially bind to the 
p85 subunit of PI 3-kinase (Yoshimura et al., 1997). 
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Insulin produces most of its metabolic actions via the PI 3-kinase pathway, an enzyme that 
promotes translocation of glucose transporter proteins, glycogen and lipids. It is also involved in 
protein synthesis, anti-lipolysis and the control of hepatic gluconeogenesis. The substitution of Gly 
(GGG) for Arg (AGG) can result in a conformational change in these binding sites, which may 
impair the association of IRS1 with the PI 3-kinase p85 regulatory unit (Schmitz-Peiffer & 
Whitehead, 2003; Pederson, 1999; Porzio et al., 1999). Cells expressing G971R have shown a 
reduction in PI 3-kinase activity due to a reduced association with PI 3-kinase (Yoshimura et al., 
1997). Studies in vitro have shown that the Arg972 allele leads to a loss of the IRS1 function, 
thereby impairing insulin signalling in several target tissues, e.g. muscles, fat and pancreatic beta 
cells. However, studies in vivo have reported associations between the IRS1 Gly972Arg variant 
with both IR and reduced insulin secretion (Sesti et al., 2001; Almind et al., 1993; Marchetti et al., 
2002). In contrast, the glycine to arginine substitution in codon 972 (Gly972Arg) of the IRS1 gene 
was associated with an increased risk of insulin resistance (Burguete-Garcia et al., 2010). In view 
of the above, an investigation was carried out into the independent and joint effects of PPARG 
Pro12Ala and IRS1 Gly972Arg on markers of IR and T2DM in the mixed-ancestry population of 
South Africa, a population with an elevated risk of type 2 diabetes mellitus. 
 
3.2 RESEARCH DESIGN AND METHODS 
 
3.2.1 Ethical approval, consent and confidentiality 
The study setting, survey design and procedures have been described in detail in previous research 
(Erasmus et al., 2012; Matsha et al., 2013; Zemlin et al., 2011) as well as in chapter 2. Briefly, 
eligible participants were invited to take part in a community-based survey from January 2008 to 
March 2009 (Cohort 1) and January 2011 to November 2011 (Cohort 2). The study was approved 
by the Research Ethics Committee of Stellenbosch University (HREC Reference Number: 
N09/05/146) and the CPUT, Faculty of Health and Wellness Sciences Ethics Committee 
(Reference Numbers: CPUT/HW-REC 2008/002 and CPUT/HW-REC 2010). The study was 
conducted according to the Code of Ethics of the World Medical Association (Declaration of 
Helsinki). All participants signed consent forms after all the procedures were fully explained in the 
language of their choice. 
 
3.2.2 Clinical data 
All consenting participants received a standardised interview and physical examination during 
which their blood pressure was measured according to the World Health Organization (WHO) 
guidelines (Chalmers et al., 1999) using a semi-automated digital blood pressure monitor 
(Rossmax PA, USA) on the right arm, with the participant in a sitting position. Other clinical 
measurements included the body weight, height, waist and hip circumferences. Weight (to the 
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nearest 0,1 kg) was determined with the subject wearing light clothing and without shoes and 
socks, using a Sunbeam EB710 digital bathroom scale, which was calibrated and standardised 
using a weight of known mass. The waist circumference was measured using a non-elastic tape at 
the level of the narrowest part of the torso, as seen from the anterior view. The hip circumference 
was also measured using a non-elastic tape around the widest portion of the buttocks. All 
anthropometric measurements were performed three times and their average used for analysis. 
Participants with no history of doctor-diagnosed diabetes mellitus underwent a 75 g OGTT, as 
recommended by the WHO (Alberti & Zimmet, 1998). 
 
3.2.3 Laboratory measurements 
Blood samples were collected after an overnight fast and processed for further biochemical 
analysis. Plasma glucose was measured by the enzymatic hexokinase method (Cobas 6000, Roche 
Diagnostics, Germany) and glycated haemoglobin (HbA1c) by turbidimetric inhibition 
immunoassay (Cobas 6000, Roche Diagnostics, Germany), this being a National 
Glycohaemoglobin Standardisation Programme (NGSP) certified method. Creatinine levels were 
measured using the standardised creatinine assay (Cobas 6000, Roche Diagnostics, Germany). 
Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), triglycerides (TG) and γ-
glutamyltransferase (GGT) were estimated by enzymatic colourimetric methods (Cobas 6000, 
Roche Diagnostics). Low-density lipoprotein cholesterol (LDL-c) was calculated using 
Friedewald’s formula (Friedewald et al., 1972). Insulin was determined by a microparticle enzyme 
immunoassay (Axsym, Abbot). C-reactive protein was measured by a high-sensitivity CRP assay, 
based on the highly sensitive Near Infrared Particle Immunoassay rate methodology (Immage 
Immunochemistry System; Beckman Coulter), with a lower limit of detection of 0,2 mg/L. 
 
3.2.4 Single Nucleotide Polymorphisms genotyping 
Genomic DNA was extracted from whole blood samples collected in an EDTA tube. Single 
nucleotide polymorphisms in the IRS1 (rs1801287, G>A) and PPARG (rs1801282, C>G) were 
genotyped using a high-throughput real-time polymerase chain reaction. This was carried out in 
two independent laboratories on the ABI Prism 7900HT platform (Applied Biosystems, USA) 
and a BioRad Optica (BioRad, USA), using the Taqman genotyping assay (Applied Biosystems, 
USA). Direct sequencing was used for the analytical validation of the high-throughput genotyping 
as the gold standard. 
 
3.2.5 Definitions and calculations 
Body mass index was calculated as weight per square metre (kg/m
2
) and waist-hip-ratio (WHR) as 
waist/hip circumferences (cm). The T2DM status was based on a history of doctor diagnosis, a 
fasting plasma glucose ≥7,0 Mmol/L and/or a 2-hour post-OGTT plasma glucose ≥11,1 Mmol/L. 
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The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated according to 
the formula: HOMA-IR= [fasting insulin concentration (mIU⁄ L) x fasting plasma glucose (Mmol⁄ 
L]/22,5; while homeostasis model assessment of functional beta-cells (HOMA-β%) were estimated 
using the formula: 20 × fasting insulin (μIU/mL)/fasting glucose (Mmol/mL) − 3,5. The fasting 
insulin resistance index (FIRI) was calculated with the formula: [fasting insulin (μU/mL) × fasting 
glucose (mM)]/25 and the quantitative insulin-sensitivity check index (QUICKI) as: 1/[log (fasting 
insulin (μU/mL) × log (fasting glucose (mg/dL)]. Glomerular filtration rate (eGFR) was estimated 
by the 4-variable modification of diet in renal disease (MDRD) equation (Levey et al., 1999; Levey 
et al., 2006) applicable to standardised serum creatinine values. 
 
3.3 STATISTICAL ANALYSIS 
The general characteristics of the study group are summarised as count and percentage for 
dichotomous traits, mean and standard deviation, (SD) or median and 25
th
-75
th
 percentiles for 
quantitative traits. Where necessary, traits were log-transformed to approximate normality prior to 
analysis. The SNPs were tested for departure from the Hardy Weinberg (HWE) expectation via a 
chi square goodness of fit test. Linear regression models were used for the analysis of quantitative 
traits and logistic regression models for dichotomous traits, always assuming additive models for 
the single nucleotide polymorphisms. Using linear and logistic models enabled the adjustment of 
all analyses for known confounders, as specified in the results. The additive allelic association of 
each single nucleotide  polymorphism with each trait, overall and according to T2DM status, was 
investigated and tested for heterogeneity by adding the interaction term of T2DM and each single 
nucleotide  polymorphism to a model that contained the main effects of T2DM and the relevant 
single nucleotide  polymorphism. Results corresponding to p-values below 5% are described as 
significant. There was no adjustment for multiple testing. All analyses used the statistical package 
R (version 3.0.0 {2013-04-03}, the R Foundation for statistical computing, Vienna, Austria). 
 
3.4 RESULTS 
Of the 946 participants in the survey, 941 consented for genetic studies. Among the latter, 154 
were excluded due to missing data on the genetic variables. Therefore, 787 had valid data for the 
analyses.The clinical characteristics of the participants overall and according to their T2DM status 
are summarised in Table 3.1 (see p 48), indicating that 212 participants (26,9%) had type 2 
diabetes mellitus. As expected, the distribution of the levels of  IR/S indicators was significantly 
different between the two groups (all p<0,0001, except for the glucose/insulin ratio (p=0,016). 
Furthermore, compared with non-diabetic participants, those with T2DM had significantly higher 
levels of adipometric variables (all p≤0,028), systolic blood pressure (p<0,0001), TG (p<0,0001), 
GGT and CRP (both p<0,0001), whilst eGFR (p=0,015) and HDL-c (p=0,0001) were significantly 
lower. 
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The IRS1, Gly972Arg and PPARG, Pro12Ala variants were in HWE (p>0,05), and their genotype 
and allele distribution by T2DM status is summarised in Table 3.2 (see p 49). Overall, the genotype 
distributions of the two polymorphisms did not differ significantly between the two groups. 
However, the allele G of PPARG (12Ala) was significantly more frequent in the diabetic subjects 
than in the non-diabetic subjects (13,7% vs. 9,3%, p=0,012). The genotype frequencies, PPARG 
Pro12Ala and IRS1 Gly972Arg were 10,4% and 7,7% respectively. 
 
In the generalised linear regression analyses, which were adjusted for age, sex and T2DM (Table 
3.3: p 50), the IRS1 allele A (972 Arg) was not associated with the markers of glycaemia, IR or IS, 
both overall and in participants with and without T2DM who were analysed separately. There was 
no evidence of a significant statistical interaction by T2DM status (all interaction p>0,330), except 
in the 2-hour glucose analysis, in which the size of the effect appeared to be greater, although non-
significantly, among the diabetic participants (interaction p=0,038). In similar generalised linear 
regression models (Table 3.3: p 50), the PPARG allele C (Pro12) increased the 2-hour insulin levels 
in the overall cohort (p=0,009) and only increased in the non-diabetic group (p=0,0003) after 
stratification by T2DM status, with a significant statistical interaction (p=0,017). Otherwise, the 
PPARG C allele was not significantly associated with the marker of glycaemia, IS or IS, both 
overall and by T2DM status. However, there is evidence that the effect on the 2-hour glucose could 
be more pronounced in people with T2DM (p=0,002) for the PPARG C allele T2DM interaction. 
The main effects for IRS1 and PPARG did not change significantly when they were adjusted for 
each other in the regression models, with or without further adjustment for their interaction term. 
 
In the logistic regression models adjusted for each other, or containing age and sex, and with and 
without further adjustment for markers of IR/S (Table 3.4: p 51), neither the IRS1 allele A nor the 
PPARG was significantly associated with prevalent type 2 diabetes mellitus. However, in the model 
containing both alleles and their interaction term, the PPARG allele C was significantly associated 
with a higher risk of prevalent T2DM, odds ratio (95% confidence interval) 1,64 (1,00-2,64). 
 
3.5 DISCUSSION 
The mixed-ancestry population of South Africa has one of the highest prevalence of T2DM in 
South Africa and Sub-Saharan Africa at large. However, genetic abnormalities that can fully 
account for this have not been identified. In this study, it is shown that PPARG Pro12 was 
significantly associated with IR and T2DM in this population. It was observed that neither the IRS1 
972Arg allele nor PPARG 12Ala were associated with T2D or IR/S, but in a model containing both 
the alleles and their interaction term, the presence of the PPARG Pro12 resulted in a 64% risk of 
prevalent type 2 diabetes mellitus. Furthermore, the PPARG Pro12 was associated with increased 
levels of 2-hour post-OGTT insulin. Overall, our findings convincingly demonstrate that PPARG-
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IRS1 interactions, PPARG Pro12 and the susceptibility to environmental factors might modulate 
the relationship between IR and T2DM in this population. 
 
The gene-gene interaction between IRS1, Gly972Arg and PPARG, Pro12Ala is of interest because 
the two polymorphisms exert opposite effects on T2DM predisposition. The Gly972Arg is the most 
common polymorphism in the IRS1 gene and individuals carrying the Gly972Arg have a 25% 
increased risk for developing type 2 diabetes mellitus (Jellema et al., 2003). On the other hand, the 
PPARG Pro12Ala has been associated with a reduced risk of T2DM and insulin resistance 
(Buzzetti et al., 2004; Ludovico et al., 2007; Gouda et al., 2010; Trombetta et al., 2013). As such, 
the polymorphisms of the IRS1 and PPARG genes have been shown to interact and elevate insulin 
sensitivity. This was evident in a study done by Stumvoll et al. (2002), in which the authors 
demonstrated that IS was significantly greater in subjects with X/Ala (PPARγ2) + X/Arg (IRS1 
972) than in subjects with Pro/Pro (PPARγ2) + X/Arg (IRS1), while no differences were observed 
in X/Ala (PPARγ2) +Gly/Gly (IRS1 972) and Pro/Pro (PPARγ2) + Gly/Gly (IRS1 972) carriers 
(Stumvoll et al., 2002). Similarly, the interaction between the two polymorphisms has been 
associated with higher adiponectin levels, and the greatest increase was found in subjects who were 
homozygous for both PPARG alanine (Ala12Ala) and IRS1 glycine (Gly972Gly) (Mousavinasab et 
al., 2005). Adiponectin is secreted by the adipose tissue and is inversely associated with obesity, 
IR, T2DM and cardiovascular diseases (Weyer et al., 2001; Von Eynatten et al., 2006). All these 
reports, including the present study, confirm the combined effect of the two SNPs on IR and type 2 
diabetes mellitus. 
 
Several epidemiological studies have demonstrated that PPARG Pro12Ala is associated with IS and 
type 2 diabetes mellitus (Buzzetti et al., 2004; Ludovico et al., 2007; Gouda et al., 2010; Trombetta 
et al., 2013). In the Human Genome Epidemiology (HuGE) meta-analysis involving 32 849 T2DM 
cases and 47 456 controls, the Pro12Ala was associated with a 14% lower risk for developing type 
2 diabetes mellitus (Gouda et al., 2010). However, other investigations have failed to demonstrate 
an association between Pro12Ala and IS using the gold standard method for assessing IR/S, the 
euglycemic hyperinsulinemic clamp (Hasstedt et al., 2001;Stefan et al., 2001)  The differences 
between studies have been attributed to BMI and ethnic differences (Ludovico et al., 2007; Gouda 
et al., 2010). The frequency of the 12Ala was reported to be higher in Caucasians than in Asian 
populations (Gouda et al., 2010) but conferred a significantly greater protection against T2DM 
among Asians as opposed to Caucasians (35% vs. 15%), as demonstrated by Ludovico et al. 
(2007). However, when adjustments were made for BMI, the differences were no longer significant 
(Ludovico et al., 2007).  
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In the present study, the 10,4% frequency of Pro12Ala polymorphism is comparable to that found 
in Caucasians, and the Pro12 was strongly associated with increased 2-hour post-OGTT insulin 
levels in non-diabetic subjects.These results further add to the growing body of evidence regarding 
the association of PPARG Pro12Ala with IR and subsequent type 2 diabetes mellitus. Herein, a 
heterogeneous population was investigated, comprising 32-43% Khoisan, 20-36% Bantu-speaking 
African, 21-28% European and 9-11% Asian ancestry (De Wit et al., 2010).The present findings 
require replication in a larger study involving other homogenous populations before the results can 
be considered established in Africa. 
 
The strengths of the present study include the use of both fasting and OGTT derived indices for 
assessing T2DM and insulin resistance. The OGTT derived indices are found to have superior 
predictive power compared to simple fasting indices of IR because post-load glucose-insulin 
interaction is taken into account (Hancox & Landhuis, 2011). Furthermore, two independent 
laboratories to genotype the study population were employed. The main limitation of this study is 
the statistical power of the study, which was limited by the small sample size, and the examination 
of the gene-gene interaction effects reduced the sample further. Nevertheless, the results of this 
study provide the first preliminary evidence for genetic predisposition to IR and subsequent T2DM 
in an African population with a high prevalence of type 2 diabetes mellitus. In conclusion, the 
PPARG Pro12 is associated with IR, and this polymorphism interacts with an additional 
unfavourable genetic polymorphism, IRS1 Gly972Arg, to increase the risk of T2DM in a mixed-
ancestry population of South Africa. 
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Table 3.1 General characteristics of the overall population and by diabetes status 
 
Variable No diabetes Diabetes p-value Overall 
Number 575 212  787 
Gender, male n (%) 131 (23) 45 (21) 0,642 176 
Hypertension, n (%) 306 (53) 138 (65) 0,003 444 
Mean(SD) 
Age (years)  
 
51,3 (15,5) 
 
59,3 (13,4) 
 
<0,0001 
 
53,5 (15,4) 
Systolic blood pressure (mmHg)  123 (19) 131 (23) <0,0001 124 (21) 
Diastolic blood pressure (mmHg)  75 (12) 78 (15) 0,035 76 (13) 
Body mass index (kg/m2 ) 29,1 (7,1) 31,7 (7,2) <0,0001 29,8 (7,2) 
Waist circumference (cm)  95 (15) 102 (14) <0,0001 97 (16) 
Hip circumference (cm)  109 (14) 111 (15) 0,028 109 (14) 
Waist-to-hip ratio (cm) 0,87 (0,10) 0,92 (0,09) <0,0001 0,88 (0,10) 
HbA1c (%)  5,7 (0,4) 7,8 (2,1) <0,0001 6,3 (1,5) 
HbA1c (Mmol/mol)  39 (4,4)  62 (23)  <0,0001 45 (16,4) 
FBG (Mmol/L)  5,1 (0,7) 9,8 (4,4) <0,0001 6,4 (3,1) 
2h glucose (Mmol/L)  6,4 (1,6) 13,4 (5,3) <0,0001 7,3 (3,5) 
eGFR (mL/min)  76,0 (21,1) 71,2 (25,2) 0,015 74,7 (22,4) 
Triglycerides (Mmol/L)  1,4 (0,9) 1,7 (0,9) <0,0001 1,5 (0,9) 
HDL cholesterol (Mmol/L)  1,3 (0,4) 1,2 (0,3) 0,0001 1,3 (0,4) 
LDL cholesterol (Mmol/L)  3,6 (1,0) 3,7 (1,1) 0,191 3,6 (1,0) 
Total cholesterol (Mmol/L)  5,5 (1,2) 5,7 (1,3) 0,070 5,6 (1,2) 
Median(25th-75th percentiles) 
GGT  
 
26 [18-39] 
 
31 [23-39] 
 
<0,0001 
 
27 [19-42] 
CRP  3,4 [0,8-8,4] 5,2 [1,9-10,8] <0,0001 4,0 [1,1-9,4] 
Insulin (Mmol/L) 6,9 [3,3-12,5] 9,2 [3,7-16,6]  0,0009 7,5 [3,3-13,5] 
2h insulin (Mmol/L) 35,3 [19,2-64,5] 58,9 [22,1-115,2]  0,0009 36,8 [19,5-72,7] 
Glucose/Insulin ratio  0,72 [0,42-1,51] 0,88 [0,50-2,30]  0,016 0,75 [0,43-1,68] 
HOMA-IR  1,6 [0,7-2,9] 3,5 [1,5-6,7] <0,0001 1,9 [0,8-3,7] 
HOMA-β % 90,0 [41,1-160,0] 40,7 [12,4-77,8] <0,0001 71,2 [28,6-44,9] 
QUICKI  0,15 [0,14-0,18] 0,14 [0,13-0,15] <0,0001 0,15 [0,14-0,17] 
FIRI  1,4 [0,6-2,6] 3,1 [1,3-6,0] <0,0001 1,8 [0,7-3,3] 
1/HOMA-IR  0,64 [0,34-1,49] 0,29 [0,15-0,66] <0,0001 0,54 [0,27-1,26] 
 
Abbreviations: CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; FBG, fasting 
blood glucose; FIRI, fasting insulin resistance index; GGT, γ-glutamyltransferase; HbA1c, glycated 
haemoglobin; HDL, high-density lipoproteins; HOMA-β%, homeostasis model assessment of 
functional beta-cells; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-
density lipoproteins; QUICKI, quantitative insulin sensitivity check index; SD, standard deviation 
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Table 3.2 Genotype distributions, minor allele frequencies and unadjusted p-values for comparing 
genotype distribution according to diabetes status, including additive allelic effects between 
diabetes groups 
 
 No diabetes Diabetes p-value Overall 
N 575 212  787 
IRS1     
G/G, n (%) 526 (91,5) 199 (93,9) 0,485 725 (92,1) 
G/A, n (%) 48 (8,3) 13 (6,1)  61 (7,7) 
A/A, n (%) 1 (0,2) 0 (0)  1 (0,1) 
A, n (%) 97 (8,4) 26 (6,1) 0,131 123 (7,8) 
HWE (p-value) >0,999 >0,999  >0,999 
PPARG     
C/C, n (%) 521 (90,6) 183 (86,3) 0,161 704 (89,4) 
C/G, n (%) 53 (9,2) 29 (13,7)  82 (10,4) 
G/G, n (%) 1 (0,2) 0 (0)  1 (0,1) 
G, n (%) 107 (9,3) 58 (13,7) 0,012 165 (10,5) 
HWE (p-value) >0,999 0,605  
 
0,719 
 
 
HWE, Hardy-Weinberg Equilibrium (HWE p-values are from exact tests).  
Abbreviations: IRS1, insulin substrate receptor 1; PPARG, peroxisome proliferator-activated 
receptor gamma 
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Table 3.3 Generalised linear regression models* showing the effects of genes on markers of insulin resistance/sensitivity 
* Models are adjusted for age, sex and diabetes. 
Abbreviations: FBG, Fasting blood glucose; FIRI, fasting insulin resistance index; HbA1c, glycated haemoglobin; HOMA-IR, homeostasis model assessment 
of insulin resistance; IRS1, insulin substrate receptor 1; PPARG, peroxisome proliferator-activated receptor gamma; QUICKI, quantitative insulin sensitivity 
check index
Allele Phenotype Overall No diabetes Diabetes  p interaction 
  Effects size (95%CI) p Effects size (95%CI) p Effects size (95%CI) p  
IRS1 A FBG -0,06 (-0,66 to 0,54) 0,839 0,09 (-0,11 to 0,30) 0,372 -0,53 (-2,96 to 1,90) 0,668 0,330 
 2h glucose 0,32 (-0,36 to 0,99) 0,355 0,08 (-0,36 to 0,51) 0,723 2,33 (-2,09 to 6,75) 0,304 0,038 
 HbA1c 0,03 (-0,26 to 0,33) 0,821 0,02 (-0,10 to 0,14) 0,746 0,13 (-1,04 to 1,31) 0,823 0,853 
 Fasting insulin -1,47 (-6,09 to 3,15) 0,533 -1,02 (-3,76 to 1,71) 0,463 -3,27 (-20,75 to 14,21) 0,714 0,690 
 2h insulin 1,71 (-15,6 to 19,0) 0,846 1,62 (-15,50 to 18,75) 0,853 2,36 (-63,13 to 67,86) 0,944 0,944 
 Glucose/insulin -0,08 (-2,68 to 2,52) 0,952 -0,14 (-2,26 to 1,97) 0,894 0,30 (-8,40 to 9,00) 0,946 0,896 
 HOMA-IR -0,58 (-2,52 to 1,36) 0,558 -0,22 (-0,87 to 0,42) 0,498 -2,03 (-9,96 to 5,91) 0,617 0,448 
 QUICKI 0,001 (-0,013 to 0,014) 0,905 0,002 (-0,015 to 0,018) 0,857 -0,001 (-0,025 to 0,022) 0,903 0,877 
 FIRI -0,52 (-2,26 to 1,22) 0,558 -0,20 (-0,78 to 0,38) 0,480 -1,82 (-8,97 to 5,31) 0,617 0,448 
         
PPARG C FBG -0,02 (-0,55 to 0,52) 0,948 -0,06 (-0,26 to 0,13) 0,528 0,003 (-1,71 to 1,72) 0,995 0,970 
 2h glucose -0,47 (-1,10 to 0,16) 0,148 -0,02 (-0,44 to 0,41) 0,933 -2,46 (-5,68 to 0,76) 0,137 0,002 
 HbA1c 0,004 (-0,260 to 0,278) 0,976 0,07 (-0,04 to 0,19) 0,216 -0,18 (1,02 to 0,65) 0,663 0,362 
 Fasting insulin -2,07 (-6,17 to 2,02) 0,327 -0,56 (-3,21 to 2,09) 0,617 -5,72 (-18,00 to 6,57) 0,363 0,283 
 2h insulin 23,2 (5,8 to 40,7) 0,009 34,0 (15,9 to 52,2) 0,0003 -14,4 (-64,7 to 35,8) 0,575 0,017 
 Glucose/insulin -1,08 (-3,4 to 1,2) 0,362 -0,21 (-2,26 to 1,83) 0,840 -2,62 (-8,82 to 3,37) 0,407 0,307 
 HOMA-IR -0,70 (-2,4 to 1,0) 0,421 -0,12 (0,74 to 0,51) 0,714 -2,31 (-7,89 to 3,27) 0,417 0,299 
 QUICKI -0,003 (-0,014 to 0,009) 0,675 0,0001 (-0,015 to 0,016) 0,924 -0,007 (-0,024 to 0,009) 0,377 0,481 
 FIRI -0,63 (-2,18 to 0,91) 0,421 -0,10 (-0,67 to 0,46) 0,714 -2,08 (-7,10 to 2,94) 0,417         0,299 
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Table 3.4 Odds ratio and 95% confidence intervals from logistic regression for the prediction of 
diabetes 
 
*Interaction term 
Abbreviations: FIRI, fasting insulin resistance index; HOMA-IR, homeostasis model assessment of 
insulin resistance; IRS1, insulin substrate receptor 1; PPARG, peroxisome proliferator-activated 
receptor gamma; QUICKI, quantitative insulin-sensitivity check index 
Allele Covariates OR (95% CI) p-value 
 
IRS1 A 
 
Gene alone 
 
0,69 (0,36-1,25) 
 
0,250 
 sex, age 0,67 (0,34-1,24) 0,228 
 sex, age, insulin 0,70 (0,35-1,31) 0,290 
 sex, age, 2h insulin 0,76 (0,28-1,76) 0,562 
 sex, age, HOMA-IR 0,72 (0,35-1,39) 0,347 
 sex, age, QUICKI 0,70 (0,35-1,31) 0,285 
 sex, age, FIRI 0,72 (0,35-1,39) 0,347 
 sex, age, glucose/insulin 0,67 (0,34-1,27) 0,224 
 PPARG 0,69 (0,36-1,25) 0,248 
 PPARG, IRS1*PPARG 0,85 (0,43-1,57) 0,613 
 
PPARG C 
 
Gene alone 
 
1,48 (0,91-2,36) 
 
0,104 
 sex, age 1,40 (0,85-2,28) 0,176 
 sex, age, insulin 1,49 (0,90-2,45) 0,116 
 sex, age, 2h insulin 1,24 (0,56-2,53) 0,571 
 sex, age, HOMA-IR 1,51 (0,88-2,56) 0,131 
 sex, age, QUICKI 1,40 (0,83-2,32) 0,198 
 sex, age, FIRI 1,51 (0,88-2,56) 0,131 
 sex, age, glucose/insulin 1,41 (0,85-2,51) 0,174 
 IRS1 1,48 (0,91-2,37) 0,103 
 IRS1, IRS1*PPARG 1,64 (1,00-2,64) 0,046 
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CHAPTER 4 
 
LOW FREQUENCY MUTATIONS OF PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARG) IN 
THE MIXED-ANCESTRY POPULATION FROM SOUTH AFRICA 
 
4.1 BACKGROUND 
Peroxisome proliferator-activated receptor gamma (PPARG) is one of the three PPAR isotypes, 
which include PPAR alpha and PPAR beta. The PPARG is mainly expressed in adipose tissue, with 
PPAR alpha mostly in brown adipose tissue and liver and PPAR beta being found in many tissues 
but mostly expressed in the gut, kidney and heart (Desvergene & Wahli, 1999; Wang et al., 1999). 
The expression of peroxisome proliferator-activated receptors (PPARs) occurs when hetero-dimers 
are formed with the retinoid X receptor (RXR) and bind to specific PPAR responsive elements of 
DNA to promote transcription. The PPAR:RXR complex is activated via ligand binding to the 
PPARs, resulting in the release of co-repressors bound to the receptor and recruitment of co-
activators to initiate transcription of target genes (Mukherjee et al., 2000; Deeb et al., 1998; 
Pascual et al., 2005). For example, antidiabetic drugs of the thiazolidinedione family are believed 
to target the transcription factor PPARG to improve IS in T2DM and induce GLUT4 mRNA 
expression in fat and muscle (Armoni et al., 2003; Cariou et al., 2012; Yau et al., 2013). 
 
In several studies, naturally occurring PPARG polymorphisms have been described. The two 
common variants of the PPARG gene, Pro12Ala and His449His have been associated with 
metabolic states of obesity, IR, T2DM and metabolic syndrome (Ding et al., 2012). The His449His 
polymorphism (also referred to as C161T, C1431T or CAC478CAT, His447His) is a silent 
mutation at exon 6 and is considered a better predictor of fasting insulin levels and IR than 
Pro12Ala (Moffet et al., 2005). In an earlier study, the presence of PPARG Pro12 was found to 
produce a 64% risk of prevalent T2DM, but an association with markers of IR was not observed 
(Vergotine et al., 2014). Therefore, in the present study, the association between His449His and 
other low frequency PPARG polymorphisms with cardio-metabolic traits was investigated. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Baseline evaluations 
This investigation is based on the Bellville South Africa cohort from Cape Town, South Africa. The 
study setting, survey design and procedures have been described in detail in previous research 
(Erasmus et al., 2012; Matsha et al., 2013; Zemlin et al., 2011) as well as in chapter 2. It has 
received study approval from the Research Ethics Committee of Stellenbosch University (HREC 
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Reference number: N09/05/146) and CPUT, Faculty of Health and Wellness Sciences Ethics 
Committee (Reference Numbers: CPUT/HW-REC 2008/002 and CPUT/HW-REC 2010). The 
study was conducted according to the Code of Ethics of the World Medical Association 
(Declaration of Helsinki). All participants received a standardised interview and physical 
examination during which blood pressure was measured according to the World Health 
Organization (WHO) guidelines (Chalmers et al., 1999) in a sitting position using a semi-
automated digital blood pressure monitor (Rossmax PA, USA) on the right arm. Anthropometric 
measurements were performed three times and their averages used for analysis: weight (kg), height 
(cm), waist (cm) and hip (cm) circumferences. Participants with no history of doctor-diagnosed 
diabetes mellitus underwent a 75 g OGTT as recommended by WHO (Alberti & Zimmet, 1998). 
The following biochemical parameters were determined on the Cobas 6000 Clinical Chemistry 
instrument (Roche Diagnostics, Germany): fasting plasma glucose, insulin, creatinine, total 
cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), triglycerides (TG), C-reactive 
protein (CRP), γ-glutamyltransferase (GGT) and glycated haemoglobin (HbA1c), certified by the 
National Glycohaemoglobin Standardisation Programme (NGSP). Low-density lipoprotein 
cholesterol (LDL-c) was calculated using Friedewald’s formula (Friedewald et al., 1972). 
 
4.2.2 Single Nucleotide Polymorphisms genotyping 
Genomic DNA was extracted from whole blood samples collected in EDTA tubes. Single 
nucleotide polymorphisms in the PPARG, Pro115Gln (rs1800571,G>T), Val290Met 
(rs72551362,G>A), Pheu388Leu (rs72551363,T>A), Arg397Cys (rs72551364,C>T) and 
His449His (rs3856806,C>T) were genotyped using the high-throughput real-time polymerase 
chain reaction. This was carried out in two independent laboratories on the ABI Prism 7900HT 
platform (Applied Biosystems, USA) and a BioRad Optica (BioRad, USA), using the Taqman 
genotyping assay (Applied Biosystems, USA). Conventional polymerase chain reaction, followed 
by direct DNA sequencing, was performed for the analytical validation of high-throughput 
genotyping. 
 
4.2.3 Definitions and calculations 
The BMI was calculated as weight per square metre (kg/m
2
) and the waist-hip ratio (WHR) as 
waist/hip circumferences (cm). The T2DM status was based on a history of doctor diagnosis, a 
fasting plasma glucose ≥7,0Mmol/L and/or a 2-hour post-OGTT plasma glucose ≥11,1Mmol/L. 
The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated according to 
the formula: HOMA-IR= [fasting insulin concentration (mIU⁄ L) x fasting plasma glucose (Mmol⁄ 
L]/22,5; while homeostasis model assessment of functional beta-cells (HOMA-β%) were estimated 
using the formula: 20 × fasting insulin (μIU/mL)/fasting glucose (Mmol/mL) – 3,5. The 
fasting insulin resistance index (FIRI) was calculated with the formula: [fasting insulin (μU/mL) × 
Stellenbosch University  https://scholar.sun.ac.za
 54 
 
fasting glucose (mM)]/25 and the quantitative insulin sensitivity check index (QUICKI) as: 1/[log 
(fasting insulin (μU/mL) × log (fasting glucose (mg/dL)]. The glomerular filtration rate (eGFR) 
was estimated by the 4-variable MDRD equation (Levey et al., 1999; Levey et al., 2006), 
applicable to standardised serum creatinine values. 
 
4.3 STATISTICAL ANALYSIS 
The general characteristics of the study group are summarised as count and percentage for 
dichotomous traits, mean and standard deviation (SD) or median and 25
th
-75
th
 percentiles for 
quantitative traits. Where necessary, traits were log-transformed to approximate normality prior to 
analysis. The SNPs were tested for departure from the HWE expectation via a chi square goodness 
of fit test. Linear regression models were used for the analysis of quantitative traits and logistic 
regression models for dichotomous traits, always assuming additive models for the single 
nucleotide polymorphisms. Using linear and logistic models enabled the adjustment of all analyses 
for known confounders, as specified in the results. The additive allelic association of each SNP 
with each trait was investigated, overall and according to the T2DM status, and tested for 
heterogeneity by adding the interaction term of T2DM and each SNP to a model that contained the 
main effects of T2DM and the relevant single nucleotide polymorphism. Results corresponding to 
the p-values below 5% are described as significant, with borderline defined statistically as p>0,005 
but p<0,1. There were no adjustments for multiple testing. All analyses used the statistical package 
R (version 3.0.0 {2013-04-03}, the R Foundation for statistical computing, Vienna, Austria). 
 
4.4 RESULTS 
Of the 946 participants in the survey, 941 consented to genetic studies. Among the latter, 121 were 
excluded due to missing data on the genetic variables. Therefore, 820 had valid data for the current 
analyses.The clinical characteristics of participants overall and according to diabetes status are 
summarised in Table 4.1 (see p 58), indicating that 222 (27%) participants had type 2 diabetes 
mellitus. As expected, the distribution of the level of IR/S indicators was significantly different in 
the two groups (all p<0,0001, except for the glucose/insulin ratio (p=0,0304). Furthermore, 
compared with the non-diabetic participants, those with diabetes were significantly older (58,9 
years vs. 51,0 years, p<0,0001)and had higher levels of adipometric variables (all p≤0,014), 
systolic blood pressure (p<0,0001), TG (p<0,0001), GGT and CRP (both p<0,0001), whilst eGFR 
(p=0,029) and HDL cholesterol (p=0,0002) were significantly lower. 
 
No mutations were found for the following SNPs of PPARG Pro115Gln, Val290Met, Pheu388Leu 
and Arg397Cys. ThePPARG, His449His variant was in HWE (p>0,05).The genotype and allele 
distribution by diabetes status is summarised in Table 4.2 (see p 59). The frequency of the PPARG 
(rs3856806), C/T genotype was 23,8% in the overall population group and the genotype 
Stellenbosch University  https://scholar.sun.ac.za
 55 
 
distributions did not differ significantly between the non-diabetes  and diabetes groups. Overall, 
the T allele frequency was 14%, however, although not significant (p=0,128) the T allele did occur 
more in the non-diabetes (14,8%) than in the diabetes (11,7%) participants. 
 
In the generalised linear regression analyses adjusted for age, sex and diabetes (Table 4.3: p 60), 
the PPARG allele T was not associated with any markers of glycaemia, IR/S overall and by 
diabetes status. There was a borderline statistical interaction in the effect by diabetes status for the 
association with fasting blood glucose (interaction p=0,092), HOMA-IR and FIRI indexes (both 
p=0,076). Furthermore, the effects always appeared to be sizeable and negative (although non-
significant) among the diabetes and almost null in the non-diabetes participants. 
 
In the logistic regression models (Table 4.4: p 61), the PPARG allele T was associated with an odd 
ratio of 0,76 (95% confidence interval (CI): 0,55–1,06) for prevalent diabetes. The effect generally 
remained within the same range after adjustment for age and sex, with or without further 
adjustment for the various indices of insulin resistance/sensitivity. However, in the model 
containing sex, age and the 2-hour insulin, the PPARG allele T was significantly associated with a 
lower prevalent diabetes risk, demonstrating an odd ratio of 0,56 (95% CI: 0,31–0,95). 
 
4.5 DISCUSSION 
The present study reports on five PPARG SNPs: rs1800571, rs72551362, rs72551363, rs72551364 
and rs3856806. Only one of these PPARG variants, His449His (rs3856806) was found in the mixed 
ancestry population and demonstrated an association with diabetes. The T allele frequencies were 
about 14% and, in an additive genetic model we observed that the presence of the T allele 
significantly reduced the risk of diabetes by 44%. Furthermore, the T allele was associated with 
reduced fasting blood glucose levels, HOMA-IR and FIRI indices. However, these associations 
were borderline and did not reach statistical significance. 
The nuclear transcription receptor, PPARG, acts as a regulator of adipocyte differentiation, 
pancreatic beta cell function, lipid and glucose metabolism (Spiegelman, 1997; Rosen et al., 2003; 
Hevener et al., 2003). Despite its biological plausibility, previous reports that have studied the 
association with obesity (Valve et al., 1999; Meirhaeghe et al., 1998; Dongxia et al., 2008), IR 
(Moffet et al., 2005; Dongxia et al., 2008), T2DM (Tai et al., 2004; Vergotine et al., 2014) and 
MetS (Youssef et al., 2014) have been inconsistent. Some studies have reported that carriers of the 
T allele of His449His (rs3856806) have an increased obesity risk (Valve et al., 1999) and a poor 
lipid profile (Gu et al., 2013; Yilmaz-Aydogan et al., 2013; Rhee et al., 2006), as well as an 
increased risk of MetS (Youssef et al., 2013) and coronary heart diseases (CHD) (Ding et al., 
2012). On the other hand, others have failed to demonstrate an association between PPARG SNPs, 
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including C161T with CHD susceptibility (Xu et al., 2013). Additional research has shown an 
association with increased IS (Moffet et al., 2005; Dongxia et al., 2008), decreased CHD, BMI and 
diabetes risk (Dongxia et al., 2008; Tai et al., 2004; Rhee et al., 2006; Liu et al., 2007) in subjects 
harbouring the T allele. 
 
In this study, the presence of the T allele was associated with reducing the risk of prevalent 
diabetes and levels of the IR indices. The inconsistencies observed in these studies include 
variations in the ethnic distribution of the PPARG polymorphisms, power of the studies, 
environmental-gene, gene-gene interaction as well as different levels of adjustment for the 
potential confounding factors across studies. For example, in this study, the T allele frequency of 
the His449His variant was 14%, which is similar to that reported in Australian Caucasians at 
16,3% (Wang et al., 1999) and in Tunisians at 18,3% (Youssef et al., 2014), whilst in Chinese 
subjects a frequency of 29,2% has been reported (Luo et al., 2013). Furthermore, two recent studies 
have shown that gene-gene interaction analysis is superior to single PPARG polymorphisms, 
particularly regarding low frequency SNPs, for the quantification of effects with cardiometabolic 
traits (Luo et al., 2013; Chan et al., 2013). Luo et al. (2013) investigated the association of ten 
PPARG SNPs with obesity and showed that only two SNPs, rs2016520 and rs10865170, were 
associated with a lower obesity risk. However, in generalised multifactor dimensionality reduction 
analysis to assess the effect of interaction among the ten SNPs, an additional SNP, rs9794, was 
identified, which showed a potential gene-gene interaction with rs2016520 and rs10865170 (Luo et 
al., 2013). 
 
The low frequency PPARG SNPs, rs1800571, rs72551362, rs72551363, rs72551364, were also 
genotyped, but no genetic variations were observed. The rs1800571, Pro115Gln gain-of-function 
mutation has only been found in five German morbidly obese subjects since its initial identification 
by Ristow et al. (1998), where three of the four obese subjects with the genetic variant also had 
type 2 diabetes mellitus.  In another German population study, another carrier of the mutant with 
severe IR was identified (Bluher & Paschke, 2003). However, other studies involving German, 
Danish and American populations failed to find this mutation (Hamann et al., 1999; Evans et al., 
2000; Ek et al., 1999; Shuldiner et al., 2000; Hegele et al., 2002). Similarly, there has not been 
more than one individual in which either rs72551362, rs72551363 or rs72551364 has been found 
(Hegele et al., 2002; Barosso et al., 1999; Agarwal & Garg, 2002).  
 
The rare nature of these mutations suggests that standard population-based type studies are likely 
not the suitable design to investigate them, considering the requirements for very large sample size. 
Rather targeting specific segments of the population such as people with morbid obesity for 
screening may increase the likelihood of uncovering some with the mutation.It is also possible that 
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mutations other than those reported so far could be present in other populations, indicating the need 
for genome-wide scanning studies in different setting to capture additional mutations.  
 
The present study has limitations and these include the invesitgation of only five SNPs and the 
small sample size. However, the participants in this study were well characterised with both fasting 
and oral gluocse tolerance test derived indices, which were used for the assessment of T2DM and 
insulin resistance. In consclusion, this study confirmed the almost zero occurences of rare PPARG 
SNPs and has shown that one of the common SNPs, His449His may be protective against type 2 
diabetes mellitus. Future larger studies with more SNPs involving populations from Africa need 
further exploration. 
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Table 4.1 General characteristics of the overall population and by diabetes status 
 
Abbreviations: CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; FBG, Fasting 
blood glucose; FIRI, fasting insulin resistance index; GGT, γ-glutamyltransferase; HbA1c, glycated 
haemoglobin; HDL, high density lipoproteins; HOMA-β%, homeostasis model assessment of 
functional beta-cells; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low 
density lipoproteins; QUICKI, the quantitative insulin sensitivity check index; SD, standard 
deviation 
Variable No diabetes Diabetes p-value Overall 
Number 598 222  820 
Gender, male n (%) 130 (22) 48 (22) 0,9474 178 
Hypertension, n (%) 314 (53) 133 (60) 0,05859 447 
Mean(SD) 
Age (years)  
 
51,0 (15,1) 
 
58,9 (13,4) 
 
<0,0001 
 
53,2 (15,1) 
Systolic blood pressure (mmHg) 122 (19) 130 (23) <0,0001 124 (21) 
Diastolic blood pressure (mmHg) 75 (12) 77 (14) 0,0506 76 (13) 
Body mass index (kg/m2 )  29,2 (7,0) 31,8 (7,1) <0,0001 29,9 (7,1) 
Waist circumference (cm) 95 (15) 102 (14) <0,0001 97 (15) 
Hip circumference (cm) 109 (14) 112 (15) 0,014 109 (14) 
Waist-to-hip ratio (cm) 0,87 (0,10) 0,91 (0,10) <0,0001 0,88 (0,09) 
HbA1c (%) 5,7 (0,4) 7,8 (2,1) <0,0001 6,3 (1,4) 
FBG (Mmol/L) 5,1 (0,7) 9,8 (4,5) <0,0001 6,4 (3,2) 
2h glucose (Mmol/L) 6,4 (1,6) 13,4 (5,3) <0,0001 7,5 (3,6) 
eGFR (mL/min)  76,2 (21,2) 72,0 (25,2) 0,029 75,0 (22,4) 
Triglycerides (Mmol/L) 1,4 (0,9) 1,7 (0,9) <0,0001 1,5 (0,9) 
HDL cholesterol (Mmol/L) 1,3 (0,4) 1,2 (0,3) 0,0002 1,3 (0,4) 
LDL cholesterol (Mmol/L) 3,6 (1,0) 3,7 (1,1) 0,179 3,6 (1,0) 
Total cholesterol (Mmol/L) 5,5 (1,2) 5,7 (1,3) 0,068 5,6 (1,2) 
Mean(25th -75th percentiles) 
GGT  
 
26 [17-39] 
 
32 [23-49] 
 
<0,0001 
 
27 [19-42] 
CRP (mg/L) 3,3 [0,9-8,3] 5,4 [2,2-10,9] <0,0001 4,0 [1,2-9,4] 
Insulin (Mmol/L) 7,2 [3,4-12,9] 10,2 [4,4-17,6] 0,0001 7,7 [3,5-14,1] 
2h insulin (Mmol/L) 36,0 [19,3-65,7] 53,3[22,1-117,0] 0,0015 37,3 [19,5-72,7] 
Glucose/insulin  0,71 [0,40-1,45] 0,82 [0,48-2,05] 0,0304 0,72 [0,41-1,58] 
HOMA-IR  1,63 [0,69-3,00] 3,67 [1,71-7,29] <0,0001 1,94 [0,86-3,82] 
HOMA-β%  92,8 [43,5-165,1] 42,1 [13,6-83,4] <0,0001 74,2 [32,2-149,2] 
QUICKI  0,15 [0,14-0,18] 0,14 [0,12-0,15] <0,0001 0,15 [0,14-0,17] 
FIRI  1,46 [0,62-2,70] 3,31 [1,54-6,56] <0,0001 1,74 [0,77-3,44] 
1/HOMA-IR  0,61 [0,33-1,44] 0,27 [0,14-0,58] <0,0001 0,52 [0,26-1,16] 
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Table 4.2 The genotype distributions, minor allele frequencies and unadjusted p-values for 
comparing genotype distribution according to diabetes status, including additive allelic effects 
between diabetes groups 
 
HWE, Hardy-Weinberg Equilibrium (HWE p-values are from exact tests). 
Abbreviations: PPARG, peroxisome proliferator-activated receptor gamma 
 
 No diabetes Diabetes p-value  Overall 
 
N 
 
598 
 
222 
 
 
 
 
820 
 
PPARG (rs3856806) 
    
 
C/C, n (%) 
 
436 (72,9) 
 
172 (77,5) 
 
0,215 
 
 
608 (74,1) 
 
C/T, n (%) 
 
147 (24,5) 
 
48 (21,6) 
  
 
195 (23,8) 
 
T/T, n (%) 
 
15 (2,5) 
 
2 (0,9) 
  
 
17 (2,1) 
 
T, n (%) 
 
177 (14,8) 
 
52 (11,7) 
 
0,128 
 
 
229 (14,0) 
 
HWE (p-value) 
 
 
0,517 
 
 
0,747 
 
 
 
 
 
0,771 
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Table 4.3 Generalised linear regression models* showing the effects of genes on markers of insulin sensitivity /resistance 
 
Allele Phenotype Overall No diabetes Diabetes p interaction 
  Effects size (95%CI) p Effects size (95%CI) p Effects size (95%CI) p  
PPARG(rs3856806)T FBG -0,140 (-0,480 to 0,199) 0,417 0,0002 (-0,112 to 0,112) 0,996 -0,606 (-1,934 to 0,722) 0,372 0,092 
 2h glucose -0,114 (-0,494 to 0,266) 0,557 -0,098 (-0,341 to 0,144) 0,426 -0,147 (-2,826 to 2,533) 0,915 0,847 
 HbA1c -0,018 (-0179 to 0,143) 0,826 0,034 (-0,031 to 0,099) 0,303 -0,211 (-0,829 to 0,407) 0,504 0,164 
 Fasting insulin -0,915 (-3,362 to 1,533) 0,464 0,022 (-1,420 to 1,463) 0,976 -4,516 (-13,448 to 4,416) 0,323 0,125 
 2h insulin -1,716 (-11,818 to 8,386) 0,739 0,408 (-9,473 to 10,289) 0,936 -20,212 (-62,232 to 1,807) 0,348 0,190 
 Glucose/insulin -0,488 (-1,905 to 0,929) 0,500 -0,083 (-1,258 to 1,091) 0,890 -1,743 (-6,271 to 2,785) 0,451 0,334 
 HOMA-IR -0,437 (-1,481 to 0,608) 0,413 0,021 (-0,327 to 0,368) 0,907 -2,228 (-6,336 to 1,880) 0,289 0,076 
 QUICKI 0,001 (-0,006 to 0,009) 0,738 0,0008 (-0,008 to 0,010) 0,851 0,004 (-0,009 to 0,016) 0,564 0,752 
 FIRI -0,393 (-1,333 to 0,547) 0,413 0,019 (-0,294 to 0,332) 0,907 -2,005 (-5,703 to 1,692) 0,289 0,076 
 
* Models are adjusted for age, sex and diabetes 
Abbreviations: FBG, Fasting blood glucose; FIRI, fasting insulin resistance index; HbA1c, glycated haemoglobin; HOMA-IR, homeostasis model assessment 
of insulin resistance; PPARG, peroxisome proliferator-activated receptor gamma; QUICKI, quantitative insulin sensitivity check index 
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Table 4.4 Odds ratio and 95% confidence intervals from logistic regression for the prediction of 
diabetes 
 
Allele Covariates OR (95% CI) p 
PPARG T Gene alone 0,76 (0,55 to 1,06) 0,112 
 sex, age 0,74 (0,53 to 1,03) 0,082 
 sex, age, insulin 0,75 (0,53 to 1,05) 0,098 
 sex, age, 2h insulin 0,56 (0,31 to 0,95) 0,042 
 sex, age, HOMA-IR 0,77 (0,53 to 1,10) 0,157 
 sex, age, QUICKI 0,75 (0,53 to 1,04) 0,094 
 sex, age, FIRI 0,77 (0,53 to 1,10) 0,157 
 sex, age, glucose/insulin 0,75 (0,53 to 1,04) 0,092 
 
Abbreviations: FIRI, fasting insulin resistance index; HOMA-IR, homeostasis model assessment of 
insulin resistance; PPARG, peroxisome proliferator-activated receptor; QUICKI, 
quantitative insulin sensitivity check index 
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CHAPTER 5 
 
INDICES OF INSULIN RESISTANCE AND MARKERS OF  
SUB-CLINICAL CARDIOVASCULAR 
DISEASE/ATHEROSCLEROSIS 
5.1 BACKGROUND 
Insulin resistance predisposes populations to several metabolic abnormalities such as 
dysglycaemia, dyslipidaemia, elevated blood pressure, a procoagulant state, inflammation and 
endothelial dysfunction. These are strongly associated with the development of diabetes and 
subsequently, cardiovascular diseases. As such, indices of IR have been developed using particular 
sampling protocols during the OGTT for the estimation of insulin sensitivity. This is an important 
metabolic normality parameter due to its potential role in the development of cardiometabolic 
alterations (Reaven, 2005; Bobbioni-Harsch et al., 2012). These surrogate markers were validated 
against the euglycaemic clamp technique (Matsuda & DeFronzo, 1999; Hanley et al., 2003) and 
are used for CVD risk stratification (Kannan & Chernoff, 2013). 
 
However, these IR indices perform differently in different populations. For example, the 
homeostasis model of assessment of insulin resistance (HOMA-IR) is the most frequently used 
index to evaluate IR using measures derived from fasting states (Matthews et al., 1985). In a recent 
study, a significant positive correlation was reported between log HOMA-IR and the severity of 
coronary artery disease in diabetic patients (Srinivasan et al., 2013), thus highlighting the possible 
key role of IR in atherosclerosis. However, in a multi-ethnic study, the determination of HOMA-IR 
did not improve the detection of subclinical atherosclerosis (Bertoni et al., 2007). Another 
surrogate marker, the product of fasting triglycerides (TG) and the glucose (TyG) index, showed 
high sensitivity and specificity when compared to the clamp technique in identifying subjects with 
a decreased insulin sensivity. This was also approved as an alternative assessment of IR to HOMA-
IR when measures of insulin are not available (Guerrero-Romero et al., 2010). Although traditional 
vascular risk factors are important in the development of atherosclerosis, it is claimed that they 
only explain 50% of the risk of cardiovascular diseases (Bartels et al., 2012). Thus, more studies 
are investigating additional surrogate markers in the search for new therapies to reduce CVD 
mortality. 
 
In previous studies, mixed-ancestry South Africans were reported to have the second highest 
prevalence of diabetes (Levitt et al., 1993), and in the mixed ancestry was identified as the major 
factor responsible for the increased CVD risk in the 30-year cardiovascular risk profile study 
(Matsha et al., 2012). The mortality from CVD is two-to-fourfold higher in those with diabetes (Gu 
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et al., 1998), which could explain why CVD is the second leading cause of death after HIV/AIDS 
in South Africans (Bradshaw et al., 2003). Furthermore, the study by Matsha et al. (2012) the 
distribution of traditional diabetes risk factors, such as obesity, is not appreciably different in 
mixed-ancestry South Africans with and without diabetes (Matsha et al., 2012). Therefore, this 
study investigated whether indices of IR can aid in the stratification of high-risk individuals by 
using carotid intima media thickness. 
 
5.2 RESEARCH DESIGN AND METHODS 
 
5.2.1 Study setting and population 
The study setting, survey design and procedures have been described in detail in previous research 
(Erasmus et al., 2012; Matsha et al., 2013; Zemlin et al., 2011) as well as in chapter 2. Briefly, 
eligible participants were invited to take part in a community-based survey from January 2008 to 
March 2009 (Cohort 1) and January 2011 to November 2011 (Cohort 2). The study was approved 
by the Research Ethics Committee of Stellenbosch University (HREC Reference Number: 
N09/05/146) and the Cape Peninsula University of Technology, Faculty of Health and Wellness 
Sciences Ethics Committee (Reference Numbers: CPUT/HW-REC 2008/002 and CPUT/HW-REC 
2010). The study was conducted according to the Code of Ethics of the World Medical Association 
(Declaration of Helsinki). All participants signed consent forms after all the procedures were fully 
explained in the language of their choice. 
 
5.2.2 Clinical data 
All consenting participants received a standardised interview and physical examination during 
which blood pressure was measured according to the World Health Organisation (WHO) guidelines 
(Chalmers et al., 1999) using a semi-automated digital blood pressure monitor (Rossmax PA, USA) 
on the right arm, with the participant in a sitting position. Other clinical measurements included the 
body weight, height, waist and hip circumferences. Weight (to the nearest 0,1 kg) was determined 
for a subject wearing light clothing and without shoes and socks, using a Sunbeam EB710 digital 
bathroom scale, which was calibrated and standardised using a weight of known mass. The waist 
circumference was measured using a non-elastic tape at the level of the narrowest part of the torso, 
as seen from the anterior view. The hip circumference was also measured using a non-elastic tape 
around the widest portion of the buttocks. All anthropometric measurements were performed three 
times and averaged then used for analysis. Participants with no history of doctor-diagnosed 
diabetes mellitus underwent a 75 g OGTT as recommended by WHO (Alberti & Zimmet, 1998). 
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5.2.3 Laboratory measurements 
Blood samples were collected after an overnight fast and processed for further biochemical 
analyses. Plasma glucose was measured by the enzymatic hexokinase method (Cobas 6000, Roche 
Diagnostics, Germany) and glycated haemoglobin (HbA1c) by turbidimetric inhibition 
immunoassay (Cobas 6000, Roche Diagnostics, Germany).This is a National Glycohaemoglobin 
Standardisation Programme (NGSP) certified method. Creatinine levels were measured using the 
standardised creatinine assay (Cobas 6000, Roche Diagnostics, Germany). Total cholesterol (TC), 
high density lipoprotein cholesterol (HDL-c), triglycerides (TG) and γ-glutamyltransferase (GGT) 
were estimated by enzymatic colorimetric methods (Cobas 6000, Roche Diagnostics). Low density 
lipoprotein cholesterol (LDL-c) was calculated using Friedewald’s formula (Friedewald et al., 
1972). Insulin was determined by a microparticle enzyme immunoassay (Axsym, Abbot).  
C-reactive protein was measured by a high-sensitivity CRP assay, based on the highly sensitive 
Near Infrared Particle Immunoassay rate methodology (Immage Immunochemistry System; 
Beckman Coulter), with a lower limit of detection of 0,2 mg/L. 
 
5.2.4 Definitions and calculations 
Body mass index (BMI) was calculated as weight per square metre (kg/m
2
) and the waist-hip-ratio 
(WHR) as waist/hip circumferences (cm). The glomerular filtration rate was estimated by the  
4-variable MDRD equation (Levey et al., 1999; Levey et al., 2006) applicable to the standardised 
serum creatinine values. Type 2 diabetes mellitus status was based on a history of  
doctor-diagnosis, a fasting plasma glucose ≥7,0 Mmol/L and/or a 2-hour post-OGTT plasma 
glucose ≥11,1 Mmol/L. 
 
5.2.5 Surrogate measures of insulin resistance 
The HOMA-IR was calculated according to the formula: HOMA-IR= [fasting insulin 
concentration (mIU⁄L) x fasting plasma glucose (Mmol⁄L]/22,5; while homeostasis assessment of 
functional beta-cells (HOMA-β%) were estimated using the formula: 20 × fasting insulin 
(μIU/mL)/fasting glucose (Mmol/mL) – 3,5. The fasting insulin resistance index (FIRI) was 
calculated with the formula: [fasting insulin (μU/mL) × fasting glucose (mM)]/25 and the 
quantitative insulin sensitivity check index (QUICKI) as: 1/[log (fasting insulin (μU/mL) × log 
(fasting glucose (mg/dL)]. 
 
5.2.6 Measurement of carotid intima media thickness  
Two qualified sonographers measured the CIMT in longitudinal section at the far wall of the distal 
common carotid arteries, 2 cm from the bifurcation, at three consecutive end-points, 5 mm to 10 
mm apart. The CIMT was reported in millimetres and used as a measure of subclinical 
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CVD/atherosclerosis. The ultrasound examination was performed according to the ALARA 
principle to avoid biological effects that may be associated with ultrasound. The exposure output of 
the machine was kept to a low value with the thermal index <1, which still gave an accurate 
diagnosis (Kremkau, 2006). The mean of six readings (three from each side) was calculated for 
each participant using a portable B-mode and spectral Doppler ultrasound scanner equipped with 
cardiovascular imaging software. 
 
5.3 STATISTICAL ANALYSES 
Data are presented as mean (standard deviation, SD) or median [25th-75th percentiles] for 
continuous variables and as count and percentage for categorical variables. For group (sex, 
diabetes status) comparisons, the chi square test and student t-test were used. Continuous 
associations between CIMT and the indices were assessed graphically with the use of a correlation 
matrix, before and after applying the Box-Cox power transformations to improve the shape of the 
associations. This was followed by the ‘Covariance Estimation for Multivariate t Distribution’ 
method to derive the correlation coefficients, while minimising the potential effects of outliers. The 
Steiger t-test was used to compare the correlation coefficients among the indices. Regression 
coefficients to indicate the size of the association of each of the indices with the CIMT 
measurements were derived from robust multiple linear regression models that included each of the 
four variables of interest: age, sex, BMI and diabetes status. Analyses were carried out using R 
statistical software (version 3.0.0 {03-04-2013}, the R Foundation for Statistical Computing, 
Vienna, Austria). The significance level was set at 0,05. 
 
5.4 RESULTS 
General characteristics of participants 
Of the 515 participants included in this analysis, 137 (26,6%) were men and 150 (29,1%) had 
diabetes. The BMI (p=0,002), waist circumference (p<0,0001), waist-to-hip ratio (p=0,0009), 
systolic blood pressure (p=0,0002), TG (p<0,0001) and CIMT (p<0,0001) were significantly 
higher in the diabetic participants, whilst the HDL-c (p=0,004) was lower in the diabetic 
participants (Table 5.1: p 68). Significant differences were also apparent when comparing men and 
women with a number of variables including BMI, waist-hip ratio, TC, HDL-c, CRP, HbA1c, 
fasting blood insulin (FBI), IR markers, γ-glutamyltransferase, serum creatinine and carotid intima 
media thickness (Table 5.1: p 68). 
 
Bivariate correlations  
In the overall study sample, there was a weak positive correlation between CIMT and fasting 
glucose [r=0,22 (95% confidence intervals: 0,14 to 0,30)], HOMA-IR, FIRI and glucose/insulin 
ratio with a similar correlation coefficient of 0,09 (0,01 to 0,18), as seen in Table 5.2 (see p 69). In 
Stellenbosch University  https://scholar.sun.ac.za
 66 
 
participants with and without diabetes analysed separately, no significant correlation was observed 
between CIMT and markers of IR, with no differential effect between the two groups (all p>0,47). 
The correlation coefficients were compared in the overall cohort and it was apparent that the 
correlation of CIMT with fasting blood glucose was stronger than that of CIMT with any of the 
other markers of insulin resistance (all p<0,02). 
 
The correlation of CIMT with fasting blood insulin was less than that with HOMA-IR or FIRI 
(both p<0,0001) but not appreciably different from QUICKI (p=0,400) or the glucose/insulin ratio  
(p = 0,340). Furthermore, the correlation of CIMT with QUICKI was significantly weaker than that 
with the glucose/insulin ratio (p<0,0001) but only slightly weaker when compared to the 
correlation of CMIT with HOMA-IR and FIRI (both p=0,072).See Table 5.2: p 69. The regression 
curves showing the linear correlations of CIMT with markers of IR are illustrated in Figure 5.1 
(see p 70). 
 
Multiple linear regression analyses 
In a multiple robust linear regression model containing age, sex and BMI, the three variables were 
all significantly associated with CIMT (all p<0,003) and explained 26,5% of variation in the CIMT 
values (Table 5.3: p 71). When the diabetes status was added to this model, the four variables in 
the model (basic model) were all significantly associated with CIMT (all p<0,023) and together 
explained the 29.1% variation in the CIMT. In the presence of these four variables, fasting blood 
glucose (β=0,087; p=0,042) and glucose/insulin ratio (β=0,026; p=0,026) were positively 
associated with CIMT, while the association with other markers of IR did not reach statistical 
significance. Adding fasting blood glucose and glucose/insulin ratio to the basic model had a trivial 
effect on the overall performance of the model, with the highest achieved R
2
 being only 29,7% 
(Table 5.3: p 71). 
 
5.5 DISCUSSION 
The findings of this study demonstrate that in a model containing traditional risk factors age, sex, 
adiposity and diabetes, the IR indices namely; FBG and glucose/insulin ratio were positively 
associated with carotid intima media thickness. However, the effect on the overall model 
performance by these IR indices were marginal, with the highest achieved R
2
 of only 29,7%. The 
variance in CIMT explained by these IR indices did not differ much when compared to that of the 
traditional risk factors of 29,1%. Furthermore, CIMT as an independent predictor of CVD risk was 
found to be significantly higher in males and in participants with diabetes in the mixed-ancestry 
population.  
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A strong link between diabetes and CVD through the development of IR has been previously 
reported (Reviewed by Ikmal et al., 2013). Various epidemiological studies have shown an 
association between IR indices and carotid atherosclerosis, however, the results have been 
inconsistent (Bertoni et al., 2007; Kannan & Cherhoff, 2013; Jeppesen et al., 2007; Mehta et al., 
2011; Sourij et al., 2008; Srinivasan et al., 2013; Vasques et al., 2011; Irace et al., 2013). Of the IR 
indices, HOMA-IR was  found to be beneficial to identify patients with a higher CVD risk 
(Jeppesen et al., 2007; Sourij et al., 2008; Mehta et al., 2011; Srinivasan et al., 2013; Kannan & 
Cherhoff, 2013) with similar results reported for  the TyG index (Vasques et al., 2011; Irace et al., 
2013), fasting blood insulin, 2 hour postload insulin (Fontbonne et al., 1991) and the area under the 
plasma insulin response curve (Pyörälä et al., 1998). In contrast, a number of studies showed no 
evidence of association between IR indices such as HOMA-IR and TyG index for cardiovascular 
diseases (Bertoni et al., 2007; Vasques et al., 2011). 
 
The positive and significant association of the IR indices, FBG and the glucose/insulin ratio with 
CIMT was found beyond the traditional risk factors in this study. Both these IR indices are derived 
from fasting blood levels representing the basal steady-state condition with respect to glycaemia, 
insulinaemia and hepatic glucose, reflecting primarily hepatic insulin resistance/sensitivity 
(Muniyappa et al., 2007). A stronger correlation of CIMT with FBG was observed in this study 
similar to the results obtained by Karbek et al. (2013). Fasting blood glucose has been previously 
associated with the risk of vascular disease in all concentrations, including at levels lower than 7 
Mmol/L, the threshold for diabetes, however, data from studies are inconclusive (Coutinho et al., 
1999; Lawes et al., 2004; Emerging Risk Factors Collaboration, et al., 2010; Emerging Risk 
Factors Collaboration et al., 2011). Changes in the glycaemic status can alter lipoprotein and lipid 
flux, which in turn can modulate IS and glucose disposal (Mazzone et al., 2008). The role of 
hyperglycaemia as a risk factor for CVD in T2DM has been linked to induced damage to the 
endothelium and arterial vasoconstriction, associated with vascular smooth muscle proliferation 
and increased intimal thickness (Massi-Benedetti & Federici, 1999). In two recent studies impaired 
glucose, which indirectly represents IR (Kim et al., 2013), and FBG levels were progressively 
associated with an increased risk of atherosclerosis cardiovascular diseases (Park et al., 2013). 
 
Lastly, the measures of IR are weakly associated with CIMT, as there was only a small statistical 
difference when compared to subclinical disease linked to traditional risk factors for CVD, such as 
age, sex, adiposity and diabetes. In conclusion, the IR indices did not add independent value to the 
assessment of subclinical CVD risk in this mixed-ancestry population of South Africa. 
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Table 5.1 General characteristics of the overall population and by diabetes status 
 
Variables Overall Sex Diabetes 
  Men Women p No Yes p 
N 515 137 378  365 150  
Female, n (%) 378 (73,4) 0 378   263 115 0,282 
 
Mean(SD) 
Age (years) 
 
 
54,4 (13,3) 
 
 
55,5 (13,6) 
 
 
54,0 (13,1) 
 
 
0,274 
 
 
52,4 (13,4) 
 
 
59,3 (11,6) 
 
 
<0,0001 
Body mass index (kg/m2) 31,4 (8,1) 27,4 (7,0) 32,8 (8,0) <0,0001 30,6 (7,4) 33,4 (9,4) 0,002 
Waist circumference (cm) 96 (15) 94 (15) 97 (16) 0,096 95 (16) 101 (13) <0,0001 
Waist-to-hip ratio (cm)     0,89 (0,12) 0,93 (0,12) 0,87 (0,12) <0,0001 0,88 (0,12) 0,92 (0,12) 0,0009 
Systolic blood pressure (mmHg) 136 (26) 138 (24) 136 (27) 0,313 133 (23) 144 (30) 0,0002 
Diastolic blood pressure (mmHg) 82 (14) 84 (15) 81 (13) 0,074 81 (14) 83 (14) 0,064 
FBG (Mmol/L) 6,5 (3,1) 6,1 (2,4) 6,6 (3,2) 0,112 5,2 (0,7) 9,6 (4,1) <0,0001 
HbA1c (%) 6,6 (1,6) 6,3 (1,4) 6,7 (1,7) 0,007 5,9 (0,4) 8,3 (2,2) <0,0001 
Total cholesterol (Mmol/L) 5,5 (1,1) 5,6 (1,0) 5,5 (1,1) 0,660 5,5 (1,1) 5,6 (1,1) 0,610 
HDL cholesterol (Mmol/L) 1,4 (0,4) 1,3 (0,5) 1,4 (0,4) 0,050 1,4 (0,4) 1,3 (0,4) 0,004 
LDL cholesterol (Mmol/L) 3,4 (1,0) 3,4 (1,0) 3,5 (1,0) 0,776 3,5 (1,0) 3,4 (1,0) 0,633 
Triglycerides (Mmol/L) 1,5 (0,9) 1,7 (1,1) 1,5 (0,8) 0,066 1,4 (0,8) 1,9 (1,1) <0,0001 
Creatinine (µM) 
 
74,9 (25,2) 89,3 (34,6) 67,8 (18,3) <0,0001 73,3 (18,5) 78,8 (36,6) 0,080 
Median(25th -75th percentiles) 
CIMT (mm)  
 
0,80 [0,67-1,01] 
 
0,96 [0,70-1,20] 
 
0,80 [0,65-0,95] 
 
<0,0001 
 
0,77 [0,63-0,93] 
 
0,97 [0,77-1,15] 
 
<0,0001 
CRP (mg/L) 5,0 [2,0-8,9] 3,7 [1,5-7,6] 5,4 [2,2-9,2] 0,020 5,0 [1,9-8,6] 5,0 [2,5-9,8] 0,213 
GGT (IU/L) 28 [19-44] 32,5 [24,0-47,7] 25,0 [17,0-41,0] <0,0001 27,0 [19,9-42,0] 29,0 [22,0-50,0] 0,014 
Insulin (Mmol/L) 11,7 [6,9-17,4] 10,5 [6,2-15,9] 12,3 [7,3-10,1] 0,023 10,1 [6,2-15,9] 14,8 [9,2-23,2] <0,0001 
Glucose/insulin  0,51 [0,33-0,85] 0,57 [0,34-1,09] 0,52 [0,32-0,77] 0,047 0,49 [0,33-0,81] 0,62 [0,32-0,92] 0,222 
HOMA-IR  2,99 [1,66-5,00] 2,7 [1,3-4,2] 3,2 [1,8-5,3] 0,021 2,31 [1,31-3,74] 6,63 [3,52-10,77] <0,0001 
HOMA-β%  110,8 [58,6-185,2] 90,4 [44,7-172,2] 114,0 [65,9-190,4] 0,039 125,3 [78,3-208,7] 59,1 [35,8-121,9] <0,0001 
QUICKI  0,14 [0,13-0,15] 0,14 [0,13-0,16] 0,14 [0,13-0,15] 0,021 0,15 [0,14-0,16] 0,13 [0,12-0,14] <0,0001 
FIRI  2,69 [1,49-4,50] 2,46 [1,17-3,81] 2,93 [1,60-4,76] 0,021 2,08 [1,18-3,37] 5,07 [3,17-9,69] <0,0001 
1/HOMA-IR  0,33 [0,20-0,60] 0,37 [0,24-0,77] 0,31 [0,19-0,56] 0,021 0,43 [0,27-0,76] 0,18 [0,09-0,28] <0,0001 
 
Abbreviations: CRP, C-reactive protein; CIMT, carotid intima media thickness; FBG, fasting blood glucose; FIRI, fasting insulin resistance index; GGT, γ-
glutamyltransferase; HbA1c, glycated haemoglobin; HDL, high density lipoproteins; HOMA-β%, homeostasis model assessment of functional beta-cells; 
HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low density lipoproteins; QUICKI, quantitative insulin sensitivity check index; SD, 
standard deviation 
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Table 5.2 Robust correlation of carotid intima media thickness with markers of insulin resistance/sensitivity 
 
Correlates No diabetes Diabetes p-value Overall 
FBI FBG HOMA-IR QUICKI FIRI Glucose/insulin 
ratio 
FBI -0,01 (-0,12 to 0,09) -0,04 (-0,20 to 0,12) 0,80 0,01 (-0,07 to 0,10) NA      
FBG 0,15 (0,04 to 0,25) 0,16 (0,0 to 0,31) 0,89 0,22 (0,14 to 0,30) 0,00014 NA     
HOMA-IR 0,02 (-0,08 to 0,12) 0,03 (-0,13 to 0,19) 0,91 0,09 (0,01 to 0,18) <0,0001 0,0015 NA    
QUICKI 0,0 (-0,10 to 0,10) -0,02 (-0,18 to 0,14) 0,81 -0,06 (-0,14 to 0,03) 0,400 0,00017 0,072 NA   
FIRI 0,02 (-0,08 to 0,12) 0,03 (-0,13 to 0,19) 0,91 0,09 (0,01 to 0,18) <0,0001 0,0015 >0,999 0,072 NA  
Glucose/insulin ratio 0,06 (-0,04 to 0,17) 0,13 (-0,03 to 0,29) 0,47 0,09 (0,0 to 0,18) 0,340 0,021 0,97 <0,0001 0,97              NA 
 
Abbreviations: FBG, fasting blood glucose; FBI, fasting blood insulin; FIRI, fasting insulin resistance index; HOMA-IR, homeostasis model assessment of 
insulin resistance; QUICKI, quantitative insulin sensitivity check index; NA, not applicable 
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Figure 5.1 Correlations of markers of insulin resistance with carotid intima-media thickness 
Participants are grouped by diabetes status with the triangles representing those with diabetes and 
the solid circles representing those without diabetes. The superimposed regression lines are for the 
overall sample (solid line) and participants with diabetes (broken line) and without diabetes (dotted 
lines). Accompanying correlations coefficients are shown in Table 5.2.  
Abbreviations: FIRI, fasting insulin resistance index; HOMA-IR, homeostasis model assessment of 
insulin resistance; QUICKI, quantitative insulin sensitivity check index  
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Table 5.3 Regression coefficients from multiple robust linear models for the prediction of carotid intima media thickness by indices of insulin resistance 
accounting for the potential effect of sex, age, diabetes and adiposity 
 Age-Sex-BMI Diabetes FBI FBG HOMA-IR QUICKI FIRI Glucose/Insulin 
 β P β p β p β p β p β p β p β p 
Index - - - - -0,020 0,123 0,087 0,042 -0,011 0,359 0,113 0,157 -0,011 0,359 0,026 0,039 
Age 0,009 <0,0001 0,008 <0,0001 0,008 <0,0001 0,008 <0,0001 0,008 <0,0001 0,008 <0,0001 0,008 <0,0001 0,008 <0,0001 
Sex 
(men) 
0,155 <0,0001 0,155 <0,0001 0,156 <0,0001 0,153 <0,0001 0,155 <0,0001 0,155 <0,0001 0,155 <0,0001 0,156 <0,0001 
BMI 0,004 0,003 0,003 0,023 0,004 0,007 0,002 0,054 0,003 0,013 0,004 0,008 0,003 0,013 0,004 0,004 
Diabetes - - 0,122 <0,0001 0,127 <0,0001 0,072 0,027 0,131 <0,0001 0,135 <0,0001 0,131 <0,0001 0,115 <0,0001 
R
2
 0,265 0,291 0,295 0,296 0,293 0,294 0,293 0,297 
 
All indices of insulin resistance are log-transformed. 
Abbreviations: BMI, body mass index; FBG, fasting blood glucose; FBI, fasting blood insulin; FIRI, fasting insulin resistance index; HOMA-IR, homeostasis 
model assessment of insulin resistance; QUICKI, quantitative insulin sensitivity check index  
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CHAPTER 6 
 
DISCUSSION/CONCLUSION/RECOMMENDATIONS 
 
6.1 SUMMARY OF FINDINGS 
In this study, the genetic results within the mixed-ancestry South African participants uncovered a 
gene-gene interaction between two previously identified IR loci namely, the PPARG and IRS1 gene 
variants. The PPARG Pro12 allele was strongly associated with IR and its interaction with an 
additional unfavourable genetic polymorphism, IRS1 Gly972Arg, conferred an increased risk of type 2 
diabetes mellutis. In addition, the PPARG His449His variant showed a reduced T2DM risk. 
Furthermore, the measures of IR in the presence of traditional risk factors, namely age, sex, body mass 
index and diabetes, were weakly associated with carotid intima media thickness. Based on these results 
the indices of IR were found not to be a viable marker of CVD risk estimation within this population. 
 
6.2 DISCUSSION AND CONCLUSION 
The role of specific SNPs in genes related to IR and T2DM have been well established in Caucasians 
with studies reporting varying degree of associations in these population groups. Following the global 
trend observed in other populations, the prevalence of T2DM has also increased at an alarming rate in 
mixed-ancestry South Africans over the last two decades from 10,8% to 26,4% (Levitt et al., 1999; 
Erasmus et al., 2012) that is not only attributed to environmental factors but a genetic link as well. 
Although a vast amount of literature is available on the contribution of genetic factors to the 
development of IR that consequently leads to T2DM, limited data is available on the South African 
populations. The interest of this study was to investigate specific candidate genes of IR that possible 
predispose South Africans, particularly the mixed ancestry population to the early onset and high 
incidence of type 2 diabetes mellitus. 
 
The etiologic cascade leading to IR, and subsequently T2DM, has been mainly investigated in 
European Caucasian cohorts with the genome-wide analysis identifying a strong genetic basis that 
contributes to T2DM suscepitibility (Ayub et al., 2014; Dupuis et al., 2010; Povel et al., 2012; Morris 
et al., 2012; Vioght et al., 2010; Wanatabe, 2010; Brunetti et al., 2014). By far, the PPARG Pro12Ala 
variant has been shown to be a strong candidate gene associated with IR and T2DM with positive 
replication reported in most studies with an protective effect against type 2 diabetes mellitus (Deeb et 
al., 1998; Buzzetti et al., 2004; Tönjes et al., 2006; Gouda et al., 2010; Dupuis et al., 2010; Trombetta 
et al., 2013). In the African population studies, however, the protective allele against T2DM of the 
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PPARG Pro12Ala variant was rare in Ghanaians but absent in black South Africans from Zulu descent 
(Danquah et al., 2013; Pirie et al., 2010). However, the PPARG Pro12 at risk allele was identified in 
Ghanaians but no association was evident with IR or T2DM, which could be due to the sample size 
used in the study (Danquah et al., 2013). In Tunisians no association with T2DM was found with the 
PPARG gene (Turki et al., 2012; Mtiraoui et al., 2012). Similarly, results in mixed-ancestry South 
Africans showed evidence regarding the association of the risk Pro12 allele in the PPARG gene with 
insulin resistance. However, the PPARG Pro12Ala variant did not have a protective effect againt the 
risk of type 2 diaebtes mellitus. Although there were differences in the risk allele frequencies when 
compared to other ethnic populations, the allelic effect associated with the IR and T2DM risk seems 
consistent in the mixed-ancestry population. Moreover, the combined effect, i.e. gene-gene interaction, 
of the PPARG Pro12Ala and IRS1 Gly972Arg gene-variants observed in this population has also 
previously been reported in terms of their effect on IS (Stumvoll et al., 2002) and adiponectin levels 
(Mousavinasab et al., 2005) associated with IR and diabetes. Furthermore, the genetic prediction of 
disease is greatly improved if genetic variants with stong effects are identified, either on their own or 
with other variants, i.e. gene-gene interaction or gene-environment interactions (Janssens & van Duijn, 
2008; Luo et al., 2013; Chan et al., 2013).  
Regarding the low frequency PPARG polymorphisms investigated, only the PPARG His449His variant 
was found in the mixed-ancestry population. As far as is known, this is the first study that demonstrates 
the T allele of the PPARG His449His variant to have a protective effect against the risk of developing 
diabetes. Although the contribution of rare variants to disease risk is known to be limited, there is 
strong evidence that they may play a role in complex disease etiology and could possibly have greater 
genetic effects than common variants. Further development of sequencing technology and methods 
may increase the possiblity to detect rarer complex trait associations that could result in new 
discoveries related to their underlying effects on disease risk (Manolio et al., 2009; De La Vega et al., 
2011). Lack of association was found between the IRS1 Gly972Arg variant and IR in this population, 
which is similar to results reported in African Americans (Lei et al., 1999), Mexican Americans (Celi et 
al., 2000) and Asians (Abate et al., 2003). However, this does not exclude the possibility that other 
polymorphisms of IRS1 could have an effect on diabetes. 
In conclusion, this current study advances the research knowledge relating to the genetic basis for the 
development of IR and risk of T2DM in a South African population. Furthermore, the results provide 
evidence in support of the role of specific mutations of the PPARG and IRS1 genes associated with 
diabetes through effects on IR, which may explain the high prevalence of T2DM within mixed-
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ancestry South Africans. The early detection of subjects with IR at high risk for T2DM could be a 
valuable factor in confronting the rising prevalence of diabetes already observed in this population. 
6.3 LIMITATIONS 
Due to the origin of the mixed-ancestry ethnic group, associations identified in this study may be due 
to population stratification, and this was not taken into account. Therefore, the findings of this study 
require replication in a larger study involving other homogeneous populations before they can be 
considered as established in Africa. The candidate gene approach used for association analysis in this 
study has been proven to be extremely powerful for studying genetic traits of complex diseases like 
diabetes. However, the disadvantage of this approach is the low replication of results and the limited 
ability to include all possible causative agents. The power of the study is limited due to the small 
sample size. This is because most genes contributing to complex disorders confer only a very modest 
increase in disease risk and to detect these with higher power requires larger sample sizes. Although 
the simple indices of IR were useful for determining whether a disease was associated with IR, the 
evaluation of other independent measures of IR could be used to further confirm the findings reported 
in this population. The number of males versus females is skewed, which is characteristic of 
epidemiology studies in South African populations. 
The strengths of this study are that the participants were well characterised with both fasting and 
OGTT derived indices used for the assessment of T2DM and insulin resistance. Genotyping was 
carried out by two independent laboratories. Overall, in spite of the limitations, the study represented a 
significant advance in the knowledge of the genetic determination of IR and the risk of developing 
diabetes in an African mixed-ancestry population with a high incidence of type 2 diabetes mellitus. 
6.4 RECOMMENDATIONS 
The findings of in this study provides a starting point for future studies in other African populations to 
investigate additional candidate genes as well as genome wide association studies that could possibly 
identify further functional variants related to IR and T2DM risk. The relative contributions of these 
genes to T2DM susceptibility could possibly shed more light on the etiological cascade of IR within 
African populations. Since different ethnic associations of the genetic variations have been associated 
with IR, the gene-to-gene or gene-to-environment interactions and certain related risk factors may 
influence the susceptibility to metabolic disorders. 
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Appendix B Consent form for genetic analysis 
THE BELLVILLE SOUTH DIABETES SURVEY CONSENT FORM 
Investigators: Prof Matsha (CPUT)  
Mr Shafick Hassan (CPUT)  
Prof Rajiv Erasmus (University of Stellenbosch) 
Mr Soita David Jonah (MTech student)  
Address: Faculty of Health and Wellness Sciences, Cape  
Peninsula University of Technology (CPUT), Bellville Campus  
Symphony Way, 7535  
Chemical Pathology Department, Faculty of Health Sciences, University of Stellenbosch 
(Tygerberg Campus), Tygerberg, 7505.  
Dear Participant, 
You are being invited to take part in a research project. Please take some time to read the 
information presented here, which will explain the details of this project. Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand. It 
is very important that you are fully satisfied and that you clearly understand what this 
research entails and how you could be involved. Also, your participation is entirely voluntary 
and you are free to decline to participate. If you say no, this will not affect you negatively in 
any way whatsoever. You are also free to withdraw from the study at any point, even if you do 
initially agree to take part.  
This study has been approved by the Committee for Human Research at Cape University of 
Technology and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research.  
What is this research study all about?  
Worldwide new causes of certain diseases or conditions are continuously being discovered 
by research on the cells and molecules of the body. For research to be carried out on certain 
diseases it is necessary to first establish the incidence and prevalence of the disease. This 
project aims to determine the incidence and prevalence of diabetes and glucose intolerance. 
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Additionally, this project aims to collect genetic material (blood) to analyze for certain variants 
and to store excess material for future research. When a large group of patients with similar 
diseases has been collected, meaningful research into the disease processes may become 
possible.  
Why have you been invited to participate?  
The prevalence of diabetes of diabetes in South Africa is not well documented and few 
studies have been conducted since 1994. Many subjects with diabetes are unknown to the 
health service, often because they are not yet diagnosed. In order to assess the magnitude of 
the problem, you have been approached to participate in this project to determine the 
incidence of diabetes amongst our adult population.  
You have randomly been selected by means of a computer program to participate in the 
above-mentioned study. Adults of all races, gender, age (between ages 35 and 60 years) and 
weight will be approached as subjects.  
What will your responsibilities be? 
The participant will be requested to provide information about his/her medical history, family 
history and information on eating, drinking and smoking habits. Completion of the 
questionnaire will take no longer than 10 minutes. Measurement such as weight, height, waist 
and hip will be done. Fasting Venous Blood will be collected thereafter you will be asked to 
drink a glucose solution (glucose content 75g). After two hours another venous blood will be 
collected. The blood will be used to determine whether you have diabetes or glucose 
intolerance. The other tests that will be determined from your blood sample are: Cholesterol 
and Triglycerides levels. The remainder of the blood sample will be used for genetic and 
future research studies. The DNA may be stored for several years until the technology for 
meaningful analysis becomes available. No pharmaceutical agent (medication) will be tested 
in the study.  
Will you benefit from taking part in this research?  
You will be notified of your glucose tolerance state or whether you are diabetic by the medical 
nurse or doctor. Thereafter, you will be referred to your local health centre or general 
practitioner for further investigations and treatment.  
In the unlikely event that the research may lead to the development of commercial 
applications, the participant or the participant’s heirs will not receive any compensation, but 
profits will be reinvested into supporting the cause of further research which may bring 
benefits to my/*the participant’s family and to the community, such as health screening, 
medical treatment, educational promotions, etc.  
Are there any risks involved in my taking part in this research? 
A slight bruising might occur after blood has been drawn from the arm but this will heal 
quickly. After the administration of the glucose solution, you may feel nauseous and dizzy in 
which case you must notify the medical personnel. A medical nurse will be present on all 
occasions. In addition, the research team will be in contact with medical doctors should you 
need emergency care by a medical doctor.  
Who will have access to your medical records?  
The participant’s identity will be kept confidential throughout. Information will not be 
associated with the participant’s name. The research staff will use only a coded number, 
access will be limited to authorized scientists and any scientific publications, lectures or 
reports resulting from the study will not identify me/*the participant.  
Some insurance companies may mistakenly assume that taking part in research indicates a 
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higher risk for disease. Thus no information about you or your family will be shared with such 
companies. 
Will you or your child be paid to take part in this study and are there any costs 
involved?  
You will not be paid to take part in the study, but your transport, if required will be covered for 
each study visit. It is envisaged that you may be hungry since you would have come fasting, 
therefore, biscuits or fruit will be provided. There will be no costs involved for you if you take 
part in the project.  
Is there anything else that you should know or do?  
You should inform your family practitioner or usual doctor that you are taking part in a 
research study.  
You will receive a copy of this information and consent form for your own records if it is 
requested  
DECLARATION BY PARTICIPANT: 
I declare that:  
I have read or had read to me this information and consent form and that it is written in a 
language with which I am fluent and comfortable.  
I have had a chance to ask questions and all my questions have been adequately answered.  
I understand that taking part in this study is voluntary and I have not been pressurized to take 
part.  
I may choose to withdraw from the study at any time and will not be penalized or prejudiced 
in any way.  
I may be asked to leave the study before it has finished if the study doctor or researcher feels 
it is in my best interests, or if I do not follow the study plan as agreed to.  
I also consent that my blood may be: 
Used and stored for future research studies 
Used and discarded 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2007 
Signature of participant________________ Signature of witness_______________ 
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DECLARATION BY THE INVESTIGATOR 
I (name) ……………………………………………..……… declare that:  
I explained the information in this document to (Names of 
participant)………………………………….………  
I encouraged him/her to ask questions and took adequate time to answer them.  
I am satisfied that he/she adequately understand all aspects of the research, as discussed 
above  
Signed at (place) ......................…........…………….. on (date) …………....……….. 2007. 
Signature of investigator_______________ Signature of witness_____________ 
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Appendix C Questionnaire of lifestyle factors 
Progressive research on risk factors of type 2 diabetes and cardiovascular diseases in South Africa. 
Principal Investigator:  Prof Tandi Matsha 
Name of Interviewer: ……………………………. 
Date of Interview: ……./…..../….... Ref No …… 
To the respondent: 
Thank you very much for your willingness to participate in the completion of this questionnaire. The 
information obtained on this questionnaire will provide us with information on all the possible health, 
family, life style and dietary risk factors within your house hold that might influence the development 
of diabetes. This is because many health conditions develop slowly over time yet could be prevented if 
diagnosed early or if pre determined. This questionnaire therefore aims at getting information which 
may be used to determine the extent of diabetes and those likely to develop diabetes in the future. The 
questionnaire should not take long and we hope you find it interesting and enjoyable. All answers 
provided will be treated as confidential and anonymous.  
Note 
No special knowledge is needed to fill this questionnaire. Please feel free to ask for clarification if 
needed. 
Postal Address: ---------------------------------------------------------- 
 ---------------------------------------------------------- 
---------------------------------------------------------- 
Residential address: ---------------------------------------------------------- 
---------------------------------------------------------- 
---------------------------------------------------------- 
Telephone OR  
Cell phone Contacts: ---------------------------------------------------------- 
1 
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A. PERSONAL DATA 
Instructions: 
Please complete the following general information about yourself by ticking in 
the box next to the appropriate answers. Please take your time and read 
through questions carefully. 
I. What is your date of birth? 
2. What is your gender? 
Male D 
3. What is your marital status? 
Female D 
Married D Single D Widowed D 
Divorced D Other D 
4. How would you describe your self? 
Black D White D 
Colored D Asian D 
D 
D 
D 
D 
5. What is the highest level of education you have completed? 
(a) Primary School or less 
(b) High School (Not Completed) 0 
(c) High School graduate 
(d) College Or Technical College (Not Completed) 
(e) College or Technical College Graduate 
(f) University or technikon (Not CompletedO 
(g) University or technikon graduate 
6. What is your Profession/Occupation? 
Please state......... . ........................ ........ .. ... .. .. .. . ....................... 0 
7 How long have you been living in Bellville South? 
Less than 6 Months 0 
1-5 Years 0 
Less than 1 Year 
5 years and above 
2 
D 
D 
D 
n 
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B. FAMILY HEALTH HISTORY 
Instructions: 
The following questions will tell us about your family health history. Please 
complete all the questions by placing a tick next to the appropriate answer 
or writing in the answer. 
8. Are you currently on any medication? Yes D NoD D 
9. If Yes, Please list .......... .. .. .......... · .. · ... ··· .. ·· ...... · .... .. . ·.......... .. .... D 
10. Have you ever been told that you have diabetes? 
Yes D No D D 
11. Have any of the following in your family ever had or are being treated for 
diabetes? 
(a)Mother 
Yes D NoD D 
(b) Father 
YesO NoD D 
(c) Sister(s) 
YesD D D No 
(d) Brother(s) 
YesD D D No 
(e) Husband/Wife D 
Yes No D D 
(f) Children 
Yes D D D No 
(g) Grandchildren 
YesD D D No 
3 
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12. Have any of the following extended family members ever suffered or are 
suffering from diabetes? 
(a) Paternal (Fathers Side) 
(i) Uncles 
YesD 
(ii) Aunties 
YesD 
(iii) Grandparents 
YesD 
(b) Maternal (mothers Side) 
(i) Uncles 
Yes D 
(ii) Aunties 
Yes D 
(iii) Grand Parents 
YesD 
NoD 
NoD 
NoD 
13. Have you or any of the following ever been treated for heart problems? 
(a) Yourself 
D NoD Yes 
(b) Spouse 
D D Yes No 
(c) Mother 
D D Yes No 
(d) Father 
D D Yes No 
(e) Children 
Yes 0 NoD 
4 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
D 
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(f) Grandparents 
D No 0 D Yes 
(g) Sisters 
D D Yes 
No 
D 
(h) Brothers 
YesD D NoD 
14. Have any of the following ever been treated for High Blood pressure? 
(a) Yourself 
D NoD D Yes 
(b) Spouse 
D NoD D Yes 
(c) Mother 
D NoD D Yes 
(d) Father 
D NoD D Yes 
(e) Children 
D NoD D Yes 
(f) Grandparents 
YesD No[] D 
(g) Sisters 
YesD NoD D 
(h) Brothers 
YesD NoD D 
15. Did either of your natural parents ever die of a heart attack? 
(a) Before the age of 60? 
Yes 
D 
NoD D 
(b) After the age of 60? 
D NoD D Yes 
5 
Stellenbosch University  https://scholar.sun.ac.za
119 
16. Have you or any of the following ever been treated for High Cholesterol? 
(a) Yourself 
Yes D NoD D 
(b) Spouse 
Yes D NoD D 
(c) Mother 
Yes D No D D 
(d) Father 
Yes D No D D 
(e) Children 
YesD No D D 
(f) Grandchildren D 
Yes NoD D 
(g) Brother 
Yes D NoD D 
(h) Sisters 
YesD No D D 
6 
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E. ALCOHOL USE 
22. Have you ever consumed any alcoholic drinks (Wine, Beer, and Spirits)? 
Yes D No D 
23. Do you still consume alcoholic drinks? 
Yes D No D 
24. If you consume or consumed alcohol, how old were you when you first 
started drinking? 
Please state. . ... . ....... years 
25. If you stopped, how old were you when you stopped drinking? 
Please state. . ....... . 
26. Which type of alcohol do you or did you drink? 
WineD BeerO Spirits D 
D Others, please indicate ..... . .. .. . . ....... .. .... . . 
27. When you drink or drank alcoholic drinks, how many drinks or glasses 
do you or did you consume daily? Indicate the number ..... 
28. How many days a week do you or did you consume alcohol? 
1-2 0 3-4 0 5-6 0 everyday 0 
29. Have you or did you ever feel you should cut down your drinking? 
Yes 0 No 0 
30. Have people ever annoyed you by criticizing your drinking? 
Yes 0 No 0 
31. Have you ever felt bad about your drinking? 
Yes D No 0 
32. Have you ever had a drink first thing in the morning to steady your nerves 
or get rid of a hangover (Eye Opener) 
Yes D No 0 
7 
D 
D 
0 
D 
0 
D 
0 
0 
D 
D 
D 
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F. BODY MEASUREMENTS. 
33. Weight and Height. 
Body Weight (kg) 
Body height (em) 
Body Mass Index 
Interviewers Name ................... .. .. . 
34 CALLIPERS MEASUREMENTS 
Biceps 1(cffi) 
Biceps 2 .. (cm) 
Biceps 3 (em) 
Total 
Triceps 1 (em) 
Triceps 2 (em) 
Triceps 3 (em) 
Total 
Sub-Scapular 1 (em) 
Sub-Scapular 2 (em) 
Sub-Scapular 3 (em) 
Total 
Suprailiac 1 (em) 
Supra-iliac 2 (em) 
Supra- Iliac 3 (em) 
Total 
35 CIRCUMFERENCE MEASUREMENTS 
Waist Circumference 1 (em) 
Waist Circumference 2 (em) 
Waist Circumference 3 (em) 
Total 
36 
Hip Circumference (em) 
Hip Circumference (em) 
Hip Circumference (em) 
Total (em) 
37 BLOOD PRESSURE MEASUREMENTS Interviewers Name . .. .. ... . 
Systolic Pressure 1 (mmHg) 
Systolic Pressure 2 (mmHg) 
Systolic Pressure 3 (mmHg) 
Diastolic Pressure 1 (mmHg) 
Diastolic Pressure 2 (mmHg) 
Diastolic Pressure 3 (mmHg) 
8 
I 
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Pulse I (Beat per Minute) 
Pulse 2 (Beat per MinutE) _ 
Pulse 3 (Beat per Minute) 
G. BLOOD ANALYSIS. Interviewers Name ...................... . 
38. (a) Fasting State Measurements 
(i) Did subject eat this morning? ........... If yes state time ... . ....... .. . 
(ii) When did subject eat the last meal last evening? ... .................... .. . . 
(iii) Please indicate the time when fasting blood taken . . . ... . ..... . .... . 
(iv) Please indicate the time when Glucose was given ........... . . . ..... . 
Glucose mmoVJ 
Cholesterol mmol/1 (L= l , N=2, H=3) 
Triglycerides mmoVI (L=l, N =2, H=3) 
(b) Post Prandial Measurements 
Please indicate time when post pradial blood was taken ..... . . 
Glucose mmoVl 
Cholesterol mmol/1 
Tri&lycerides mmoVI 
9 
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H. Researchers Check list. 
Please make a tick or cross against each of the following questions 
I. Were all personal data questions answered? D 
2. Were all Family Health History questions answered? D 
3. Were all questions on Tobacco use answered? D 
4. Were all questions on Alcohol use answered? D 
5. Were all dietary questions answered? D 
6. Were all body measurements carried out? D 
7. 
(a) Was fasting blood taken? D 
(b) Was Glucose Given? D 
8. Was Post Pradial Blood taken? D 
9. Was B.P Taken D 
10 
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Appendix D Principles and performance characteristics of assays used 
Assay/Analyte Principle/CAT # CV Linearity/ 
Measuring range 
Plasma glucose Glucose is oxidised by glucose oxidase to 
produce gluconate and hydrogen peroxide (HP). 
The HP then reacts with 4 amino-antipyrene (4-
AAP) and phenol in the presence of peroxidase 
to yield a red quinoneimine dye. The absorbance 
of the dye at 505 nm is proportional to the 
concentration of glucose in the sample. 
3,0 0,11-41,6 Mmol/L 
Insulin Microparticle enzyme immunoassay. 2,4 1,39-6945 pmol/L 
High sensitive 
(CRP) 
C-reactive protein (CRP) agglutinates with latex 
particles coated with monoclonal antibodies 
against CRP. The precipitate is measured 
turbidimetrically. 
2,1 0,15-20,0 mg/L 
Glycosylated 
haemoglobin 
(HbA1c) 
Total haemoglobin (Hb) is determined in an 
alkaline medium based on the formation of a 
brownish-green chromophore whose colour 
intensity corresponds to the concentration of Hb 
in the sample and is determined by the increase 
in absorbance at 552 nm. HbA1c is measured 
using monoclonal antibodies that bind the β-N-
terminal fragments of HbA1c. The final 
percentage HbA1c [HbA1c(%)] is computed 
from the ratio of both concentrations 
[HbA1c(%) = (HbA1c/Hb) × 87,6 + 2,27)]. 
Alanine 
aminotransferase 
(ALT) 
Alanine catalyses the reaction between L-alanine 
and oxoglutarate forming pyruvate and 
glutamate. Lactate dehydrogenase then catalyses 
the reduction of the pyruvate forming L-lactate 
and nicotinamide adenine dinucleotide (NAD+). 
The rate at which the NADH is oxidised is 
directly proportional to the catalytic ALT 
activity and is determined by measuring the 
decrease in absorbance at 340 nm. 
3,0 5-700 U/L 
γ -glutamyl 
transferase 
(GGT) 
GGT-catalysed transfers of an γ-glutamyl group 
from L-γ-glutamyl-3-carboxy-4-nitroanilide to 
glycylglycine liberate 5-amino-2-nitrobenzoate 
at a rate proportional to the GGT activity in the 
sample and are determined by measuring the 
increase in absorbance at 409 nm. 
1,3 5-720 U/L 
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Total cholesterol Cholesterol esterase (CE) hydrolyses cholesterol 
esters to form free cholesterol and fatty acids. 
Cholesterol oxidase (CHOD) then catalyses the 
oxidation of cholesterol to form cholest-4-ene-3-
one and H2O2. Hydrogen peroxide leads to the 
oxidative coupling of phenol and 4-amino-
antipyrine (4-AAP) to form a red-coloured 
quinoneimine chromogen whose intensity is 
directly proportional to the cholesterol 
concentration. 
2,5 0,25-20,7 Mmol/L 
High-density 
lipoprotein 
(HDL) 
Polyethylene glycol (PEG)-modified cholesterol 
esterase catalyses the breakdown of HDL-
cholesterol (HDL-c) esters to free cholesterol 
and fatty acids. The free cholesterol is then 
oxidised by PEG-cholesterol oxidase to Δ4-
cholestenone and H2O2, which oxidises 4-AAP 
forming a blue quinoneimine dye, whose 
intensity correlates with the HDL-c 
concentration and is determined by measuring 
the increase in absorbance at 583 nm. 
1,5 0,08-7,2 Mmol/L 
Triglycerides 
(TG) 
Lipoprotein lipase hydrolyses triglycerides (TG), 
producing glycerol, which is then 
phosphorylated by adenosine triphosphate 
(ATP) to glycerol-3-phosphate (G-3-P) in a 
glycerol kinase catalysed reaction. Oxidation of 
G-3-P in the presence of glycerol phosphate 
oxidase yields H2O2, which drives the reaction 
of 4-chlorophenol and 4-aminophenazone 
forming a red-coloured chromogen measured at 
512 nm. The increase in absorbance corresponds 
to the concentration of TG in the sample. 
1,3 0,1-10,0 Mmol/L 
Creatinine Creatinine reacts with picrate forming a yellow-
orange complex at a rate that is proportional to 
the creatinine concentration in the specimen. 
1,3 15-2200 μmol/L 
Abbreviations: CV, Coefficient of Variation (%); CAT#, Catalogue reference number 
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Appendix E Primers designed 
Polymorphism Chromosome 
Location 
Primer Sequence Tm GC
% 
Product 
size 
PPARG 
Pro12Ala 
rs1801282 
3:12351626 F: GAGCGCCCAGATGAGATTAC=20 
R: CTGGATCTTGTTCTTGTGAATGG=22 
59,8 
59,6 
55 
45,5 
300bp 
PPARG 
Pro115Gln 
rs1800571 
3:12381349 F:TGAAGGTGTACTATGGTGGCTTGC=24 
R:CCACAGACACGACATTCAATTGCC=24 
58,8 
58,5 
50 
50 
205bp 
PPARG 
His447His 
rs3856806 
3:12434058 F:GATGAGTTGCTTGGTAGAGCTG=22 
R:TGGAAGAAGGGAAATGTTGG=20 
59,1 
59,9 
50 
45 
386bp 
PPARG 
Val290Met 
rs72551362 
3:12416836 F:TTGCAGCCATTCGTTATCTATG=22 
R:TCGGATATGAGAACCCCATC=20 
60,1 
59,7 
40,9 
 50 
299bp 
PPARG 
Pheu388Leu 
rs72551363 
3:12417048 F:TGTGCAGGAGATCACAGAGTATGC=24 
R;CCATCATCCCACCCTCTTTC=20 
63,9 
61,6 
50 
55 357bp 
PPARG 
Arg397Cys 
rs72551364 
3:12433900 F:CAGATGAGTTGCTTGGTAGAGC=22 
R:TCCGTGACAATCTGTCTGAGG=21 
59,1 
61,3 
50 
52,4 257bp 
IRS1 
Gly972Arg 
rs1801278 
2:226795828 F:CAGCTCCCAGAGAGGAAGAG=20 
R:TGTTCGCATGTCAGCATAGC=20 
59,3 
61,0 
60 
50 266bp 
Abbreviations: F, Forward primer; R, Reverse primer; Tm, melting temperature in degree Celsius; GC, 
rich template guanine cytosine content in percentage; bp, base pairs, PPARG; peroxisome proliferator-
activated receptor gamma, IRS1; insulin receptor substrate 1 
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